Characterization of pathogenic auto-antibodies directed against desmoglein 3 and desmocollin 3 in sera of pemphigus patients. by Rafei-Shamsabadi, David Ali & Eming, Rüdiger (PD Dr. med.)
  
 
Aus der Klinik für Dermatologie und Allergologie 
Geschäftsführender Direktor: Prof. Dr. med. Michael Hertl 
 
 
des Fachbereichs Medizin der Philipps-Universität Marburg 
 
 
 
 
 
 
 
 
Characterization of pathogenic auto-antibodies directed against 
desmoglein 3 and desmocollin 3 in sera of pemphigus patients 
 
 
 
Inaugural-Dissertation zur Erlangung des Doktorgrades  
der gesamten Humanmedizin 
 
 
dem Fachbereich Medizin der Philipps-Universität Marburg 
vorgelegt von 
 
 
David Ali Rafei-Shamsabadi aus Gießen 
 
 
Marburg 2013 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Angenommen vom Fachbereich Medizin der Philipps-Universität Marburg  
 
am: 14.06.2013 
 
 
 
Gedruckt mit Genehmigung des Fachbereichs. 
 
 
 
 
 
Dekan:   Prof. Dr. Matthias Rothmund 
 
Referent:   PD Dr. Rüdiger Eming 
 
Korreferent:  Prof. Dr. Markus Schnare 
 
  
Inhaltsverzeichnis 
 
Abkürzungsverzeichnis………………………………………………...I 
Abbildungs- und Tabellenverzeichnis…………………………......III 
Summary…………………………………………………………………V 
Zusammenfassung...…………………………………………………VII 
 
1 Introduction ............................................................................. 1 
1.1 The skin ......................................................................................................... 1 
1.1.1 Structure and functions.......................................................................................... 1 
1.1.2 The epidermis ........................................................................................................ 2 
1.1.3 Cellular adhesion ................................................................................................... 3 
1.1.4 Desmosomes ......................................................................................................... 4 
1.2 From desmosome to disease..................................................................... 10 
1.2.1 Clinical subtypes of pemphigus ........................................................................... 12 
1.2.2 Auto-antibody profiles .......................................................................................... 19 
1.2.3 Knowledge from mice .......................................................................................... 19 
1.3 Pemhigus pathogenesis ............................................................................. 21 
1.3.1 Cellular autoimmunity in pemphigus ................................................................... 22 
1.3.2 Disrupting adhesion of epidermal keratinocytes ................................................. 25 
1.3.3 Epitope spreading ................................................................................................ 34 
1.3.4 Desmoglein compensation theory ....................................................................... 35 
1.4 Non-desmosomal antigen targets in pemphigus ..................................... 36 
1.5 Current therapeutic strategies in pemphigus ........................................... 37 
1.6 Aims of this study ....................................................................................... 39 
2 Materials and Methods .......................................................... 40 
2.1 Pemphigus patients and healthy controls ................................................ 40 
2.2 Antibodies and enzymes ............................................................................ 41 
2.3 Solutions, buffers, media and technical devices ...................................... 42 
2.4 Expression and purification of recombinant proteins ............................. 46 
2.5 Purification of antigen-specific auto-antibodies from pemphigus sera .. 46 
  
2.5.1 Affinity chromatography ....................................................................................... 46 
2.5.2 Preparation of affinity chromatography columns ................................................. 47 
2.5.3 Auto-antibody purification .................................................................................... 48 
2.5.4 Determination of protein concentrations.............................................................. 48 
2.6 Enzyme-linked immunosorbent assay (ELISA) ........................................ 49 
2.7 Western blot analysis ................................................................................. 50 
2.8 Immunofluorescence studies .................................................................... 51 
2.9 Dispase-based keratinocyte dissociation assay ...................................... 53 
3 Results ................................................................................... 55 
3.1 Purification and characterisation of desmoglein 3 extracellular 
subdomain-specific auto-antibodies from pemphigus vulgaris patients’ sera .... 55 
3.1.1 Clinical and serological characteristics of pemphigus vulgaris patients .............. 56 
3.1.2 Purification of antigen-specific auto-antibodies via affinity chromatography ....... 59 
3.1.3 Purified pemphigus vulgaris immunoglobulin G is antigen-specific for 
recombinant extracellular subdomains of desmoglein 3 .................................................... 60 
3.1.4 Extracellular subdomain 4-specific auto-antibodies belong to the immunoglobulin 
G1 and immunoglobulin G4 isotype classes ........................................................................ 62 
3.1.5 Recognition of desmoglein 3 extracellular subdomain 4 is calcium independent, 
whereas desmoglein 3 extracellular subdomain 1-reactive immunoglobulin G binds to 
conformational epitopes...................................................................................................... 63 
3.1.6 Desmoglein 3 subdomain-specific imunoglobulin G recognizes native desmoglein 
3  ............................................................................................................................. 64 
3.1.7 Desmoglein 3 extracellular subdomain 4-specific immunoglobulin G induces loss 
of keratinocyte adhesion in vitro ......................................................................................... 65 
3.2 Purification and characterisation of desmocollin 3-specific auto-
antibodies in atypical pemphigus patients ............................................................. 67 
3.2.1 Clinical and serological characteristics of atypical pemphigus patients .............. 68 
3.2.2 Desmocollin 3-reactive auto-antibodies in the sera of four patients with atypical 
pemphigus .......................................................................................................................... 69 
3.2.3 Desmocollin 3-specific immunoglobulin G recognizes both recombinant and 
native desmocollin 3 ........................................................................................................... 70 
3.2.4 Desmocollin 3-specific immunoglobulin G induces loss of keratinocyte adhesion 
in vitro  ............................................................................................................................. 72 
  
4 Discussion ............................................................................. 74 
4.1 Role of anti-desmoglein 3 auto-antibodies recognizing carboxy-terminal 
epitopes in the pathogenesis of pemphigus ........................................................... 74 
4.1.1 Epitope spreading and synergistic effects of “non-pathogenic” pemphigus 
vulgaris auto-antibodies ...................................................................................................... 75 
4.1.2 Possible pathogenic molecular mechanisms of desmoglein 3 extracellular 
subdomain 4-specific immunoglobulin G ............................................................................ 77 
4.1.3 Immunoglobulin G isotype distribution patterns of auto-antibodies ractive with 
amino- and carboxy-terminal epitopes of desmoglein 3 ..................................................... 81 
4.1.4 Conformation dependence of amino- and carboxy-terminal epitopes of 
desmoglein 3 ...................................................................................................................... 81 
4.1.5 Role of carboxy-terminal subdomains of desmoglein 3 in maintaining 
keratinocyte adhesion ......................................................................................................... 82 
4.2 Role of desmocollin 3-specific auto-antibodies in the pathogenesis of 
pemphigus ................................................................................................................ 83 
4.2.1 Evidence for pathogenic desmocollin 3-specific auto-antibodies ........................ 83 
4.2.2 Presence of desmocollin-reactive immunoglobulin G in clinical pemphigus 
variants  ............................................................................................................................. 85 
4.3 Potential role of antigen-specific immunoadsorption in the therapy of 
pemphigus ................................................................................................................ 87 
5 Conclusions ........................................................................... 90 
6 Outlook ................................................................................... 91 
7 Literaturverzeichnis .............................................................. 92 
8 ELISA-Messdaten und dissociation scores ....................... 105 
9 Lebenslauf .............................. Fehler! Textmarke nicht definiert. 
10 Verzeichnis der akademischen Lehrer .............................. 109 
11 Danksagung ......................................................................... 110 
12 Ehrenwörtliche Erklärung ................................................... 112 
 
 
___________________________________________________Abkürzungsverzeichnis 
 
I 
 
Abkürzungsverzeichnis 
aa   amino acid 
Ab   antibody 
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auto-Ab  auto-antibody 
APC   antigen preenting cell 
CD   cluster of differentiation 
COOH-  carboxy- 
Dsc   desmocollin 
Dsg   desmoglein 
Dsg3EC1-5  recombinant protein containing the entire ectodomain (aa 1- 
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Dsg3EC1  recombinant protein including aa 1–161 of desmoglein 3 
Dsg3EC2  recombinant protein including aa 87–227 of desmoglein 3 
Dsg3EC3  recombinant protein including aa 184–349 of desmoglein 3 
Dsg3EC4  recombinant protein including aa 313–451of desmoglein 3 
Dsg3EC5   recombinant protein including aa 424–566 of desmoglein 3 
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EDTA   ethylenediaminetetraacetic acid 
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PNP   paraneoplastic pemphigus 
PV   pemphigus vulgaris 
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SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Th   T helper cell 
Treg   regulatory T cell
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Summary 
Pemphigus vulgaris (PV) represents the most frequent clinical type of the 
pemphigus group of autoimmune bullous skin disorders. There is substantial 
evidence that blister formation in pemphigus patients is mediated by auto-
antibodies (auto-Abs) targeted against certain desmosomal cadherins, namely 
desmoglein1 (Dsg1) and desmoglein3 (Dsg3). Several pathogenic epitopes of 
Dsg3 are located at the amino-(NH2)-terminal end of the Dsg3 ectodomain, 
namely the extracellular domain 1 (EC1). On the other hand a great number of 
pemphigus patients exhibit auto-Abs directed against the more carboxy-
(COOH)-terminal epitopes of Dsg3, e.g. within the EC4- and EC5-domain and 
these domains may play an essential role in maintaining desmosomal adhesion. 
Some pemphigus patients exhibit additional or solely auto-Abs against other 
desmosomal cadherins, especially desmocollin 3 (Dsc3). However, the 
pathogenic relevance of Dsc3-reactive immunoglobulin G (IgG) has not been 
directly shown. This study aimed to first establish a method to specifically 
isolate Dsg3-reactive IgG from PV sera and to further investigate their 
pathogenic capacity using a keratinocyte based in vitro assay. This method was 
further applied to sera of four Japanese patients suffering from atypical 
pemphigus all of them exhibiting a positive IgG reactivity against Dsc3. 
Sepharose based affinity chromatochraphy columns coated with recombinant 
baculovirus produced proteins of the extracellular domains of Dsg3 and Dsc3, 
respectively, were used to specifically isolate auto-Abs from pemphigus sera. 
Affinity purified IgG fractions were subsequently tested for antigen specificity 
using enzyme-linked immunosorbent assay (ELISA) and immunoblotting (IB). 
Reactivity with native Dsg3- and Dsc3-protein, respectively, was proven by 
immunofluorescence (IF) on cultured human keratinocytes, monkey esophagus 
and frozen sections of normal human skin. Finally, a keratinocyte based so-
called dissociation assay served to investigate the in vitro pathogenicity of the 
affinity purified IgG fractions. Eight Dsg3-reactive PV patients showed Dsg3-
domain-specific auto-antibodies by ELISA. Four of these patients were selected 
for further investigation based on their antibody profile, i.e. their epitope 
specificity. Two patients (#1 and #8) exhibited IgG directed against Dsg3EC1 
and Dsg3EC4. Patient #2 exclusively expressed auto-Abs directed against 
Dsg3EC1 whereas patient #6 showed IgG reactivity against Dsg3EC4, only. 
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Serum IgG was then affinity purified using the respective recombinant Dsg3-
subdomains. Antigen specificity of the eluted IgG-fractions was subsequently 
verified by IB and ELISA. Isolated IgG fractions showed a characteristic 
intercellular staining pattern by IF using cultured human keratinocytes indicating 
positive reactivity with native Dsg3-protein. Recognition of Dsg3EC1 but not of 
Dsg3EC4 by the isolated IgG fractions of patients #1 and #8 was Ca2+-
dependent. Finally Dsg3-, Dsg3EC1- and Dsg3EC4-specific IgG caused 
keratinocyte dissociation which was comparable to the positive control, a 
monoclonal antibody (AK23) directed against the NH2-terminus of Dsg3. These 
techniques were then applied to the sera of four atypical, i.e. two pemphigus 
vegetans and two pemphigus herpetiformis patients, in order to isolate Dsc3-
specific IgG. All but one of these patients, who showed additional Dsg1 
reactivity, exhibited IgG reactivity exclusively against Dsc3 but no other 
desmosomal cadherin. From all sera IgG fractions were successfully isolated 
and antigen specificity to Dsc3 was verified. Dsc3-reacitve IgG showed a 
characteristic intercellular staining pattern by IF on cultured human 
keratinocytes, monkey esophagus and human skin. Finally all isolated IgG 
fractions were able to induce loss of keratinocyte adhesion in vitro.Taken 
together this data strongly suggests a significant acantholytic effect of IgG 
directed against COOH-terminal epitopes of Dsg3 in addition to the well known 
pathogenic epitopes at the NH2-terminus of this auto-antigen. Furthermore 
recognition of COOH-terminal epitopes seems to be Ca2+ independent which 
goes in line with previous studies of our group. Moreover Dsc3-reactive IgG 
isolated from patients with atypical pemphigus variants proved to be pathogenic 
in vitro. For the first time these results directly show the acantholytic effect of 
Dsc3-reactive IgG and provides evidence for the pathogenic relevance of Dsc3-
IgG in pemphigus patients lacking reactivity against other desmosomal 
cadherins. Further investigations are needed to elucidate the mechanisms by 
which auto-Abs directed against COOH-terminal epitopes of Dsg3 induce 
acantholysis. The pathogenic relevance of other epitopes of Dsg3, especially 
within the Dsg3EC5-domain, needs to be addressed. Finally screening of 
pemphigus patients’ sera for Dsc3-reactive IgG should provide further 
knowledge about their correlation with atypical pemphigus variants. 
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Zusammenfassung 
Pemphigus vulgaris (PV) repräsentiert die häufigste klinische Variante innerhalb 
der Pemphigus-Gruppe der autoimmunen bullösen Hautkrankheiten. 
Blasenbildung beim Pemphigus wird durch Auto-Antikörper (auto-Ak) gegen die 
desmosomalen Cadherine Desmoglein 1 (Dsg1) und Desmoglein 3 (Dsg3) 
ausgelöst. Einige pathogene Epitope des Dsg3 liegen im amino-(NH2)-
terminalen Bereich dieses Moleküls, genau genommen in der extrazellulären 
Domäne 1 (EC1). Auf der anderen Seite weist eine große Anzahl an Pemphigus 
Patienten auto-Ak gegen Carboxy-(COOH)-terminale Epitope des Dsg3, z.B. 
innerhalb der EC4- oder EC5-Domänen auf und möglicherweise spielen diese 
Domänen eine essentielle Rolle in der Aufrechterhaltung desmosomaler 
Zelladhäsion. Manche Pemphigus Patienten besitzen zusätzlich oder 
ausschließlich auto-Ak gegen andere desmosomale Cadherine, besonders 
Desmocollin 3 (Dsc3). Die pathogenetische Relevanz dieser Dsc3-reaktiven 
auto-Ak konnte bislang nicht direkt gezeigt werden. Zunächst wurde eine 
Methode etabliert, um Dsg3-reaktives Immunglobulin G (IgG) aus PV Seren 
spezifisch zu isolieren und die pathogenetische Wirkung mithilfe eines Zell-
basierten in vitro Assays zu untersuchen. Diese Methode wurde anschließend 
auf Seren von vier japanischen Patienten mit atypischem Pemphigus, welche 
alle eine positive IgG-Reaktivität gegen Dsc3 aufwiesen, angewendet. Mithilfe 
von Affinitätschromatographie-Säulen, die rekombinante, im Baculovirus-
System produzierte, Proteine der extrazellulären Domänen von Dsg3 bzw. Dsc3 
enthielten, wurden auto-Ak aus den Seren von Pemphigus Patienten spezifisch 
isoliert. Die isolierten IgG-Fraktionen wurden anschließend bezüglich ihrer 
Antigenspezifität mittels enzyme-linked immunosorbent assay (ELISA) und 
Immunoblotting (IB) getestet. Immunfluoreszenz (IF) Untersuchungen auf 
kultivierten humanen Keratinozyten, Affenösophagus und Gefrierschnitten 
menschlicher Haut wiesen die Reaktivität mit nativem Dsg3 bzw. Dsc3 nach. 
Schließlich diente ein mit Keratinozyten durchgeführter, funktioneller, so 
genannter Dissoziations-Assay der Untersuchung der in vitro-Pathogenität der 
aufgereinigten IgG-Fraktionen. Acht PV Patienten zeigten im ELISA Dsg3-
spezifische auto-Ak. Vier dieser Patienten wurden aufgrund ihres geeigneten 
Antikörperprofils, d.h. der Epitopspezifität, für die weiteren Untersuchungen 
ausgewählt. Zwei Patienten (#1 und #8) zeigten IgG-Reaktivität gegen 
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Dsg3EC1 und Dsg3EC4. Das Serum von Patient #2 beinhaltete ausschließlich 
auto-Ak gegen Dsg3EC1, wohingegen Patient #6 nur IgG-Reaktivität gegen 
Dsg3EC4 zeigte. Serum-IgG wurde anschließend mithilfe der jeweils 
entsprechenden rekombinanten Dsg3-Ektodomäne spezifisch aufgereinigt. Die 
Antigenspezifität der eluierten IgG-Fraktionen konnte anschließend mittels IB- 
und ELISA-Analysen verifiziert werden. Alle isolierten IgG-Fraktionen zeigten 
ein charakteristisches interzelluläres Färbemuster in der IF auf kultivierten 
humanen Keratinozyten. Durch diese Experimente wurde die positive 
Reaktivität mit rekombinantem und nativem Dsg3 nachgewiesen. IgG-
Fraktionen der Patienten #1 und #8 zeigten eine Ca2+-abhängige Reaktivität 
gegen Dsg3EC1, wohingegen die Reaktivität gegen Dsg3EC4 nicht Ca2+-
abhängig war. Dsg3-, Dsg3EC1- und Dsg3EC4-spezifisches IgG induzierte die 
Dissoziation von Keratinozyten in einem vergleichbaren Ausmaß wie die 
Positivkontrolle, ein monoklonaler Antikörper gegen den NH2-Terminus von 
Dsg3 (AK23). Diese Technik wurde anschließend auf die Seren von vier 
atypischen, d.h. zwei Pemphigus Vegetans und zwei Pemphigus Herpetiformis 
Patienten, angewendet, um Dsc3-spezifisches IgG zu isolieren. Alle außer 
einem dieser Patienten, welcher zusätzlich Dsg1-reaktives IgG aufwies, zeigten 
ausschließlich Serum-Reaktivität gegen Dsc3 aber gegen kein anderes 
desmosomales Cadherin. Von allen vier Seren konnte Dsc3-reaktives IgG 
erfolgreich isoliert und die Antigenspezifität bestätigt werden. Die IgG-
Fraktionen zeigten ein charakteristisches interzelluläres Färbemuster in der IF 
auf kultivierten humanen Keratinozyten, Affenösophagus und humaner Haut 
und induzierten den Adhäsionsverlust epidermaler Keratinozyten in vitro. 
Zusammengefasst legen diese Daten nahe, dass auch IgG gegen COOH-
terminale Epitope des Dsg3, zusätzlich zu den bereits bekannten pathogenen 
NH2-terminalen Epitopen, einen akantholytischen Effekt aufweist. Die 
Erkennung COOH-terminaler Epitope ist  Ca2+-unabhängig, was im Einklang mit 
Ergebnissen vorheriger Arbeiten aus unserer Gruppe steht. Dsc3-reaktives IgG, 
isoliert aus Seren von atypischen Pemphigus Patienten, ist pathogen in vitro. 
Diese Untersuchungen zeigen erstmalig den akantholytischen Effekt von Dsc3-
reaktivem IgG und geben Hinweise auf die pathogene Relevanz von Dsc3-IgG 
in Seren von Pemphigus Patienten die keine Reaktivität gegen andere 
desmosomale Cadherine aufweisen. Weitere Untersuchungen sind nötig, um 
_______________________________________________________Zusamenfassung 
 
IX 
 
die Mechanismen zu untersuchen, die dem akantholytischen Effekt von auto-Ak 
gegen COOH-terminale Dsg3-Epitope zugrunde liegen. Zudem sollte die 
pathogene Relevanz anderer Epitope des Dsg3, besonders innerhalb der 
Dsg3EC5-Domäne, näher untersucht werden. Schließlich erscheint das 
Screening von Pemphigus Patienten hinsichtlich Dsc3-reaktiven IgG sehr 
vielversprechend, um weitere Erkenntnisse über mögliche Korrelationen mit 
atypischen Varianten des Pemphigus zu erhalten. 
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1 Introduction 
1.1 The skin 
1.1.1 Structure and functions 
The skin or cutis and its underlying layer consisting of connective and fatty 
tissue, the subcutis or tela subcutanea, together form the integumentum 
commune (Lüllmann-Rauch 2003). With a total surface area of 1.5 – 2m2 and a 
weight of 3.5 – 10kg it is the largest organ of the human body (Moll 2010). The 
skin is composed of three layers: right on top there is a squamous epithelium, 
i.e. the epidermis, followed by a part mainly composed of connective tissue, 
called dermis. At the bottom lies the subcutis which is mainly formed by lobules 
of fatty tissue (Fritsch 2009). Integral parts of the skin are the skin appendages 
including cornifying products (hairs and nails) as well as the skin glands 
(sebaceous and sweat glands) (Lüllmann-Rauch 2003). The epidermis is a 
cornifying, multilayered squamous epithelium whose cells regenerate every four 
weeks (Welsch 2003). It is tightly interlocked with the dermis at the undulant 
running dermo-epidermal junction zone by cone shaped extensions of the 
dermis, called papillae, which are interjected by rete ridges of the epidermis. 
This fact and abundance of collagen and elastic fibers in the dermis contribute 
to the strong mechanical resistance of the cutis (Lüllmann-Rauch 2003). 
Whereas the dermis is very well vascularised via terminal blood vessels, the 
epidermis is completely vessel-free. The subcutis mainly consists of univacuolar 
fatty tissue. It builds the connection between the cutis and deeper structures like 
the fasciae of muscles or the periost of bones. Furthermore it functions as a 
cushioning layer and facilitates the flexibility of the integumentum (Lüllmann-
Rauch 2003; Welsch 2003). The skin protects the body from mechanical 
trauma, high and low temperatures, dehydration, penetration of foreign animate 
and inanimate agents as well as ultraviolet radiation and finally builds the 
outermost part of the immune system (Fritsch 2009). Harbouring sensing 
organs the skin is able to perceive diverse stimuli from the environment and the 
complex vessel architecture together with the sweat glands makes it an 
important element of thermoregulation (Lüllmann-Rauch 2003). Finally the skin 
plays an essential role in the immune system of the body providing barrier 
functions like an acidic coverage as well as cellular and humoral immune 
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response mechanisms towards foreign organisms (Lüllmann-Rauch 2003; 
Welsch 2003). 
 
1.1.2 The epidermis 
The predominant cell type of this squamous epithelium is composed of 
keratinocytes, which form the different epidermal layers via their alternating 
phenotype (Lüllmann-Rauch 2003). In addition, there are pigment-producing 
melanocytes and neuroendocrine merkel cells, both immigrated from the neural 
crest. Finally bone marrow derived Langerhans cells play an outstanding role in 
the innate and adaptive immune system (Braun-Falco 2005).  
 
The epidermis can be subdivided into 4 different layers: 
 Stratum basale 
One layer of cubic cells directly connected to the basement membrane zone. 
It supports the epidermis with a permanent cell-supply deriving from clusters 
of stem cells that split frequently and migrate to higher levels. In healthy 
skin, mitosis takes place only within this area. 
 Stratum spinosum 
2-5 cell layers of polygonal shaped cells which received their name from 
spinous ectensions that contact neighbouring cells via desmosomes. Cells 
are filled with a mesh-work of keratin filaments that insert into desmosomes 
exerting mechanical strength.   
 Stratum granulosum 
About 3 layers of keratinocytes harbouring basophil keratohyalin granules 
that contain keratin filaments and Profillagrin important for the cornifying 
process. 
 Stratum corneum 
Uppermost layers composed of completely cornified cells that have lost their 
nucleus and any other organelle. They are disk shaped with a diameter of 
about 30µm and form 25 to 100 cell layers depending on the site of the body 
 
(Lippert 2003; Lüllmann-Rauch 2003; Welsch 2003). 
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The 3 lower layers are formed by living keratinocytes whereas the stratum 
corneum comprises dead corneocytes which are finally scaled off by 
succeeding cells from below. The complete turnover of the normal epidermis 
usually takes 28 days and from basal towards superficial layers keratinocytes 
undergo several differentiation steps (Lüllmann-Rauch 2003; Braun-Falco 
2005). Reaching complete cornification keratinocytes form a nearly water tight 
diffusion barrier (Welsch 2003). Keratinocytes harbour certain cell surface 
structures which mediate cell-adhesion taking place between adjacent cells and 
cells anchored to the extracellular matrix (Lüllmann-Rauch 2003; Welsch 2003). 
 
1.1.3 Cellular adhesion 
Adhesion is mediated by so called cell adhesion molecules (CAM) which are 
mainly transmembrane proteins and belong to different subfamilies, i.e 
cadherins, selectins, connexins or integrins each of them delivering cellular 
adhesion to different structures (Welsch 2003). Sites of cell-cell or cell-
extracellular matrix contact share a common feature: at the inner side of the 
involved plasma membrane there is a dense zone called plaque in which the 
cytoskeleton inserts (Franke 2009; Moll 2010). There are three major 
components: 
1. Transmembrane proteins, that establish binding to neighbouring cells or 
the extracellular matrix mediated by their extracellular domain. 
2. Plaque proteins, which mediate and stabilize cytoskeleton anchoring at 
the inner side of the plasma membrane. 
3. Filaments of the cytoskeleton, which belong to either intermediate or 
actin filaments depending on the type of contact.  
(Lüllmann-Rauch 2003; Franke 2009). 
 
Cell-cell and cell-matrix contacts with mechanical functions are: 
 Desmosomes / hemidesmosomes, insertion spot for intermediate filaments  
 Adherens junctions / focal contacts, insertion spot for actin filaments 
The transmembrane proteins of desomosomes and adherens junctions belong 
to the superfamily of calcium dependent adhesion molecules (cadherins) and 
bind to cadherins of adjacent cells (Lüllmann-Rauch 2003; Welsch 2003; 
Franke 2009; Moll 2010). Differences between these two contact types are 
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found within the structure, the types of cadherins (classical cadherins and 
desmosomal cadherins, respectively), the plaque proteins and the inserting 
filaments (Franke 2009). Important functions of cell adhesion include cell-cell 
identification in order to establish and maintain well regulated tissue structures, 
connection of the cytoskeleton to the cellular environment or temporary 
attachment of migrating cells. In addition many of the proteins involved are 
connected to intracellular signalling pathways via adaptor proteins and therefore 
are able to influence several functions such as cell proliferation and 
differentiation (Lüllmann-Rauch 2003). Keratinocytes are attached to each other 
by numerous desmosomes. Instead, the basal keratinocytes are anchored to 
the basement membrane zone via hemidesmosomes or focal contacts using 
integrins as CAMs (Welsch 2003). Both, desmosomes and hemidesmosomes 
are connected to the cytokeratin network (tonofilaments) which crosses the 
keratinocyte in various directions (Lüllmann-Rauch 2003). 
 
1.1.4 Desmosomes 
Desmosomes are dot-shaped, circumscribed intercellular junctions that are 
crucial to tissues which are subjected to mechanical stress like the stratified 
squamous epidermis, the myocardium, bladder, the mucous membranes or the 
arachnoidea mater (Delva et al. 2009; Franke 2009). These discoid junctions 
have a diameter of about 0,2-0,5µm and form an intercellular cleft of 24-30nm 
(Farquhar et al. 1963). Using electron microscopy there are three 
morphologically identifiable zones corresponding to overlapping/contacting sites 
of the different desmosomal proteins: An extracellular core region, an outer 
dense plaque and an inner dense plaque (both located intracellular) the latter 
being connected to the cytoskeleton network (Kelly 1966; Kelly et al. 1976) 
(figure 1.1). The architecture of a desmosome consists of three different types 
of proteins: desmosomal cadherins (trasmembrane proteins), as well as 
armadillo and plakin family members (plaque proteins) (Getsios et al. 2004; 
Garrod et al. 2008) (figure 1.1). Together they form a “half-desmosome” at the 
cell surface of one cell before finding its binding partner (another “half-
desmosome”) on the adjacent cell and depending on a sufficiently high Ca2+ 
concentration resulting in the generation of a functional desmosome (Garrod 
2010). The extracellular core region, sometimes called dense midline, is 
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supposed to be the site where cellular adhesion occurs mediated by 
desmosomal cadherins (Garrod et al. 2008). Desmosomal cadherins can be 
further subdivided into two separate subfamilies: desmogleins (Dsgs) and 
desmocollins (Dscs) (Nollet et al. 2000). The cytoplasmic tail of desmosomal 
cadherins interacts with members of the armadillo (plakoglobin and 
plakophilins) and plakin (desmoplakin) family of linker proteins thereby forming 
the outer dense plaque (Kowalczyk et al. 1994; Getsios et al. 2004). 
Plakoglobin directly binds to the cytoplasmic tails of both Dsgs and Dscs (Wahl 
et al. 1996; Witcher et al. 1996) and further interacts with desmoplakin (Cowin 
et al. 1996) which finally tethers the whole adhesion complex to the 
intermediate filament network of the cytoskeleton corresponding to the site of 
the inner dense plaque (Kowalczyk et al. 1994; Getsios et al. 2004; Garrod et 
al. 2008; Delva et al. 2009). A schematical illustration of the desmosomal 
architecture is shown in figure 1.1.  
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Figure 1.1: Molcular architecture of desmosomes. Schematic and electron microscopic 
picture of the molecular structure of a desmosome. Cadherin molecules span the intercellular 
space heading with their NH2-terminus (N) forming the dense midline (DM) the site where cell 
adhesion takes place. Desmosomal cadherins comprise desmoglein (DSG) and desmocollin’a’ 
and ‘b’ (DSC 'a' and 'b') isoforms. Further desmosomal proteins are plakoglobin (PG) which can 
interact with COOH-terminal (C) intracellular ends of DSG recognized by electron microscopy 
as the outer dense plaque (ODP), plakophilins (PKP) and the intermediate-filament (IF)-binding 
protein desmoplakin (DP) forming the inner dense plaque (IDP). Bar indicates relative distance 
(in nm) from the plasma membrane (PM) (Getsios et al. 2004). 
 
1.1.4.1 Desmosomal cadherins 
Desmosomal cadherins share multiple features with the classical cadherins 
found in adherens junctions. Both classical and desmosomal cadherins are type 
one integral membrane glycoproteins (Garrod et al. 2002). They contain 5 
extracellular subdomains (ECs): four cadherin repeats (EC1-4) of about 110 
amino acids, connected via calcium-sensitive flexible linkers, and a less related 
membrane proximal domain (EC5), sometimes called extracellular anchor 
domain (Pertz et al. 1999; Garrod et al. 2002; Dusek et al. 2007). A highly 
conserved, short amino acid sequence is present in the amino-(NH2 )-terminal 
EC1 subdomain of cadherins, the so called cell adhesion recognition (CAR) 
sequence which seems to be crucial for cell cohesion (Blaschuk et al. 1990). 
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Dsgs and Dscs share similarities in their cytoplasmic domains beginning with a 
juxtamembranuous anchor (IA) region that at least in the case of Dsc1 can 
interacts with desmoplakin (Troyanovsky et al. 1994b). Each Dsc-gene can be 
translated into two different forms by alternative splicing: An “a”-isoform with a 
cytoplasmic domain that is closely related to that of classical cadherins, and a 
shorter “b”-isoform lacking several carboxyterminal aminoacid-sequences 
(Collins et al. 1991) (figure 1.2). All Dsg- and Dsc”a”-isoforms contain a 
common intracellular cadherin typical sequence (ICS) which mediates binding 
to plakoglobin (Troyanovsky et al. 1994a). The Dsg isoforms have unique 
sequences further downstream of the cytoplasmic domain: an intracellular 
proline-rich linker (IPL) domain and a variable number of repeated-unit domains 
(RUD), followed by a glycine-rich desmoglein terminal domain (DTD) which 
forms the carboxyterminus (figure 1.2). The functions of these three domains 
however remain unclear (Getsios et al. 2004; Dusek et al. 2007). So far four 
desmoglein (Dsg1-4) and three desmocollin isoforms (Dsc1-3) are described 
and their genes are all clustered tightly on chromosome 18 (Cowley et al. 1997; 
Garrod et al. 2002; Whittock et al. 2003). Figure 1.2 gives a summary of the so 
far known desmosomal cadherins. The distribution pattern of the different 
isoforms varies according to the type of tissue. In the epidermis all seven 
desmosmal cadherins are present; however their genes are differentially 
expressed as keratinocytes undergo terminal differentiation (Delva et al. 2009). 
Dsg2 and Dsg3 can be found in the lower (basal and suprabasal) layers of the 
epidermis, whereas Dsg1 is present throughout the epidermis with much higher 
expression levels in the upper (subcorneal) layers (Kottke et al. 2006; Holthofer 
et al. 2007). Dsg4 is a major desmosomal component in the hair follicles and 
the granular layers of the epidermis (Kljuic et al. 2003). Dsc2 and Dsc3 like their 
desmoglein namesakes are expressed in the basal and spinous epidermal 
layers. And finally Dsc1 expression is most abundant in the granular layers 
(Kottke et al. 2006; Holthofer et al. 2007). However the expression pattern of 
desmosomal cadherins in non-cornifying stratified epithelium of the mucous 
membranes differs in respect to the epidermis. Here, Dsg3 is the predominant 
Dsg-isoform and can be found throughout all epithelial layers (Mahoney et al. 
2006). These distribution patterns of desmsosomal cadherins are very important 
to keep in mind since the impaired or abolished function of only one Dsg or Dsc 
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molecule can lead to pathogenic effects that may be restricted to certain sites in 
the epidermis. This issue will be discussed later in more detail.  
 
 
Figure 1.2: Structure of human desmosomal cadherins. The so far known human 
desmosomal cadherins comprise four desmoglein (Dsg1–4) and three desmocollin (Dsc1–3) 
genes which are found on the long arm of chromosome 18 (18q12). Desmosomal cadherins are 
type one integral membrane glycoproteins and harbor four highly conserved extracellular 
subdomains (EC1–4) and a more variable extracellular anchor (EA) also called EC5 domain. 
After a single transmembrane domain (TM) follows an intracellular anchor (IA) and depending 
on the type of cadherin additional cytoplasmic subdomains. The cell adhesion recognition 
(CAR) site is found within the EC1 subdomain (asterisks) mediating the adhesive function of the 
desmosomal cadherins. Dsc'a' and 'b' isoforms, as well as the Dsgs contain an intracellular 
cadherin-typical sequence (ICS). DSC isoforms however harbor a shorter cytoplasmic region 
that contains unique sequences (purple). Finally, desmoglein proteins possess an extended 
cytoplasmic region downstream of the ICS comprising an intracellular proline-rich linker domain 
(IPL), a variable number of repeated-unit domains (RUD) and a desmoglein-specific terminal 
domain (DTD). However, the function of these last three domains remains unclear at the 
moment (Getsios et al. 2004).   
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1.1.4.2 Desmosome assembly 
Desmosomes represent very stable however not static structures. They underlie 
permanent changes of their cadherin repertoire also called cadherin trunover. 
Cadherins are constantly synthesized as propeptides and delivered to the 
plasma membrane through the classical secretory route (Green et al. 2010). 
Before reaching the cell surface they are processed via a furin-dependent 
mechanism, probably to prevent premature intracellular adhesion (Posthaus et 
al. 1998; Muller et al. 2004; Yokouchi et al. 2009). At the cell surface cadherins 
can be incorporated into existing desmosomes or may form new cell-cell 
contacts. In response to de novo cell contact or an elevation of extracellular 
calcium, cadherins cluster and become stabilized (Green et al. 2010). 
Desmosomal membrane and plaque proteins are delivered separately to the 
cell surface where they assemble to form an intact desmosome. In particular, 
desmoplakin is found at the cell membrane attached to intermediate filaments 
shortly after two adjacent cells get into contact. Groups of several cadherins 
then associate with desmoplakin allowing formation of cadherin transdimers and 
later incorporation into mature desmosomes (Green et al. 2007). Desmosomal 
and non-desmosomal cadherin transdimers are involved in cellular adhesion 
and may represent different targets in disease (Muller E.J. et al. 2008). In vitro 
studies on human keratinocytes suggest that in low-calcium-medium (LCM) 
desmosomal proteins form half desmosomes that are transported to the cell 
surface where they are unable to participate in adhesive binding and are 
therefore internalized and degraded leading to a short half-life (Penn et al. 
1987; Demlehner et al. 1995). However when the extracellular calcium 
concentration is raised adhesion is triggered and desmosomes assemble at cell 
interfaces (Watt et al. 1984). A calcium concentration of 1mM is necessary to 
convert the extracellular cadherin domains from a clustured to a more 
extended/rigidified, adhesion competent configuration (Garrod 2010). 
 
1.1.4.3 Mediating adhesion 
Different ways of cadherin-cadherin interaction have been described. 
Intermolecular binding of two cadherin molecules on the same cell surface is 
called cis interaction, whereas between adjacent cells trans interaction (He 
et al. 2003; Getsios et al. 2004). Al-Amoudi and colleagues found two 
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predominant Dsg-interactions, which are presumably confined to the EC1 
regions: A most favorable trans, W-shaped interaction between molecules 
emanating from opposing cell surfaces where a highly conserved amino-
terminal tryptophan residue inserts into a hydrophibic pocket of the cell 
adhesion recognition-(CAR)-site of the corresponding cadherin forming an 
adhesive dimer of adjacent cells (Boggon et al. 2002; Al-Amoudi et al. 2007). 
The importance of this interaction has been shown by several studies where 
artificially synthesized peptides or antibodies targeting the CAR-site were able 
to block desmosomal adhesion (Tselepis et al. 1998; Runswick et al. 2001). The 
second EC1-mediated interaction has a cis, V-shaped appearance and occurs 
between molecules emanating from the same cell membrane leading to lateral 
dimerization which is considered a fundamental determinant of cell adhesion 
(He et al. 2003). Finally, densities observed at the positions close to the 
interdomain EC4-EC5 region suppose another cis interaction between proximal 
regions of neighboring molecules (Al-Amoudi et al. 2007). The EC1 subdomain 
of desmosomal cadherins seems to play an outstanding role in maintaining 
intercellular adhesion since targeting of the predicted binding motif of the EC1 
domain of Dsg3 by a monoclonal antibody (AK23) is pathogenic in vivo 
(Tsunoda et al. 2003). In contrast to classical cadherins which exclusively 
undergo homophilic interactions, desmosomal cadherins are able to interact 
both homophilically and heterophilically. Homophilic binding of Dsg2, Dsc2 and 
Dsg3 was shown to occur in vitro as well as hetreophilc interactions between 
Dsg2 and Dsc1 or Dsc2 (Amagai et al. 1994b; Syed et al. 2002). However 
binding of Dsg1 to Dsg3 has been ruled out (Heupel et al. 2008). Using atomic 
force miscroscopy (AFM) and lazer tweezer experiments Spindler et al. found 
evidence which suggest that heterophilic binding of Dsgs and Dscs may induce 
an even stronger intercellular adhesion compared to homophilic interactions 
(Spindler et al. 2009). All these findings support an outstanding role of 
demsosomes in mediating cellular adhesion, especially in the epidermis.  
 
1.2 From desmosome to disease 
The first evidence for the involvement of disrupted desmosomal adhesion in the 
pathogenesis of a blistering skin disease evolved from findings in the early 
1960s. Beutner and colleagues using immunofluorescence (IF) studies on 
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human skin detected circulating IgG auto-antibodies in sera of patients suffering 
from a blistering skin disease called pemphigus vulgaris (PV) which were 
directed against the cell surface of keratinocytes (Beutner et al. 1964; Beutner 
et al. 1965). Pemphigus derives from the Greek word “pemphix” meaning blister 
and stands for a group of chronic autoimmune blistering diseases of the skin 
and mucous membranes, characterized by intra-epidermal split formation 
(Lever 1953). The knowledge about the pathophysiologic backround of this 
relatively rare disease was very limited so far. According today’s knowledge, 
auto-antibodies of the IgG subclass are supposed to be the key players in the 
pathogenesis of PV by inducing loss of cell-cell adhesion, a process called 
acantholysis (Amagai 2010). This knowledge has been profoundly shaped by 
works from Schiltz and Anhalt in 1976 and 1982, respectively, which revealed 
the pathogenic effects of patients’ IgG in vitro and in vivo (Schiltz et al. 1976; 
Anhalt et al. 1982). More precisely, purified PV-auto-Abs were added to human 
skin cultures leading to a histological appearance indistinguishable from that of 
PV-lesions, i.e. extensive epidermal acantholysis of basal and suprabasal 
layers and IgG binding in an intercellular pattern at the site of blister formation 
(Schiltz et al. 1976). Furthermore, when injected intraperitoneally into neonatal 
mice, PV-IgG caused cutaneous blisters and erosions with ultrastructural and IF 
features resembling pemphigus in a dose dependent manner (Anhalt et al. 
1982). Subsequently enormous effort was put into the identification of the auto-
antigens detected by PV-IgG. Stanley et al. showed that sera from 5 out of 7 PV 
patients were able to specifically immunoprecipitate a 130kDa molecule from 
keratinocyte cell lysates which shared features of a membrane glycoprotein 
(Stanley et al. 1982). In addition, two years later the same group identified 
another molecule immunoprecipitated by sera from pemphigus foliaceus (PF) 
patients, a clinical subtype of pemphigus distinct from PV. This 160kDa protein 
could not be precipitated by PV sera indicating two different antigen specificities 
in line with the different clinical appearance of PV and PF (Stanley et al. 1984). 
Eyre et al. demonstrated biochemical similarities between the now called PV- 
and PF-antigen (PVA and PFA), i.e. PVA and PFA both seem to be cell surface 
glycoproteins, have the same isoelectric point and are capable of disulfide 
linkage to a 85kd polypeptide (later identified as plakoglobin (Cowin et al. 
1986)). Immunoprecipitated PVA and PFA could be obtained from cultured 
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human keratinocytes and from human skin extracts, respectively (Eyre et al. 
1988). Hashimoto et al. confirmed these results using immunoblot (IB) analysis. 
Nearly all PV sera but none of the PF sera were able to detect the 130kDa PVA, 
whereas sera from PF patients partially reacted with a 150kDa protein, most 
likely Dsg1, thereby introducing immunobloting as a method to routinely 
differentiate PV- and PF-Abs (Hashimoto et al. 1990). Jones and colleagues 
were able to demonstrate that PV and PF sera recognize desmosomes using IF 
and IB analysis of cell free desmosome preparations suggesting that PVA and 
PFA most likely play important roles in the adhesion of cells (Jones et al. 1986a; 
Jones et al. 1986b). Finally isolation of certain desmosomal proteins using 
monoclonal antibodies or PV/PF sera, respectively, and subsequent 
identification of their corresponding cDNA revealed that target antigens in 
pemhigus are desmogleins, namely Dsg1 and Dsg3 (Eyre et al. 1987; Koch et 
al. 1990; Amagai et al. 1991). The identification of Dsg3 as the target antigen in 
PV was a milestone in research on autoimmune bullous skin disorders since the 
presence of auto-Abs against desmosomal cadherins in pemhigus patients and 
the clinical appearance of mucocutaneous blisters could now be explained. 
These and other findings lead to the picture of pemphigus as a paradigm of an 
auto-ab mediated autoimmune disease. In order to get a better understanding 
of the clinical characteristics of this autoimmune disease the different 
pemphigus phenotypes will be subsequently described in more detail.  
 
1.2.1 Clinical subtypes of pemphigus 
Pemphigus can be subdivided according to the clinical and histological 
phenotype of the patients, i.e. the site of blister manifestation and the level of 
intraepithelial split formation (Mahoney et al. 1999a). The majority of pemphigus 
cases belong to three major subtypes, namely pemphigus vulgaris (PV), 
pemphigus foliaceus (PF) and paraneoplastic pemphigus (PNP) (Kneisel et al. 
2011a). Furthermore there are rare and/or atypical pemphigus variants like IgA 
pemphigus, pemphigus herpetiformis, pemphigus erythematosus or pemphigus 
vegetans. They share certain antigenic targets as well as clinical and 
histological findings with the three major pemphigus variants (Hertl 2005) (see 
table 1.1). 
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1.2.1.1 Pemphigus vulgaris 
Although being the most common pemphigus subtype PV is still a rare disease 
with an incidence of about 0.1 to 0.5 per 100,000 (Hertl et al. 2001b). It primarily 
affects individuals in the third to fifths decade without sex preference (Hertl 
2005). The clinical picture of PV is characterized by painful erosions of the 
mucous membranes and the skin. Early Lesions can present as flaccid, fraglile 
walled blisters on erythematous ground which rupture easily leading to sharply 
outlined erosions that heal without scarring (Hertl 2005; Amagai 2010). 
Histologically, blister formation in PV occurs in the deep epidermis/mucosa 
caused by split formation between the basal and suprabasal keratinocyte layers 
(Mahoney et al. 1999a). Most of the PV patients exhibit involvement of the oral 
and pharyngeal mucosa, called mucosal dominant type, however other mucous 
membranes like the esophagus, conjunctiva, nasal mucosa, vagina, penis, anus 
and labia maybe involved as well (Amagai 2010). Chronic painful lesions of the 
mouth and pharynx can lead to reduced food or drink intake, hoarseness and 
difficulty in swallowing (Amagai 2010). On disease progression lesions can 
spread to the skin with a preferential involvement of the trunk resulting in a 
mucocutaneous PV type (Hertl 2005). According to the site of blister formation 
patients with exclusive mucous membrane involvement exhibit IgG 
autoantibodies against Dsg3 whereas appearance of mucocutaneous lesions 
correspond to a mixed anti-Dsg3/anti-Dsg1 antibody profile measured by ELISA 
using recombinant Dsg1/3 (Amagai et al. 1999b). Skin blisters can be induced 
by applying mechanical stress on healthy-appearing epidermis, a phenomenon 
called Nikolsky sign (Hertl et al. 2001b). Prior to the introduction of 
immunosuppressive therapies the prognosis of PV used to be fatal (75% died 
within a year) since the chronically disturbed barrier function of the skin and 
mucosa can lead to profound dehydration and bacterial superinfections, the 
latter still remains a serious clinical problem (Hertl 2005; Murphy et al. 2008; 
Amagai 2010). 
 
1.2.1.2 Pemphigus foliaceus 
In contrast to PV, PF predominantly affects the epidermis of the seborrheic 
areas, including the face, scalp and upper trunk. Lesions appear as scaly, 
crusted and well demarcated erosion often on an erythematous base (Amagai 
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2010). Another difference in relation to PV is the fact that splitting occurs 
between the upper granular layers of the epidermis (Mahoney et al. 1999a). PF-
patients express IgG auto-antibodies against Dsg1 only (Amagai et al. 1999b), 
however a positive Nikolsky sign can be seen in PF as well. In very severe 
cases lesions can spread to nearly the whole integument resulting in 
erythrodermic exfoliative dermatitis (Hertl 2005; Waschke 2008; Amagai 2010). 
An endemic variant of PF is fogo selvagem which is most endemic in distinct 
regions of Brazil (Diaz et al. 1989). It is clinically indistinguishable from PF 
however the endemic appearance suggests that environmental factors initiate 
the autoantibody response in the host. Fogo selvagem seems to be an 
infectious disease, since it can be initiated by the bite of the black fly, which is 
thought to function as a vector for a so far unknown infectious organism or virus 
(Diaz et al. 1989). Recently however, Brazilian pemphigus foliaceus anti-
desmoglein 1 autoantibodies have been shown to cross-react with a sand fly 
salivary antigen supporting the hypothesis of molecular mimicry (Qian et al. 
2012). 
 
1.2.1.3 Paraneoplastic pemphigus 
PNP usually occurs in patients with an underlying neoplasm, mainly B-cell 
lymphoma (Hertl 2005). It is characterized by painful mucosal ulcerations and 
polymorphous skin lesions usually with progression to blistering eruptions on 
the trunk and extremities like erythematous macules, flaccid blisters and 
erosions, tense blisters, erythema multiforme like lesions, and lichenoid 
eruptions (Anhalt et al. 1990). The most constant clinical feature is a severe 
stomatitis that in the majority of cases presents as the first sign and 
characteristically extends to the vermillion of the lips. It presents with erosions 
and ulcerations and is very resistant to therapy (Amagai 2010). Contrary to PV 
and PF patients with PNP may present with involvement of lung epithelium 
leading to progressive respiratory failure (bronchiolitis obliterans) and is 
therefore the only pemphigus form affecting non-stratified squamous epithelium 
(Nousari et al. 1999; Amagai 2010). Lung involvement accounts for up to 30% 
of the terminal complications in PNP (Nousari et al. 1999). Like the clinical 
appearance the histologic findings are very heterogeneous. Keratinocyte 
necrosis and acantholysis may occur in various levels of the involved epithelia. 
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PNP-patients can develop IgG-auto-Abs against almost every desmosomal, 
hemidesmosomal as well as plaque-protein (Hertl 2005; Waschke 2008; 
Amagai 2010).  
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Table 1.1: Different clinical pemphigus variants. 
 
 
Pemphigus variant 
(representative clinical picture) 
Target antigen 
Clinical 
Phenotype 
Histology/DIF 
 
Pemphigus vulgaris 
 
 
 
desmoglein 3 
desmoglein 1 
 
 
 
 
 
 
flaccid blisters, 
painful erosions, 
erythematous skin 
(skin + mucous 
membranes) 
a) mucosal 
dominant 
b) mucocutaneous 
 
IgG deposits at 
basal/suprabasal 
levels of the 
epidermis, 
suprabasal split 
formation 
 
 
Pemphigus foliaceus 
 
 
desmoglein 1 
 
 
scaly crusted 
erosions on 
erythematous 
ground, sebborheic 
distribution (only 
skin) 
 
Subcorneal IgG 
deposits + 
subcorneal split 
formation 
 
Paraneoplastic 
pemphigus 
 
 
desmoplakins I,II 
BP230 
desmoglein 1 
desmoglein 3 
periplakin/envoplakin 
HD1/plektin 
 
Mucosal ulcers + 
polymorphic skin 
lesions (blisters, 
erosions, macules), 
severe stomatitis, 
involvement of lung 
epithelium  
bronchiolitis 
obliterans 
(skin and mucous 
membranes) 
 
IgG deposits on 
entire epidermal 
cell surfaces +/- 
granular linear 
complement 
deposition along 
basement 
membrane zone; 
suprabasilar 
intraepithelial 
acantholysis, 
keratinocyte 
necrosis, 
vacuolar-interface 
change 
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Pemphigus variant 
(representative clinical picture) 
Target antigen 
Clinical 
Phenotype 
Histology/DIF 
 
Pemphigus vegetans 
 
 
desmocollins 
cholinergic receptor 
pemphaxin 
α9 acetylcholine 
receptor 
 
blisters + 
pustules, 
verruciform + 
papillomatous 
vegetations (skin 
 intertriginous 
areas), PV-like 
oral lesions 
 
Pustules and 
flaccid blisters; 
vegetations on 
erosive ground; 
hyperkeratotic 
plaques 
 
IgA pemphigus 
-  intraepidermal 
neutrophilic IgA 
dermatosis (IEN) type 
 
 
- subcorneal pustular 
dermatosis (SPD) type 
 
desmoglein 1 
desmoglein 3 
 
 
 
 
 
 
 
 
 
 
 
desmocollin 1 
 
Pruritic, flaccid 
vesicles and/or 
pustules in an 
annular pattern 
with central 
crusting, 
sometimes 
hypopyon 
(skin + rarely 
mucous 
membranes) 
 
- IEN type: 
suprabasal 
pustules, 
neutrophil 
infiltration, scanty 
acantholysiss; IgA 
deposits in lower 
or entire 
epidermal cell 
surfaces 
 
 
 
- SPD type: 
subcorneal 
pustules, 
neutrophil 
infiltration, scanty 
acantholysis; IgA 
deposits on upper 
epidermal cell 
surfaces 
 
 
 
____________________________________________________________Introduction 
 
18 
 
 
 
 
 
Pemphigus variant Target antigen 
Clinical 
Phenotype 
Histology/DIF 
 
Pemphigus 
herpetiformis 
 
desmoglein 1 
desmoglein 3 
 
 
pruritic, 
erythematous, 
vesicular, bullous, 
or 
papular lesions, 
herpetiform 
pattern 
(skin + 
occasionally 
mucous 
membranes) 
 
Eosinophilic 
spongiosis +/- 
acantholysis, 
intaepidermal 
pustules filled with 
eosinophils or 
neutrophils; 
IgG deposits in 
upper or entire 
epidermal cell 
surfaces 
 
Pemphigus 
erythematosus 
 
desmoglein 1 
 
Sharply 
demarcated 
erythematous 
plaques with 
scaling 
(Skin of face and 
upper trunk) 
 
IgG and C3 
deposits along the 
dermoepidermal 
junction zone 
similar to lupus 
erythematosus 
 
Shown are clinical pictures and characteristics, known or suspected antigens, histopathological 
and immunofluorescence findings of the different clinical pemphigus variants. Adapted from 
(Robinson et al. 1999; Hertl 2005; Hertl et al. 2010; Kneisel et al. 2011a; Oktarina et al. 2012). 
Pictures (Kneisel et al. 2011a). DIF = direct immunofluorescence. C3 = complement component 
C3. 
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1.2.2 Auto-antibody profiles 
Dsg1 and Dsg3 auto-antibody titers usually correlate with disease activity in 
pemphigus when measured by ELISA using recombinant proteins (Ishii et al. 
1997). However, in some cases correlation between antibody titers and clinical 
phenotype was not found (Kwon et al. 2008). In PV pathogenic auto-Abs are 
polyclonal and initially belong to the IgG4 subclass which is unable to activate 
the classical complement pathway. During disease progression patients can 
develop additional anti-Dsg3 IgG1 titers with occasional appearance of IgA and 
IgE antibodies. Patients in remission mainly express low titers of Dsg3-reactive 
IgG1, highlighting IgG4 as the main pathogenic subclass in PV indicating a cell-
independent directly pathogenic capacity (Bhol et al. 1995; Spaeth et al. 2001; 
Hertl et al. 2010). Finally a work examining the Th2-response in pemphigus 
patients has shown that acute onset PV is correlated with the occurrence of 
Dsg3-reactive IgG4 and IgE, respectively (Nagel et al. 2010).  
 
1.2.3 Knowledge from mice 
To study the function of single desmosomal cadherins a very elegant approach 
is to use genetically engineered knockout (KO)-animal models. In a KO-mouse 
a certain gene has been turned off through targeted mutations, indicated as: 
gene-/- , leading to the inability of these mice to express the gene product from 
the time point of fertilization. Subsequently the putative phenotypic effects of a 
targeted gene deletion can be studied macroscopically and microscopically. 
Conditional KO-models lead to the abrogated expression of a molecule 
restricted to a certain site of the organism or tissue, for example the skin. 
Several groups investigated the effects of targeted gene deletion of 
desmosomal cadherins in mice. Table 1.2 gives an overview of the established 
KO-mice. In line with the topic of this dissertation the gene deletions of Dsg3 
and Dsc3 are of particular interest. Works by Koch and colleagues in 1997 and 
1998 clearly demonstrated that Dsg3-/- -mice developed oropharyngeal 
inflammatory erosions by day 8-10 after birth as well as muscosal lesions 
exhibiting suprabasilar acantholysis with separation of desmosomes leading to 
a runted phenotype mainly due to reduced food intake (Koch et al. 1997). In 
adult mice lack of Dsg3 caused a patchy telogen hair loss and histological 
examination of the hair follicles revealed acantholysis between the cells 
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surrounding the telogen club and the basal layer of the outer root sheath 
epithelium (Koch et al. 1998). These data indicated an important role for Dsg3 
in maintaining cellular adhesion at certain sites of the mucous membranes as 
well as providing the anchorage of telogen hair in the epidermis via 
desmosomal adhesion (Koch et al. 1997; Koch et al. 1998). In addition the 
phenotype of these mice was very similar to the mucosal lesions found in the 
human autoimmune blistering disease pemphigus vulgaris (Koch et al. 1997). 
Den et al. showed that complete deletion of Dsc3 leads to embryonic death in 
mice before implantation can take place (Den et al. 2006). Furthermore most 
mutants died before mature desmosomes were formed suggesting the 
importance of Dsc3 in early embryonic development (Den et al. 2006). A work 
by the same group in 2008 developed a conditional Dsc3 KO-mouse where 
Dsc3 gene inactivation is exclusively restricted to stratified epithelia using a 
K14-Cre transgene which is constitutively active in the basal layer of the 
epidermis beginning at embryonic day 14 (Chen et al. 2008). About 10% of 
these mice developed severe epidermal blistering within hours after birth and 
further lesion could be induced by mild mechanical stress. However these 
lesions were all restricted to the skin and microscopically revealed 
ancantholysis just above the basal cell layer and appearance of half 
desmosomes (Chen et al. 2008). Keratinocytes isolated from mutant mice 
showed significantly reduced adhesion properties in vitro. Finally mice that 
reached adulthood developed severe skin erosions and telogen hair loss (Chen 
et al. 2008). Taken together Dsg3 and Dsc3 seem to have profound influence 
on proper cellular adhesion in stratified epithelia and their Absence can 
independently lead to intraepidermal/-mucosal splitting of the basal and 
suprabasal epidermal keratinocytes.  
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Table 1.2: Desmoglein and desmocollin knock out mouse models. 
KO-Gene Author Phenotype (mouse) 
Dsc1 Chidgey et al. 
2001 
Epidermal flaking, defective barrier function, 
hyperproliferation, and granular layer acantholysis 
Dsc3 Den et al. 
2006 
Leathal before implantation 
Dsc3 
(conditional) 
Chen et al. 
2008 
Intraepidermal blistering in newborn; weak cell 
adhesion between mutant keratinocytes; skin 
erosions in adults; telogen hair loss,  
Dsg2 Eshkind et al. 
2002 
Lethal shortly after implantation; decreased 
proliferation of embryonic stem cells 
Dsg3 Koch et al. 
1997, 1998 
Runting, erosions of oral mucosa, supra-basilar 
epidermal acantholysis, patchy hair loss 
Dsg4 
(spontaneous) 
Kljuic et al. 
2003 
Defective hair keratinization and premature 
differentiation of keratinocytes with 
hyperproliferation 
 
Summarised are the established desmoglein (Dsg) / desmocollin (Dsc) knock out (KO) mouse 
models and their corresponding phenotypes. Adapted from (Green et al. 2007) 
 
1.3 Pemhigus pathogenesis 
The best characterised auto-antigens in pemphigus are Dsg1 and Dsg3 
(Stanley et al. 1984; Eyre et al. 1988; Hashimoto et al. 1990; Karpati et al. 
1993). Compelling evidence is available supporting the opinion that Dsg3-
/Dsg1-specific auto-Abs alone are sufficient to induce acantholysis in vitro and 
in vivo, without help of the complement system or proinflammatory leukocytes 
(Anhalt et al. 1982; Takahashi et al. 1985; Amagai et al. 1992). Using the 
neonatal mouse model of pemphigus (established by Anhalt and colleagues 
1982) affinity-purified human Dsg1- and Dsg3-specific auto-Abs have been 
proven to induce a blistering PV-like phenotype when injected intraperitoneally 
into newborn mice; injection of human IgG from healthy individuals had no 
pathologic effect at all (Anhalt et al. 1982). Furthermore preincubation of PV 
sera with recombinant Dsg1 and Dsg3, respectively, abolished their pathogenic 
ability in this passive transfer assay showing that the injection of antigen-
specific pathogenic antibodies alone is sufficient to induce blisters in vivo 
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(Amagai et al. 1992; Amagai et al. 1994a; Amagai et al. 1995a). Studies by 
Amagai and colleagues in 2000 provided the first active mouse model for PV 
using the Dsg3-KO-mouse established by Peter Kochs’ group (Koch et al. 1997; 
Amagai et al. 2000b). In detail: Dsg3-deficient mice were immunized by multiple 
intraperitoneal injections of recombinant Dsg3 leading to the production of anti-
Dsg3 IgG titers. Splenocytes of these immunized mice were subsequently 
adoptively transferred into Dsg3 expressing recombination activating gene 2 
(Rag-2)-/- recipient mice which lack the ability to produce an own T cell or B cell 
repertoire and therefore accept adoptive transfer of foreign immune cells. Anti-
Dsg3 IgG was stably produced up to 6 months in the recipient mice without 
further boostering. Furthermore the Rag-2-/- mice developed lesions of their 
mucous membranes, like oral erosions, that strongly resembled PV lesions in 
humans and the Dsg3-/- phenotype (Amagai et al. 2000b). Further analysis of 
this disease model revealed that transplantation of both autoreactive T and B 
cells (which lost self-tolerance against Dsg3) from immunized Dsg3-/- animals 
are necessary to induce a PV-like phenotype in the recipient mice (Tsunoda et 
al. 2002). Even adoptive transfer of splenocytes from non-immunized Dsg3-/- 
mice induced a stable production of anti-Dsg3-IgG in Rag-2-/- recipient mice 
(Aoki-Ota et al. 2004). Together these findings show that impaired Dsg3-
mediated adhesion either by mere Absence of Dsg3 in KO-mice or targeted via 
anti-Dsg3 IgG in an active mouse model can lead to a blistering phenotype in 
mice highly reminiscent of PV.  
 
1.3.1 Cellular autoimmunity in pemphigus 
Since the production of (auto-)antibodies by B cells requires the help of CD4+ T 
helper lymphocytes (Th cells) the latter have been investigated according their 
pathogenic role in pemphigus. Hertl et al. proposed a crucial role for 
autoreactive CD4+ T lymphocytes that recognize distinct epitopes of the Dsg3 
ectodomain in initiating the autoimmune response. These T cells share a Th2 
phenotype and secrete the interleukins (IL) IL-4, IL-5 and IL-13 upon Dsg3-
stimulation in vitro probably leading to the production of anti-Dsg3 IgG4 (Hertl et 
al. 2006) (figure 1.3). Especially IL-4 but not IL-10 seems to be the driving force 
in this process (Takahashi et al. 2008). However the appearance of 
autoreactive Th1 cells in PV patients has been reported as well (Hertl et al. 
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2006). Dsg3-reactive CD4+ T-cells in peripheral blood of PV patients vary in 
their frequencies within the different stages of disease. Autoreactive Th2 cells 
are predominantly present in acute onset and remittent PV, whereas Dsg3-
reactive CD4+ T-cells expressing a Th1 phenotype exceed the number of Th2 
cells in chronic active disease (Eming et al. 2000). These findings support a 
concept of auto-ab control in PV by Dsg3-reactive Th1 cells leading to the 
production of Dsg3-reactive IgG1 and on the other hand by Th2 cells inducing 
secretion of Dsg3-reactive IgG4 and IgE, which is preferentially seen in active 
stages of PV (Bhol et al. 1995; Spaeth et al. 2001; Nagel et al. 2010). PV is 
associated with certain human leukocyte antigen (HLA) class II alleles, namely 
HLA-DRB1*0402 and HLA-DQB1*0503 alleles (Hertl et al. 2006) (figure 1.3). 
However expressing these alleles does not implicate the onset of disease since 
carriers of these alleles which may harbour autoreactive Th clones do not 
necessarily develop a phenotype (Veldman et al. 2004b). Th1 and Th2 cell 
recognition of Dsg3 peptides seems to be restricted by PV-associated  HLA-
DRB1*0402 and/or HLA-DQB1*0503 alleles, since anti-HLA-DR and anti-HLA-
DQ-antibodies blocked the proliferative response of autoreactive Th-cells 
(Veldman et al. 2003; Hertl et al. 2006). Furthermore, Dsg3 reactive Th1 and 
Th2 clones from PV-patients and HLA-matched healthy donors recognized, in 
association with the aforementioned HLA class II alleles, a limited set of 
immunodominant Dsg3 peptides indicating that loss of tolerance needs to take 
place on the T cell and B cell level  (Veldman et al. 2004b). Nishifuji and 
colleagues discovered Dsg3-specific IgG producing B-cells in peripheral blood 
mononuclear cells of PV patients. IgG production of these cells seemed to be 
dependent on the presence of HLA class II-restricted autoreactive CD4+ T cells 
(Nishifuji et al. 2000). Direct interaction of Dsg3-reactive CD4+ T cells and B 
cells seems to be very important for the production of Dsg3-specific auto-Abs in 
vivo. Using the active PV mouse model, Dsg3-IgG production could be blocked 
by injection of anti-CD154 monoclonal antibody which interferes with interaction 
of activated CD4+ Th cells and B cells (Yokoyama et al. 2010). Finally 
immunization of transgenic mice expressing human PV-associated HLA class II 
alleles and human CD4 receptor with recombinant human Dsg3 induced Dsg3-
specific CD4+ T cell responses and Dsg3-reactive antibody production (Hertl et 
al. 2006). Autoreactive T and B cells which escaped central tolerance 
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mechanisms in the thymus and bone marrow are thought to be controlled by 
certain peripheral T cell subsets with suppressive functions in healthy 
individuals, a process called peripheral tolerance (Murphy et al. 2008). These 
regulatory T cells (Treg) are composed of two major subsets: the forkhead box 
P3 (Foxp3) expressing, CD4+CD25+ naturally occurring regulatory T-cells 
(nTregs) and inducible, IL10 and transforming growth factor ß (TGF-ß) secreting 
Tr1 cells (Hertl et al. 2006; Murphy et al. 2008). The latter can be further 
subdivided into Foxp3+ adoptive or inducible regulatory T cells (iTreg), IL-10-
secreting T-inducible regulatory type 1 (Tr1) cells, and TGF-ß producing Th3 
cells (Yokoyama et al. 2010). Veldman et al. showed that Dsg3-reactive, IL10- 
and TGF-ß-secreting T cells (Tr1 phenotype) were present in the majority of 
healthy carriers of PV-associated HLA class II alleles, but in less than 20% of 
the studied PV patients (Veldman et al. 2004a). These cells were capable of 
cell-independent suppression of Dsg3-specific autoreactive Th1 and Th2 
effector cells in vitro by secretion of IL10 and TGF-ß indicating a protective 
function of these cells in healthy individuals (Veldman et al. 2004a). 
Furthermore there is some evidence that conversion from a Th into a Tr1 
phenotype might be obtained via cell-cell contact with naturally occurring CD4+ 
CD25+ Tregs again underlining a possible protective role for these regulatory 
cells (Veldman et al. 2006a). In line with this Sugiyama demonstrated that the 
peripheral numbers of CD4+ CD25(high) regulatory T cells are remarkably 
reduced in patients with PV (Sugiyama et al. 2007) and a possible imbalance 
between autoreactive Th2 cells and Dsg3-reactive Tr1 cells in PV patients has 
been proposed by Veldmann and colleagues (Veldman et al. 2004a). Taken 
together there seems to occur a dysregulation of Dsg3-specific Th1, Th2 and 
Treg responses in PV, with Th2 responses mainly leading to disease and 
protective Treg activity predominating in healthy individuals carrying PV-
associated HLA class II alleles (Hertl et al. 2006). Figue 1.3 gives a synopsis of 
the proposed T and B cell involvement in the pathogenesis of pemphigus. 
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Figure 1.3: Role of T cells in the pathogenesis of PV. Impaired desmosomal adhesion 
leading to intraepidermal split formation primarily caused by auto-antibodies against Dsg3 and 
Dsg1 represents the hallmark in the pathogenesis of pemphigus vulgaris. Most auto-antibodies 
belong to the IgG4 and IgG1 subclasses. Autoreactive Th1 and Th2 cells which recognize 
epitopes of Dsg3 in association with the human leukocyte antigen (HLA) class II alleles HLA-
DRβ1*0402 and HLA-DQβ1*0503 are presumably activated by antigen presenting cells (APC) 
leading to the production of auto-antibodies by autoreactive B cells. Interestingly, PV-associated 
HLA class II alleles are also found in healthy individuals who in addition harbour higher numbers 
of Dsg3-reactive type 1-regulatory (Tr1) cells thus suggesting a critical role of these cells in 
maintaining peripheral B cell tolerance to Dsg3 (Hertl et al. 2006). TCR = T cell receptor. 
 
1.3.2 Disrupting adhesion of epidermal keratinocytes 
Up to now, it remains unclear how auto-Abs induce loss of desmosomal 
adhesion. Three different pathophysiologic mechanisms have been proposed 
so far. Before the knowledge about pathogenic auto-Abs in pemphigus was 
available a favourable hypothesis was that proteolytic cleavage of cell adhesion 
molecules leads to skin blistering (Farb et al. 1978; Hashimoto et al. 1983; 
Amagai et al. 2000a; Cirillo et al. 2007; Santiago-Josefat et al. 2007). Later on 
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with the discovery of desmosomal cadherins as target antigens of PV and PF 
auto-antibodies several groups proposed a direct interference of pathogenic 
antibodies with the adhesive interface of Dsgs, a process called steric 
hindrance (Amagai et al. 1992; Futei et al. 2000; Tsunoda et al. 2003). Finally 
emerging evidence supports the idea that induction of intracellular signalling 
processes in response to auto-antibody binding may result in impaired cell-cell 
adhesion (Waschke et al. 2006; Muller E.J. et al. 2008; Grando 2012).    
 
1.3.2.1 Proteolytic cleavage hypothesis 
In 1978, Farb et al. added sera of pemphigus patients to cultured murine 
keratinocytes and observed a detachment of these cells from the culture plates 
(Farb et al. 1978). Furthermore cell detachment could be blocked by addition of 
two different proteinase inhibitors (soybean trypsin inhibitor and alpha2-
macroglobulin) but did not interfere with cell surface binding of pemphigus IgG 
(Farb et al. 1978). Farb suggested that auto-antibody binding induces secretion 
or activation of an epithelial proteolytic enzyme which degrades proteins 
essential for cell adhesion (Farb et al. 1978). In recent years several groups 
suggested the involvement of different proteases in the pathogenesis of 
pemphigus either because of their increased expression by cultured 
keratinocytes incubated with pemphigus auto-Abs or by successful prevention 
of auto-antibody induced acantholysis by addition of specific protease inhibitors 
(Hashimoto et al. 1983; Feliciani et al. 2003). These proteases include 
plasminogen activator, urokinase-type plasminogen activator receptor (uPAR) 
system, matrix metalloproneinases (MMP) or the a disintegrin and 
metalloproteinase (ADAM) family members (Cirillo et al. 2007; Santiago-Josefat 
et al. 2007). However, no direct evidence for the induction of acantholysis by 
proteases subsequent to pemphigus IgG binding is available so far (Waschke 
2008). Nevertheless Amagai et al. showed that the cause for epidermal blister 
formation in bullous impetigo and staphylococcal scalded skin syndrome is a 
serine protease secreted by the bacteria staphylococcus aureus (Amagai et al. 
2000a). Even more striking was the fact that the specific cleavage site for this 
protease, also called exfoliative toxin A (ETA), is located within the extracellular 
portion of Dsg1 and that it’s enzymatic cleavage leads to a subcorneal split 
formation that is indistinguishable from histological findings in pemphigus 
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foliaceus (Amagai et al. 2000a). Taken together the proteolytic cleavage of 
desmosomal cadherins seems to be a less likely but still possible mechanism in 
initiating acantholysis in pemphigus. 
 
1.3.2.2 Steric hindrance hypothesis 
Since the discovery of demsosomal cadherins as antigens targeted by auto-
antibodies in pemphigus a lot of effort was put on characterising the precise 
pathogenic epitopes within the extracellular domain of Dsg-proteins. Amagai et 
al. using ß-galactosidase fusion proteins of the different Dsg3 extracellular 
domains (EC1-5) performed immunoblotting experiments with 23 PV sera. Blot 
reactivities clearly revealed that the major immunogenic regions of Dsg3 are 
located within the EC1, EC2 and EC4 domain (Amagai et al. 1992). However 
affinity purification of PV IgG using fusion proteins representing the amino-
terminus (EC1-2) and the carboxy-terminus (EC3-5) of Dsg3 showed that only 
autoantibodies directed against the amino-terminal epitopes of Dsg3 are 
pathogenic when injected into neonatal mice (Amagai et al. 1992). Futei et al. 
confirmed these findings using domain swapped recombinant Dsg3 molecules 
(Futei et al. 2000). Thus PV sera showed a clearly preferential reactivity with the 
amino-terminal residues 1-161 (EC1 domain) of Dsg3 using competition ELISA 
experiments in contrast to the carboxy-terminal domains (Futei et al. 2000). In 
addition IgG reactivity against the EC1 domain seem to coincide with active PV 
whereas the corresponding titers do not correlate with disease activity when 
analysed by ELISA using recombinant Dsg3 ectodomains expressed in an 
eukaryotic expression system (Muller et al. 2006). The same group however 
identified further EC2-, EC3- and EC4-reactive IgG in patients with active PV. 
Nearly all of these auto-antibodies reacted in a comformation-independent 
manner, i.e. Ca2+ -chelation or denaturarion of the domains EC1, EC2, EC4 and 
EC5 did not change the IgG reactivity measured by ELISA (Muller R. et al. 
2008). Nevertheless another fact favours the major pathogenic role of EC1-
reactive PV IgG. As already mentioned earlier the putative adhesive interface 
for trans-adhesion of desmosomal cadherins lies within the EC1 domain (Al-
Amoudi et al. 2007; Heupel et al. 2009b). Thus it is a striking hypothesis that 
auto-antibodies in PV might directly interfere with desmosomal adhesion 
through binding to the involved adhesion sites, a process referred to as steric 
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hindrance (Waschke 2008). Finally using the active PV mouse model Tsunoda 
et al. identified several monoclonal mouse antibodies directed against Dsg3 
(Tsunoda et al. 2003). However only the clone AK23 induced a blistering 
phenotype when its’ hybridoma was injected into mice. Even more important 
epitope mapping revealed that AK23 recognizes a calcium-dependent 
conformational epitope within the EC1 domain, which consists of Dsg3-specific 
residues that form the adhesive interface between juxtaposed Dsgs (Tsunoda et 
al. 2003). When tested under cell free conditions AK23 as well as PV-IgG were 
able to interfere directly with homophilic Dsg3 binding again supporting their 
ability of steric hindrance (Heupel et al. 2008). On the contrary PF-sera 
containing Dsg1-specific antibodies did not abrogate homophilic Dsg1 binding in 
this assay but nevertheless were tested to be pathogenic in vitro using cultured 
keratinocytes. Thus PF-IgG may carry out their pathogenic effect through cell-
dependent mechanisms, i.e. intracellular signalling (Heupel et al. 2008). 
Although antibodies against the middle or carboxy-terminal extracellular regions 
of Dsg3 did not show any pathogenic activity in the neonatal mouse model of 
PV, certain combinations of these antibodies clearly did indicating some kind of 
additive pathogenic effect (Kawasaki et al. 2006). A possible explanation for this 
finding could be allosteric effects, i.e. PV auto-antibodies directed against non-
amino-terminal epitopes remote to the adhesive interface might induce 
conformational changes within the Dsg3 molecule leading to impaired 
desmoglein binding and subsequently to acantholysis (Waschke 2008). Using 
phage display it is possible to screen the antibody repertoire of a patient and 
additionally to isolate antigen-specific monoclonal antibodies together with their 
encoding cDNA. Payne and colleagues identified several pathogenic and non-
pathogenic Dsg3-specific monoclonal auto-Abs in PV sera by phage display 
(Payne et al. 2005). As expected the epitopes of the pathogenic antibodies 
were located within the EC1 domain of Dsg3, however the effects of a 
combination of “non-pathogenic” antibodies has not been examined in this study 
(Payne et al. 2005). Very recently Di Zenzo and colleagues using proliferated 
Dsg3-reactive B cell clones isolated from the blood of two pemphigus patients 
identified a novel pathogenic epitope within the EC1 subdomain of Dsg3 which 
is crucial for the maintenance of a cis interaction between neighboring Dsg3-
molecules (Di Zenzo et al. 2012). Taken together the contribution of specific 
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auto-antibodies directed against COOH-terminal epitopes of Dsg3 to the 
pathogenesis of PV needs to be further elucidated.  
 
1.3.2.3 Signal transduction hypothesis 
There is emerging evidence that initial events leading to acantholysis in 
pemphigus may be mediated by indirect mechanisms, i.e. intracellular signalling 
pathways, in contrast to direct inhibition (Seishima et al. 1995; Berkowitz et al. 
2005). A convincing finding is that low temperature incubation of PV-IgG treated 
keratinocytes prevents cell dissociation but not antibody binding to the cell 
surfaces (Calkins et al. 2006). Furthermore, incubation of cultured keratinocytes 
with PV sera leads to a reduction of the Dsg3 half-life on the cell surface without 
changing its total amount (Cirillo et al. 2006). Interestingly PV-IgG seems to 
prevalently bind non-desmosomal Dsg3 thereby preventing its incorporation into 
mature desmosomes (Cirillo et al. 2006; Oktarina et al. 2011). In line with this 
other groups confirmed that auto-antibody binding and cell separation starts at 
inderdemosomal areas (Takahashi et al. 1985; Sato et al. 2000). Thus it’s being 
speculated if this non-junctional Dsg3 fraction may be involved in an “outside-in 
signalling” and PV-IgG binding may interfere with this function (Muller E.J. et al. 
2008). Finally, acantholysis subsequent to PV-IgG binding can be reduced or 
even abrogated by preincubation with several agents that modify intracellular 
signalling pathways. An overview of several candidate pathways proposed to be 
involved in the pathogenesis of PV is shown in table 1.3.  
 
Protein kinase C 
Ever since the discovery of a rapid and transient intracellular Ca2+ -increase in 
response to binding of PV-IgG in human keratinocytes (Seishima et al. 1995) 
the participation of several signal transduction pathways have been proposed. 
The intracellular Ca2+ (and inositol 1,4,5 triphosphate) increase for example was 
found to be phospholipase C (PLC) dependent and lead to the activation of both 
protein kinase C (PKC) and plasminogen activator (PA) (Kitajima et al. 1999; 
Seishima et al. 1999). Even more striking intracellular Ca2+ -chelation, and 
blocking of PKC or PA prevented PV-IgG induced acantholysis in vivo 
(Sanchez-Carpintero et al. 2004). However, since in PA-KO-mice still develop a 
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severe blistering phenotype after injection of PV-IgG, the PA-system is not 
believed to be crucial in this process (Mahoney et al. 1999b).  
 
P38 mitogen-activated protein kinase (p38 MAPK) 
Several studies have highlighted a possible role of the p38 mitogen-activated 
protein kinase (p38 MAPK) in the pathogenesis of pemphigus (Berkowitz et al. 
2005; Berkowitz et al. 2006; Waschke et al. 2006; Woll et al. 2007; Berkowitz et 
al. 2008). This opinion derives from findings that p38 MAPK and one of its’ 
downstream targets, heat shock protein (HSP) 25 (HSP27 = human 
homologue), get’s phosphorylated in human keratinocyte cultures already 30 
min after incubation with PV IgG (Berkowitz et al. 2005). Furthermore selective 
inhibiton of p38 MAPK prevented antibody-induced blister formation in vivo, 
blocked inactivation of the small GTPase RhoA, as well as cytokeratin retraction 
and reorganization of the actin cytoskeleton, both of the latter are known to 
precede acantholysis (Berkowitz et al. 2005; Berkowitz et al. 2006; Waschke et 
al. 2006; Chernyavsky et al. 2007). In addition high levels of phosphorylated 
p38 MAPK could be detected in skin lesions of PV patients (Berkowitz et al. 
2008). However, other studies have qualified the role of p38 MAPK activation in 
PV pathogenesis (Lee et al. 2009; Mao et al. 2011). First there seems to be an 
even more important late peak in p38 MAPK phosphorylation subsequent to 
PV-IgG binding which may occur secondary to initial acantholysis (Lee et al. 
2009). In line with this Mao et al. have shown that p38 MAPK activation is not 
necessary to induce initial Dsg3 endocytosis and blister formation but its’ late 
activation leads to the endocytosis of Dsg3 and Dsc3 and may augment blister 
formation in PV (Mao et al. 2011). Grando proposed that p38 MAPK activation 
may even be secondary to apoptotic pathways since p38 MAPK 
phosphorylation could be abolished by inhibition of executioner caspases of the 
cell death programme (Grando 2012). Finally a phase 2 multicenter open-label 
uncontrolled pilot study using the allosteric p38 MAPK inhibitor KC706 had to be 
aborted due to severe adverse reactions (Grando 2012). A possible explanation 
of how p38 MAPK may induce or enhance blister formation maybe its influence 
on the keratinocyte cytoskeleton since serine phosphorylation of cytokeratin 8 
has been shown to induce cytokeratin network disassembly which is a hallmark 
of acantholytic cells (Woll et al. 2007).  
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Several more signalling pathways involving epidermal growth factor receptor 
(EGFR), the tyrosine kinase Rous sarcoma oncogene (Src), the GTPase ras 
homolog family member A (RhoA), the desmosomal plaque protein plakoglobin 
(PG) and the cell cycle regulators myelocytomatosis viral oncogene homolog (c-
Myc) and cyclin-dependent kinase 2 (CDK2) have been studied concerning their 
contribution to pemphigus pathogenesis. Table 1.3 below gives a summary of 
recent knowledge about these signalling molecules. 
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Table 1.3: Signalling pathways presumably involved in the pathogenesis 
of pemphigus. 
Signalling 
molecule 
Involvement in PV pathogenesis references 
 
ras homolog 
family member A 
GTPase 
(RhoA) 
 PV-IgG induced keratinocyte dissociation is 
accompanied by p38 MAPK dependent 
inactivation of RhoA. 
 Specific inactivation of RhoA resulted in deep 
epidermal splitting, keratinocyte dissociation and 
actin reorganisation. 
 Specific activation of RhoA abrogated PV-IgG 
induced cytokeratin retraction, actin 
reorganization and reduction of Dsg3. 
 RhoA activity may regulate desmoglein 
cytoskeletal anchorage. 
(Izumi et al. 2004; 
Waschke et al. 
2006; Spindler et 
al. 2007) 
 
plakoglobin 
(PG) 
 Plakoglobin deficienct mice show subcorneal 
acantholysis, loss of desmosomes, impaired 
cytoskeletal anchorage of desmogleins and c-
Myc overexpression. 
 EGFR activation results in phosphorylation of 
plakoglobin, loss of desmoplakin from 
desmosomes and decreased adhesive strength. 
 PG deficient keratinocytes are resistant to PV-
IgG induced dissociation, cytokeratin retraction 
and disruption of the desmosomal plaque. 
 PG may help to transfer an “outside-in” signalling 
from auto-Ab bound Dsg3 which leads to 
disinhibition of c-Myc. 
(Yin et al. 2005; 
Williamson et al. 
2006; de Bruin et 
al. 2007; Muller 
E.J. et al. 2008) 
 
epidermal growth 
factor receptor 
(EGFR) 
 EGFR activity in cultured keratinocytes peaks 
60min after PV-IgG treatment and finally leads 
to acantholysis and apoptosis. 
 EGFR induced acantholysis is mediated by 
plakoglobin phosphorylation. 
 EGFR activation seems to reduce protein levels 
of desmosomal cadherins. 
 EGFR may act as a pro-proliferative counterpart 
to Dsg3/plakoglobin mediated signalling. 
(Lorch et al. 2004; 
Yin et al. 2005; 
Frusic-Zlotkin et 
al. 2006; 
Chernyavsky et al. 
2007) 
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Signalling 
molecule 
Involvement in PV pathogenesis references 
 
sarcoma 
oncogene 
tyrosine kinase  
(Src) 
 Src activity peaks 30min after PV-IgG treatment 
and contributes to EGFR and p38MAPK 
activation. 
 Src inhibition reduces PV-IgG induced 
acantholysis, cytokeratin retraction and 
apoptosis in vitro. 
 Non-desmosomal Dsg3 regulates activity of Src 
and its association with E-cadherin in adherens 
junction formation. 
 Src is activated early after PV-IgG binding and 
may trigger EGFR and P38MAPK induced 
acatholysis. 
(Sanchez-
Carpintero et al. 
2004; 
Chernyavsky et al. 
2007; Tsang et al. 
2012) 
 
myelocytomatosis 
viral oncogene 
homolog (c-Myc) 
and cyclin-
dependent kinase 
2 (CDK2) 
 
 PV-IgG induced PG depletion resulted in c-Myc 
overexpression (after 24h). 
 Inhibition of c-Myc and PG degradation 
abrogated PV-IgG induced skin blistering. 
 Pharmacological inhibition of cdk2 abolished 
PV-serum induced acantholysis in vivo. 
 Regulators of cell cycle progression seem to be 
involved in loss of keratinocyte adhesion in PV. 
(Williamson et al. 
2006; Lanza et al. 
2008; Muller E.J. 
et al. 2008) 
 
Taken together it is not clear at present which of the above mentioned 
mechanisms is the initial trigger inducing acantholysis in PV. For a long time 
steric hindrance of junctional desmogleins was the favoured mechanism. 
However since keratinocyte detachment starts at interdesmosomal areas and 
incubation at low temperature can abolish acantholysis this hypothesis has to 
be revisited. On the other side several signalling mechanisms that are thought 
to be involved in PV pathogenesis are activated at late time points after PV-IgG 
treatment of cells when initial acantholysis has already been initiated (Lee et al. 
2009; Mao et al. 2011). Thus the exact time kinetics of activated signalling 
molecules subsequent to antibody binding is needed to assess their relevance 
in initiating loss of cell adhesion. Finally PV-sera do not only contain antibodies 
to Dsg1 or Dsg3 (Nguyen et al. 2000c). Several studies have identified further 
keratinocyte surface molecules targeted by PV-IgG which in consequence may 
also lead to the alteration of intracellular signalling pathways that contribute to 
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acantholysis. Some of these non-Dsg targets will be discussed later in this 
chapter. 
 
1.3.3 Epitope spreading 
Findings in the active PV mouse model suggest the presence of Dsg3-reactive 
B-cells in normal individuals. These B cells may produce antibodies directed 
against non-pathogenic epitopes of the Dsg3 ectodomain (Ota et al. 2004) and 
in fact low levels of anti-Dsg3 antibodies were detected in healthy relatives of 
PV patients (Torzecka et al. 2007). However the mere presence of Dsg3-
reactive antibodies is not sufficient to develop PV (Yokoyama et al. 2010). A 
possible explanation for this phenomenon is the occurrence of epitope 
spreading. Epitope spreading enables to the inclusion of new epitopes within 
the same or a different (auto-)antigen leading to the onset of an autoimmune 
disease or a phenotypical switch in an ongoing disease (Yokoyama et al. 2010). 
Intramolecular epitope spreading was found to take place in patients of the 
endemic PF form Fogo Selvagem (Li et al. 2003). Patients in preclinical stages 
presented with antibodies against the EC5 subdomain of Dsg1 and most 
interestingly with the onset of disease patients developed anti-Dsg1EC1 and/or 
anti-Dsg1EC2 auto-antibodies (Li et al. 2003). Salato et al. using IF and ELISA 
competition assays demonstrated that an intramolecular epitope spreading from 
COOH-terminal towards NH2-terminal epitopes takes place within PV patients’ 
sera just before the transition into a mucocutaneaous phenotype (Salato et al. 
2005). Only antibodies directed against amino-terminal epitopes of Dsg3 were 
able to stain human skin in IIF analysis and their occurrence preceded an 
intermolecular epitope spreading from Dsg3 to Dsg1 (Salato et al. 2005). 
Additionally, shifts of the auto-ab profile in a group of 37 PV patients occurred 
with a frequency of 41% (Weitz et al. 2007). However no consistent relation 
between changes in anti-Dsg profile and changes in PV phenotype could be 
detected indicating the importance of other immunological mechanisms in the 
clinical manifestations of PV (Weitz et al. 2007). But how does epitope 
spreading occur on the cellular level? Takahashi et al. showed that a single 
Dsg3-reactive T cell clone is able to induce the production of anti-Dsg3 IgG by 
polyclonal naïve B cells independent of T cell epitopes on Dsg3 (Takahashi et 
al. 2009). That means a T cell clone auto-reactive against a peptide located 
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within the Dsg3 subdomain EC1 may induce IgG production by B cells specific 
for the EC4 domain of Dsg3. A possible explanation for this phenomenon is the 
fact that a B cell can act as an antigen presenting cell for T cells, i.e. a B cell 
may present various epitopes of a macromolecular complex and therefore might 
get help from a broad range of (auto-reactive) T cells (Yokoyama et al. 2010).  
 
1.3.4 Desmoglein compensation theory 
Patients with PV and PF not only present with different auto-antibody profiles, 
i.e. Dsg3- and/or Dsg1-specific IgG, they also exhibit different clinical sites of 
blister formation (Mahoney et al. 1999a). That is suprabasal blister formation of 
mucous membranes in PV and subcorneal epidermal splitting in PF, 
respectively. Furthermore patients suffering from mucocutaneous PV produce 
Dsg1 as well as Dsg3-sepecific IgG resulting in suprabasal acantholysis at 
epidermal and mucosal sites (Amagai et al. 1992; Ding et al. 1997; Amagai et 
al. 1999b; Hertl 2005). Using epidermal IF staining it has been demonstrated 
that PV and PF IgG show an inversely graded binding pattern. According to this 
PV IgG peferentially binds to the basal and suprabasal epidermal layers 
whereas PF IgG showed higher intensities in the upper epidermis. However 
both binding profiles seem to broadly overlap in the spinous layers (Shimizu et 
al. 1995; Amagai et al. 1996). These findings go in line with the expression 
patterns of Dsg1 and Dsg3 in human skin (Delva et al. 2009). Mahoney and 
colleagues could demonstrate that at least in mice Dsg1- and Dsg3-
coexpressing epidermal layers were unsusceptible to pemphigus sera 
containing auto-antibodies against only one of the Dsg isoforms, i.e. Dsg1 or 
Dsg3, respectively (Mahoney et al. 1999a). On the other site human Dsg1- and 
Dsg3-specific IgG together induced blister formation in the superficial mouse 
epidermis. In the subcorneal layers where Dsg1 but no Dsg3 is expressed 
Dsg1-reactive PF-IgG alone was able to cause acantholysis. In this regard 
Dsg3-specific PV-IgG induced suprabasal split formation at layers of 
predominant Dsg3 expression (Mahoney et al. 1999a). These observations lead 
to the hypothesis that one Dsg isoform might functionally compensate for the 
loss of the other at sites of dual expression (Mahoney et al. 1999a). For 
instance Dsg1 compensates for loss Dsg3 function in PV patients harbouring 
Dsg3-reactive IgG and as a consequence no skin lesions occur. On the other 
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hand in layers where mainly one isoform is expressed no compensation can 
take place finally leading to acantholysis as happens in suprabasal layers of the 
mucous membranes where the low Dsg1 expression can not compensate for 
the loss of Dsg3 (Mahoney et al. 1999a). However the fact that PV patients 
developing additional IgG against Dsg1 exhibit suprabasal and no subcorneal 
epidermal split formation (like in PF patients) can not be explained by this 
hypothesis (Waschke 2008). Finally recent characterizations of the expression 
patterns of Dsg1 and Dsg3 in stratified epithelia revealed substantial differences 
between mice and humans, for example Dsg1 seems to be expressed to a 
much higher extend in the mucous membranes than primarily expected 
(Mahoney et al. 2006). Taken together although numerous studies support the 
idea of a specifically targeted reduction of desmogleins via IgG auto-Abs in 
stratified epithelia this concept is not able to sufficiently explain the clinical 
manifestation of blister formation (Nguyen et al. 2000c). 
 
1.4 Non-desmosomal antigen targets in pemphigus 
Although the majority of pemphigus patients express auto-Abs against Dsg1 
and Dsg3 the occurrence of auto-antibodies directed against several other 
desmosomal components and non-desmosomal keratinocyte surface proteins in 
the sera of these patients is remarkable (Nguyen et al. 2000c; Grando 2012). 
Even before the identification of Dsg3 as a target antigen in PV, Korman and 
colleagues demonstrated that pemphigus sera also immunoprecipitate the 
demosomal plaque protein plakoglobin (Korman et al. 1989). Injection of PV-
IgG lacking auto-Abs against Dsg1 caused epidermal blistering in Dsg3-KO-
mice indicating that antibodies against keratinocyte antigens other than 
desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions (Nguyen et al. 
2000c). In some pemphigus variants neither Dsg1- nor Dsg3-reactive IgG is 
present at all but intercellular IgG deposition in the epidermis can be clearly 
detected (Nakashima et al. 2010). Very promising targets in pemphigus seem to 
be cholinergic receptors and the annexin pemphaxin, since in up to 85% of PV 
and PF sera auto-antibodies against these antigens have been found (Grando 
2006). In this context, a monoclonal antibody against the alpha9 acetylcholine 
receptor (AChR) of epidermal keratinocytes caused acantholysis in vitro and 
addition of the cholinergic agonist carbachol reversed these effects (Nguyen et 
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al. 2000a). Although antibodies against pemphaxin alone are not sufficient to 
induce blistering in vivo a synergistic action of antibodies to different 
keratinocyte self-antigens, including both acetylcholine receptors and 
desmosomal cadherins seems possible (Nguyen et al. 2000b). Finally, the 
second group of desmosomal cadherins the desmocollins (Dsc) may play a 
substantial role in the pathogenesis of pemphigus. Dsc1 has been previously 
identified as the target antigen in the subcorneal pustular dermatosis (SPD) 
type of IgA pemphigus (Hashimoto et al. 1997). Moreover, IgG auto-ab against 
Dsc1, Dsc2, or Dsc3 were detected in the sera of patients with paraneoplastic 
pemphigus and, occasionally, in patients with atypical pemphigus (Dmochowski 
et al. 1995; Hashimoto et al. 1995; Hisamatsu et al. 2004; Muller et al. 2009). 
However, the pathogenic relevance of Dsc-specific auto-Abs in these disorders 
remains unclear. The conditional Dsc3-KO-mouse provides a very useful tool to 
investigate the importance of Dsc3 in maintaining keratinocyte adhesion. These 
mice show a pronounced blistering phenotype with suprabasal loss of epidermal 
adhesion. Interestingly blistering affects in particular the epidermis and hair 
follicles and the phenotype seems more severe than in Dsg3-null mice (Chen et 
al. 2008). It has been shown that Dsc3, as Dsg3, is preferentially expressed in 
the basal and suprabasal layers of human epidermis the site where loss of 
adhesion occurs in PV (Yue et al. 1995; Delva et al. 2009). In desmosomes, 
Dsg1 and Dsg3 do not only interact via homophilic transinteraction but 
presumably also by heterophilic binding with Dsc isoforms, such as Dsc1 and 
Dsc3. Spindler and colleagues provided in vitro evidence that Dsc3 homo- and 
heterophilic trans-interaction is crucial for epidermal integrity and maybe 
impaired in pemphigus (Spindler et al. 2009). Taken together Dsc3 seems to be 
a promising antigenic target in pemphigus and further knowledge is required to 
address the pathologic relevance of Dsc3-specific auto-Abs in inducing a 
blistering phenotype.  
 
1.5 Current therapeutic strategies in pemphigus 
In PV, systemic corticicosteroids are the drugs of choice usually in combination 
with an adjuvant steroid sparing immunosuppressive drug (Hofmann et al. 2009; 
Martin et al. 2011). The aim of every therapeutic approach is to reach complete 
remission independent of the clinical phenotype. Thus initial high doses of 
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prednisolon equivalent are applied and subsequently tapered over months 
according to the clinical response (Hertl et al. 2010). Common 
immunosuppressive drugs comprise azathioprine, mycophenolate mofetil, 
cyclophosphamide and methotrexate (Hofmann et al. 2009; Martin et al. 2011). 
Most experience derives from the use of azathioprine as it has a well proven 
steroid sparing effect (Chams-Davatchi et al. 2007). However its 
immunosuppressive effect takes 8 to 12 weeks to begin. Mycophenolate mofetil 
has similar therapeutic and steroid sparing abilities but in contrast to 
azathioprine seems to be less hepatotoxic (Beissert et al. 2006; Beissert et al. 
2010). For the treatment of refractory cases cyclophosphamide appears to be a 
possible alternative when used as a pulse therapy (Pasricha et al. 1988; 
Fleischli et al. 1999). Its potential is comparable to the one of azathioprine and 
mycophenolate mofetil however it harbours a higher risk for the development of 
toxic side effects like hemorrhagic cystitis, bone marrow depression, 
teratogenesis and an elevated risk for tumor diseases (Hertl et al. 2010). 
Systemic and topic application of cyclosporin A lead to a good response in 
some cases but a combination with prednisolon shows no significant advantage 
in relation to a monotherapy with steroids (Ioannides et al. 2000). Although 
methotrexate has been proven effective in PV treatment the necessity of high 
doses in some cases increased its toxic side effects immensely (Smith et al. 
1999). The usage of high dose intravenous immune globulines (IVIG) for the 
treatment of problematic refractory cases of PV and PF has been successfully 
used as an adjuvant immune-modulatory therapy (Jolles 2001; Ahmed et al. 
2006; Enk et al. 2009; Amagai et al. 2009b). IVIG therapies of 2-4 months 
induced significant disease regression and lead to a better response to a 
subsequent treatment with immune-suppressive drugs. Even in steroid-resistant 
cases IVIG treatment was able to achieve a better disease control (Ahmed et al. 
2006; Enk et al. 2009; Amagai et al. 2009b). Further therapeutic strategies are 
based on the elimination of circulating IgG auto-antibodies using protein A 
columns or globaffin Absorber (Luftl et al. 2003; Schmidt et al. 2003; Eming et 
al. 2006b). These immunoadsorption techniques remove large amounts of IgG 
from the patients’ sera including those auto-Abs responsible for blister induction 
(Eming et al. 2006a). A combination of adjuvant immunoadsorption with an 
immunosuppressive base line therapy is able to achieve an earlier disease 
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control in refractory pemphigus cases (Zillikens et al. 2007). Finally the B-cell 
depleting anti-CD20 monoclonal antibody rituximab has been successfully used 
to treat patients suffering from severe pemphigus. B-cell depletion lasts up to 6-
9 months and correlates with reduced auto-ab titers and clinical improvement 
(Ahmed et al. 2006; Joly et al. 2007). Furthermore long term remission could be 
achieved in several cases (Espana et al. 2004). Since its profoundly positive 
effect on disease progression and its relatively mild side effects rituximab is 
likely to become a first line drug in the treatment of pemphigus (Hertl et al. 
2008).  
 
1.6 Aims of this study 
Since cis-interactions between adjacent Dsg3 melocules at the EC4/EC5 
extracellular site seem to be crucial for maintaining cellular adhesion (Al-
Amoudi et al. 2007), it is prompting to further investigate the pathogenic 
relevance of pemphigus IgG directed against COOH-terminal epitopes of Dsg3. 
Furthermore, there is emerging evidence that desmocollins seem to play an 
essential role in maintaining desmosomal adhesion and may represent crucial 
antigenic targets for auto-Abs in pemphigus patients (Chen et al. 2008; Spindler 
et al. 2009). Since there is no real antigen specific therapy to treat pemphigus 
patients so far, it is really important to further elucidate potential antigenic 
targets within this disease. However, the knowledge about a certain antigen 
reactivity of Pemphigus IgG is not sufficient to allow a conclusion about its’ 
pathogenic relevance. Therefore investigation of isolated highly antigen specific 
auto-Abs using pathogenicity assays are needed to answer this question. We 
therefore articulated the following aims of this study: 
1) establishing a suitable technique to isolate domain-specific auto-Abs in PV 
patients 
2) detection and isolation of auto-Abs in pemphigus sera specific for carboxy-
terminal epitopes of Dsg3 
3) application of this method to sera of four atypical pemphigus patients, in 
order to isolate Dsc3-specific auto-Abs 
4) investigation of the pathogenic capacity of antigen-specific isolated auto-Abs 
in an in vitro assay using cultured human keratinocytes 
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2 Materials and Methods 
2.1 Pemphigus patients and healthy controls 
For the characterisation of Dsg3-subdomain-specific auto-Abs we included 
pemphigus vulgaris patients whose diagnosis was based on clinical, serological 
and histological charactersistics. Patients presented with mucous membrane 
lesions and/or flaccid blisters and erosions on erythematous skin, as well as 
high IgG-titers against the recombinant Dsg3-ectodomain. Biopsies from 
affected and perilesional skin revealed split formation within the basal and 
suprabasal epidermal layers and immunofluorescence detected IgG-deposits at 
the surface of epidermal keratinocytes. Finally indirect immunofluorescence on 
monkey esophagus showed positive intercellular staining for IgG of epithelial 
cells. Serological characteristics of all screened PV patients using ELISA are 
shown in figure 3.3. Figure 3.2 shows representative clinical, histopathological 
and immunofluorescence pictures of PV patient 1. 
Four Japanese patients with atypical pemphigus (two pemphigus vegetans and 
two pemphigus herpetiformis) were investigated in cooperation with the 
laboratory of Dr. Takashi Hashimoto (Department of Dermatology, Kurume 
University School of Medicine, Fukuoka, Japan) who performed the clinical and 
serological analysis of the patients. Assessment of the clinical conditions 
revealed exophytic skin erosions of the fingers and oral erosions (patient 1), 
hypertrophic vegetative (verrucous) plaques with pustules and erosions on the 
foot, groin and scalp (patient 2), widespread erythema, pustules and erosions of 
the oral mucosa (patient 3) and multiple erythematous erosions on trunk and 
extremities (patient 4). The clinical diagnosis of pemphigus was confirmed by: 
histopathological evidence of intraepidermal loss of adhesion, IgG deposits on 
the surface of epidermal keratinocytes of perilesional skin by direct 
immunofluorescence, and cell surface IgG reactivity on Dsc3 transfected COS7-
cells by indirect immunofluorescence. Clinical and immunoserological 
characteristics of the atypical pemphigus patients are shown in table 3.2. 
Except for patient 2 who also had Dsg1-reactive IgG, all the other patients 
showed predominantly IgG reactivity to Dsc3. Shown in figure 3.12 are 
representative clinical pictures of the studied patients. All patients gave written 
consent to participate in this investigation, which adhered to the Declaration of 
Helsinki Guidelines and was approved by the local ethics committee.  
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2.2 Antibodies and enzymes 
Primary antibodies: 
 monoclonal mouse anti-Dsc3 (clone: U114, 1µg/ml; Progen Biotechnik 
GmbH, Heidelberg, Germany) 
 monoclonal mouse anti-E-Tag antibody (1:1000; Amersham Biosciences, 
Uppsala, Sweden) 
 monoclonal mouse anti-Dsg3 (clone: AK23, 1µg/ml; kindly provided by 
Dr. Masayuki Amagai, department of Dermatology, Graduate School of 
Medicine, Keio University, Tokyo, Japan) 
 
Secondary antibodies: 
 horseradish peroxidase(HRP)-conjugated goat anti-human IgG (1:5000; 
Dako, Glostrup, Denmark) 
 horseradish peroxidase(HRP)-conjugated rabbit anti-mouse IgG1 
(1:2000; Dako, Glostrup, Denmark) 
 FITC-labeled goat anti-human IgG (1:200; dianova, Hamburg, Germany) 
 FITC-labeled rabbit anti-mouse IgG1 (1:500; dianova, Hamburg, 
Germany) 
 
Enzmymes 
 recombinant exfoliative toxin A (0,5µg/ml; Toxin Technology, Sarasota, 
FL) 
 dispase I (1U/ml; Roche Applied Sciences, Mannheim, Germany) 
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2.3 Solutions, buffers, media and technical devices 
Affinity chromatography column preparation 
Buffer composition 
Swelling buffer 1mM HCl in Millipore-H2O 
Coupling buffer 0.1M NaHCO3 + 0.5M NaCl in Millipore-H2O, pH:8.3 
Blocking buffer (a) 0.1M Tris-HCl in Millipore-H2O, pH:8.0 
Washing buffer 1 0.1M Acetat + 0.5M NaCl in Millipore-H2O, pH:4.0 
Washing buffer 2 0.1M Tris-HCl + 0.5M NaCl in Millipore-H2O, pH:8.0 
Washing buffer 3 0.5mM CaCl2 in 1xPBS, pH:7.4 
Storing buffer 0.01% NaN3 + 0.5mM CaCl2 in 1xPBS or 
25% Ethanol + 0.5mM CaCl2 in 1xPBS 
 
Antigen specific Immunoadsorption 
Buffer composition 
Washing buffer I 0.5mM CaCl2 + 0.05% Tween in 1xPBS, pH:7.4 
Washing buffer II 0.5mM CaCl2 in 1xPBS, pH:7.4 
Elution buffer 100mM Glycin/HCl in Millipore-H2O, pH:2.7 
Neutralising buffer 1M Tris/HCl in Millipore-H2O, pH:9.0 
Storing buffer 0.01% NaN3 + 0.5mM CaCl2 in 1xPBS or 
25% Ethanol + 0.5mM CaCl2 in 1xPBS 
Regeneration buffer I 0.1M Tris-HCl + 0.5M NaCl, in Millipore-H2O, pH:8.5 
Regeneration buffer II 0.1M NaAcetate + 0.5M NaCl, in Millipore-H2O, 
pH:4.5 
 
ELISA analysis 
Buffer composition 
Coating buffer 0.5 mM CaCl2 in 1xPBS, pH:7.4 
Washing buffer I 0.5 mM CaCl2 + 0.05% Tween in 1xPBS, pH:7.4 
Blocking buffer (b) / 
Reagent diluent 
0.5 mM CaCl2 + 0.05% Tween + 5% skimmed milk 
powder in 1xPBS, pH:7.4 
Peroxidase substrate ABTS: 2,2'-azino-di(3-ethylbenzthiazoline-6-
sulphonate) 
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Immunoblot analysis 
Buffer composition 
Deterging agent / 
probe buffer 
sodium dodecyl sulphate (SDS) 
Protein separation 
agent 
polyacrylamide gel (10 and 12,5%, respectively) 
Transfer buffer 25 mM Tris + 190 mM glycine in 20% Methanol 
Blocking buffer (b) / 
Reagent Diluent 
0.5 mM CaCl2 + 0.05% Tween + 5% skimmed milk 
powder in 1xPBS, pH:7.4 
Washing buffer I 0.5 mM CaCl2 + 0.05% Tween in 1xPBS, pH:7.4 
Peroxidase substrate peroxide solution + luminol reagent (1/1) (Millipore) 
 
Immunofluorescence studies 
Buffer/medium composition 
Cultering medium Dulbecco’s modified Eagle’s medium (DMEM high 
glucose, Invitrogen, Carlsbad, CA) + 10% fetal calf 
serum (PAA, Pasching, Austria) + 50 units/ml 
penicillin-G + 50 µg streptomycin and 2 mM L-
Glutamine (Gibco, Karlsruhe, Germany) 
Growing medium Epidermal keratinocyte medium (CnT-57 medium; 
CELLnTEC Advanced Cell Systems, Bern, 
Switzerland) 
Adhesion induction 
medium (high calcium 
medium) 
keratinocyte medium (CnT-02 medium; CELLnTEC 
Advanced Cell Systems, Bern, Switzerland) + 1.2 
mM CaCl2 
Washing buffer (a) 1.2 mM CaCl2 + 1.0 mM MgCl2 6H2O in 1xPBS 
Fixative solution 1% paraformaldehyde in 1xPBS 
Membrane 
solubilisation solution 
0.5 % Triton X-100 in 1x PBS 
Secondary antibody 
solution 
1% bovine serum albumine (BSA) (dianova, 
Hamburg, Germany) + 1.2 mM CaCl2 + 1.0 mM 
MgCl2 6H2O in 1%PBS 
Mounting medium Dako, Glostrup, Denmark 
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Keratinocyte dissociation assay 
Buffer/medium composition 
Growing medium epidermal keratinocyte medium (CnT-57 medium; 
CELLnTEC Advanced Cell Systems, Bern, 
Switzerland) 
Adhesion induction 
medium 
keratinocyte medium (CnT-02 medium; CELLnTEC 
Advanced Cell Systems, Bern, Switzerland) + 1.2 
mM CaCl2 
Washing buffer (b) 1xPBS, pH:7.4 
Cell detachment 
solution 
Dispase I, 1U/ml in 1xPBS (Roche Applied 
Sciences, Mannheim, Germany) 
Fixative solution 10% formalin in Millipore-H2O 
Staining solution Crystal violet (1:100) in Millipore-H2O 
 
Technical devices  
Device company 
Analytical balance 770 Gottl. Kern & Sohn GmbH, Balingen-
Frommern 
Blotting chamber Biometra, Göttingen 
Clean bench HERAsafe® Heraeus Kendro Laboratory Products 
GmbH, Langenselbold 
CO2-incubator HERAcell
® 150 Heraeus Kendro Laboratory Products 
GmbH, Langenselbold 
ELISA reader Multiskan Ex with 
Multiskan Ascent sowtware 2.6 
Thermo Electron Corporation, 
Dreieich 
Electropheresis chamber, Mini-
Protean3 DodecaTM Cell  
Bio-Rad, München 
Electropheresis chamber, Perfect 
BlueTM Gelsystem MaxiM 
PeqLab, Erlangen 
Fluorescence microscope Nikon, Düsseldorf 
Gel documentation system 
ChemiSmart 2000 
PeqLab, Erlangen 
Inverted microscope Invertoskop Carl Zeiss MicroImaging GmbH, 
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ID03 Göttingen 
Magnetic mixer IKAMAG® RET IKA Labortechnik, Staufen 
Multichannel pipette Discovery 20-
200μl 
ABIMED, Langenfeld 
Multipipette plus Eppendorf, Hamburg 
Neubauer counting chamber Paul Marienfeld GmbH & Co. KG, 
Lauda-Königshofen 
pH-meter CyberScan pH 510 Eutech Instruments Europe bv, 
Nijkerk, Niederlande 
Pipettor BD Falcon™ Express™ Becton Dickinson GmbH, Heidelberg 
Pipettes Research® 10μl, 100μl, 
200μl, 1000μl   
Eppendorf, Hamburg 
Reflected-light microscope Axiostar Carl Zeiss MicroImaging GmbH, 
Göttingen 
Refrigerated centrifuge Megafuge 1.0 
R 
Heraeus Kendro Laboratory Products 
GmbH, Langenselbold 
Tumbler Heidolph Instruments, Schwabach 
Thermalcycler Touch Down Thermo Electron Corporation, 
Dreieich 
Vortex IKA® Genius 3 IKA Labortechnik, Staufen 
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2.4 Expression and purification of recombinant proteins 
The recombinant Dsc and Dsg proteins, including the subdomains Dsg3EC1, 
Dsg3EC4 and Dsg3EC5 were expressed in insect cells (High Five; Invitrogen, 
Carlsbad, CA) by infection with recombinant baculoviruses, as previously 
described and were kindly provided by Dr. Ralf Müller (Muller et al. 2006). In 
short: Culture supernatants of infected High Five cells were collected after 3 
days and recombinant His-tagged proteins were purified by affinity 
chromatography using nickel-nitrilotriacetic-linked agarose beads (Quiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Purified proteins 
were gradually dialysed against phosphate-buffered saline (PBS) supplemented 
with 0.5 mM CaCl2 and stored at -20°C (Muller et al. 2006). By immunoblot 
analysis, the purified recombinant proteins were detected at the expected size 
and were specifically immunoreactive using a monoclonal mouse anti-Etag 
antibody (1:1000; Amersham Biosciences, Uppsala, Sweden) (Muller et al. 
2006). In addition, serum of a patient with paraneoplastic pemphigus showed 
reactivity with recombinant Dsc1-3, Dsg1 and Dsg3 proteins (Figure 3.11 B, 
lower panel).  
 
2.5 Purification of antigen-specific auto-antibodies from pemphigus 
sera 
2.5.1 Affinity chromatography 
Affinity chromatography separates proteins on the basis of a reversible 
interaction between a protein and a specific ligand coupled to a chromatography 
matrix (Affinity Chromatograpy Handbook, GE Healthcare, Little Chalfont, 
United Kingdom). Biological interactions between ligand and target molecule 
can be a result of electrostatic or hydrophobic interactions, van der Waals’ 
forces and/or hydrogen bonding. To elute the target molecule from the affinity 
medium the interaction can be reversed, either specifically using a competitive 
ligand, or non-specifically, by changing the pH, ionic strength or polarity. Target 
molecules can be purified from complex biological mixtures, such as serum. A 
biospecific ligand is required that can be covalently attached to a 
chromatography matrix (Affinity Chromatograpy Handbook, GE Healthcare). 
The coupled ligand must retain its specific binding affinity for the target 
molecule and, after washing away unbound material, the binding between the 
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ligand and the target molecule must be reversible to allow the target molecule to 
be removed in an active form. Any component can be used as a ligand to purify 
its respective binding partner (Affinity Chromatograpy Handbook, GE 
Healthcare). A common method to isolate human antibodies from biological 
samples is purifying them via their fragment crystallizable (Fc)-region. In this 
case proteins with high affinity to the Fc-region, such as protein A or protein G, 
are used as antibody ligands which are bound covalently to a sepharose matrix. 
However this type of purification is unspecific since the Fc-region of an antibody 
is independent of its antigen-specificity. To achieve an antigen-specific isolation 
of human antibodies the antigen itself must be coupled onto the matrix as a 
ligand. By incubating this antigen-loaded column with a serum sample, antigen 
specific antibodies bind to the ligand via their fragment antigen-binding (Fab)-
fragment and can be isolated specifically. A very suitable coupling method is to 
couple the ligand via its primary amine group to a pre-activated matrix, for 
example CNBr-activated sepharose (Amersham Biosciences, Uppsala, 
Sweden).  
 
2.5.2 Preparation of affinity chromatography columns 
In this study recombinant human Dsc- and Dsg-proteins as well as the Dsg3 
extracellular subdomains Dsg3EC1 and Dsg3EC4 were used as ligands and 
were covalently attached to CNBr-activated sepharose 4B (Amersham 
Biosciences, Uppsala, Sweden) serving as the chromatography matrix. 
Sepharose 4B is a pre-activated medium for immobilization of ligands 
containing primary amines, like proteins, peptides and nucleic acids. The affinity 
columns were prepared according to the manufacturers instructions as 
following: The appropriate amount of sepharose 4B was diluted in 1mM HCl and 
let swell for 10 minutes. Washing with low pH preserves the activity of the 
reactive groups, which otherwise hydrolyse at high pH. 1g lyophilized CNBr-
activated sepharose 4B yielded approximately 3,5ml final volume of sepharose 
medium and 5-10mg ligand/protein was being used for 1ml sepharose medium. 
Swollen medium was transferred into a 10ml-Polypropylen-column, which had 
been equipped with a frit to hold back the sepharose and let sediment 
completely. The sepharose was now being washed for 15 min with 1mM HCl 
and subsequently with two column volumes of 0,1M NaHCO3 + 0,5M NaCl, 
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pH:8,3 (coupling buffer). Prior to coupling, the ligands (recombinant Dsc3, 
Dsg3, Dsg3EC1, Dsg3EC4) were dialysed against coupling buffer and 
incubated with the sepharose medium over night at 4°C on a tumbler. The next 
day, the coupled sepharose was subjected to 5 washes with coupling buffer 
followed by incubation with blocking buffer (0,1M Tris-HCl, pH: 8.0) for 2 hours 
at room temperature to remove any remaining covalent binding sites. The 
coupled sepharose was then washed 4 times with 0.1M acetate + 0.5M NaCl at 
pH 4.0 and 4 times with 0.1M Tris-HCl + 0.5M NaCl at pH 8.0 alternately. A final 
washing using PBS containing 0.5mM CaCl2 at pH 7.4 was performed and then 
the columns were loaded with storing buffer and stored at 4°C in a fridge. 
 
2.5.3 Auto-antibody purification 
Pemphigus sera were diluted at 1:5 in PBS containing 0.5 mM CaCl2 at pH 7.4. 
The respective column was incubated with the diluted sera overnight at 4°C on 
a tumbler. The next day, the preadsorbed sera were collected and the column 
was washed 3 times with PBS containing 0.5 mM CaCl2 + 0.05% Tween 20 
(PBST) at pH 7.4 and, subsequently, 3 times with PBS containing 0.5 mM 
CaCl2 at pH 7.4. Bound Abs were eluted using 100 mM Glycin-HCl (pH 2.7) and 
900 µl aliquots were collected in tubes containing 100 µl of 1 M Tris-HCl (pH 
9.0). The collected aliquots were tested for eluted Abs by western blot analysis 
(see below). The aliquots containing Abs were combined and dialysed overnight 
against PBS with 0.5 mM CaCl2 at pH 7.4. The purified IgG fractions were 
concentrated using Amicon Ultra-15 Centrifugal Filter Units (Millipore, Billerica, 
MA). The protein concentration of the eluted Abs was measured using a 
modified Lowry protein assay. Final protein concentrations ranged between 100 
and 200 µg/mL. 
 
2.5.4 Determination of protein concentrations 
In order to quantitatively determine the protein concentrations of our eluted 
antibodies we used a modified Lowry assay (DC protein assay, Bio-Rad 
Laboratories, Hercules, CA). The principle of this assay is based on a 
chemically induced colour change which is dependent on the protein 
concentration of a certain sample and can be measured using photometric 
analysis. A serial dilution of bovine serum albumin (BSA, 1360µg/ml) has been 
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used as a standard. Dilution series as well as eluted Ab samples were pipetted 
in duplicates onto flat bottom microtiter plates (Corning Acton, USA) (5µl/ml). 
Subsequently 25µl of reagent A and 200µl of reagent B were added into each 
well. After 15min incubation time protein concentrations could be measured 
photometrically at 655nm. 
 
2.6 Enzyme-linked immunosorbent assay (ELISA) 
This assay is using an enzyme as a marker to determine antigen or antibody 
concentrations on the basis of the (enzyme) substrate turnover (Bratke 2009). 
There are different techniques of an ELISA assay in which either the antigen or 
the antibody is adsorbed to a solid phase (Bratke 2009). A competitive assay is 
suitable for measuring antigens as only one antigen-specific antibody is 
needed. However the antigen itself must harbour a marker to be detected. The 
sandwich assay instead uses a capturing and an enzyme linked detection 
antibody respectively to measure antigen concentrations. Finally to detect 
antibodies, for example within hybridoma supernatants or human sera, the 
direct assay is most suitable (Bratke 2009). Here the antigen is being 
immobilized on a solid phase and incubated with the antibody containing 
solution. After a certain incubation time in which the specific antibodies can bind 
to the antigen, unbound particles are washed away. Finally these specifically 
bound antibodies are detected using a secondary enzyme linked detection 
antibody which binds to the Fc-portion of the primary antigen bound antibody. 
The amount of substrate turnover correlates with the amount of the enzyme 
linked secondary antibody and thus as well with the antigen bound primary 
antibody (Bratke 2009). In this work the direct ELISA was being used as a 
qualitative method to detect Dsg- or Dsc-specific antibodies within human sera 
and antibody eluates respectively.  
The recombinant proteins - Dsg3, Dsg3EC1, Dsg3EC2, Dsg3EC3, Dsg3EC4, 
Dsg3EC5, Dsc1, Dsc2, Dsc3 and collagen 7 were immobilized on 96-well 
polystyrene plates (Maxisorb Immunoplate; Nunc/Thermo Fisher Scientific, 
Wiesbaden, Germany) by coating each well with 0,5 µM of recombinant protein 
in PBS with 0.5mM CaCl2 at 4°C over night. For conformation testing, the 
recombinant Dsg proteins and Dsg3 subdomains were coated onto microtitre 
plates in the presence of 3M urea or 10mM ethylenediaminetetraacetic acid 
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(EDTA). ELISA plates were then washed 6 times with PBST with 0.5mM CaCl2 
and blocked for 1 hour with 100µl of 5% skimmed milk powder in PBST with 
0.5mM CaCl2 (blocking buffer) at room temperature (for denaturation 
experiments Ca2+-free washing and blocking buffers were used for the particular 
plates). Subsequently plates were incubated with pemphigus patients and 
control sera (1:50), as well as affinity-purified antibodies (1:2) or anti-E-tag 
monoclonal antibody (1:1000; Amersham Biosciences, Uppsala, Sweden) 
diluted in blocking buffer. After overnight incubation and 6 washing steps (as 
described above), plates were incubated with a horseradish peroxidase-labelled 
goat anti-human IgG (1:5000; Dako, Glostrup, Denmark) or rabbit anti-mouse 
IgG1 (1:2000; Dako, Glostrup, Denmark) respectively for one hour at room 
temperature. Plates were then subjected to a final washing (as described 
above) and IgG binding was visualized by adding the HRP-substrate ABTS 
(Calbiochem, Schwalbach, Germany). Plates were allowed to incubate for 30 
minutes at room temperature before finally reactivity was measured at an 
optical density (OD) of 405nm (ELISA Reader Multiskan Ex with 
MultiskanAscent Software 2.6; Thermo Electron Corporation, Dreieich, 
Germany). Samples were run in duplicates and for evaluation we used mean 
values.   
 
2.7 Western blot analysis 
Western blotting in combination with sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) is a useful technique to separate and detect 
different proteins according to their molecular weight (western blotting guide, 
abcam plc, Cambridge, United Kingdom). Prior to separation proteins are 
incubated with a deterging agent, normally the negatively charged sodium 
dodecyl sulphate (SDS). SDS denatures proteins by “wrapping around” the 
polypeptide backbone. It confers a negative charge to the polypeptide in 
proportion to its length. Therefore, migration is determined not by intrinsic 
electrical charge of the polypeptide, but by molecular weight (western blotting 
guide, abcam plc, Cambridge, United Kingdom). Samples are subsequently 
subjected to polyacrylamide gel-electrophoresis (PAGE) which separates the 
denatured proteins according to size. The separation of molecules within a gel 
is determined by the relative size of the pores formed within the gel. The pore 
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size of a gel is determined by two factors: the total amount of acrylamide 
present and the amount of cross-linker. When the denatured proteins have 
been transferred into the gel, the latter is subjected to an electric field causing 
the negatively-charged proteins to migrate across the gel towards the positive 
electrode (anode). Depending on their size, each protein will move differently 
through the gel matrix: short proteins will more easily fit through the pores in the 
gel, while larger ones will have more difficulty. The proteins are then transferred 
to a nitrocellulose membrane and detected using antibodies specific to the 
target protein (western blotting guide, abcam plc, Cambridge, United Kingdom).  
The recombinant Dsg- and Dsc-proteins were run in a sodium dodecyl sulphate-
polyacrylamide gel electrophoresis system (10% and 12,5% gel, respectively) 
and blotted onto nitrocellulose membranes. Membranes were blocked with 5% 
milk powder in PBS, 0.05% Tween-20 (PBS-T) with 0.5mmol/L CaCl2. 
Pemphigus sera (1:100), purified antibodies (1:20) and the monoclonal mouse 
anti-E-Tag antibody (1:1000; Amersham Biosciences, Uppsala, Sweden) were 
diluted in PBS-T with 0.5mmol/L CaCl2 and 5% milk powder and were incubated 
with the blotted membranes overnight at 4°C. After three washes with PBS-T 
supplemented with 0.5mmol/L CaCl2, the nitrocellulose membranes were 
incubated with horseradish peroxidase(HRP)-conjugated anti-human IgG  
(1:5000; Dako, Glostrup, Denmark) or HRP-conjugated anti-mouse IgG1 
(1:2000; Dako, Glostrup, Denmark) respectively for 1 hour at room temperature. 
Specific immunoreactivity was then visualized using a commercial HRP subtrate 
(Immobilon Western Chemiluminescent HRP substrate; Millipore, Billerica, MA). 
 
2.8 Immunofluorescence studies  
Since recombinant proteins, even when expressed in an eucaryotic system, 
cannot fully imitate the native expression and conformation within living cells 
additional assays are needed to confirm the binding of the eluted Abs to native 
antigens, i.e. Dsg3 and Dsc3. Immunoflurescence studies using living cells or 
tissues sections are suitable to detect antibody binding to native intra and/or 
extracellular antigens. Substrate cells are fixed on a slide and incubated with a 
blocking solution to avoid unspecific binding. Subsequently cell supernatants or 
sera are incubated on the blocked substrates for a certain amount of time. 
Finally after several washing steps bound antibodies are detected using a 
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secondary antibody coupled with a fluorescent dye. This signal is captured by a 
fluorescence microscope which harbours a certain wavelength filter. The type of 
the fluorescence pattern in correspondence to a positive control antibody gives 
information about the occurrence of antigen specific antibodies within the 
probes.  
The immortalized keratinocyte cell line HaCaT was cultured in Dulbecco’s 
modified Eagle’s medium (DMEM high glucose, Invitrogen) supplemented with 
10% fetal calf serum (PAA), 50 units/ml penicillin-G, 50 µg streptomycin and 2 
mM L-Glutamine (Gibco). For immunofluorescence staining, HaCaT cells were 
grown subconfluently in chamber slides (Nunc/Thermo Fisher Scientific) using 
epidermal keratinocyte medium (CnT-57 medium; CELLnTEC Advanced Cell 
Systems). Subconfluent keratinocyte cultures were switched to defined 
keratinocyte medium (CnT-02 medium; CELLnTEC Advanced Cell Systems) 
supplemented with 1.2 mM CaCl2 24h prior to adding the IgG fractions. 
Keratinocytes were then incubated for 2 hours at 4°C with purified antibodies 
diluted at 1:2, pooled IgG from healthy donors 1:2 diluted or anti-Dsc3 
monoclonal ab (clone U114, 1µg/mL; Progen) and anti-Dsg3 monoclanal ab 
(AK23, 1µg/ml; Dr. Amagai, Keio University Tokyo, Japan), respectively. After 3 
washes with PBS containing 1.2 mM CaCl2 and 1.0 mM MgCl2 6H2O, 
keratinocytes were fixed in 1% paraformaldehyde-PBS for 20 minutes at room 
temperature. After 3 washes, cells were incubated with PBS containing 0.5 % 
Triton X-100 for 10 minutes at room temperature and were finally incubated with 
FITC-labelled anti-human IgG (1:200, dianova) in 1% BSA-PBS. Frozen 
sections of normal human skin were blocked for 30 minutes with PBS 
supplemented with 10% normal goat serum. Samples were incubated for 1 hour 
at room temperature with purified antibodies (diluted in PBS- with 2% goat 
serum at 1:2), IgG pooled from healthy donors at the same dilution or anti-Dsc3 
monoclonal IgG (U114, 1µg/mL; Progen) as positive control for Dsc3 reactivity. 
After 3 washes with PBS, the skin sections were incubated with FITC-labelled 
rabbit anti-human IgG (1:200; dianova) for 30 min at room temperature. Indirect 
immunofluorescence on monkey esophagus was performed following a 
standardized protocol according to the manufacturer’s instructions (The Binding 
Site, Birmingham, UK). 
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2.9 Dispase-based keratinocyte dissociation assay  
There are several cell-free and cell-based in vitro approaches to study the 
pathogenicity of Dsg- or Dsc-specific auto-Abs. Ishii et al. presented the “In vitro 
keratinocte dissociation assay for evaluation of the pathogenicity of anti-
Desmoglein 3 IgG autoantibodies in Pemphigus Vulgaris” (Ishii et al. 2005). In 
this assay primary human keratinocytes expressing high levels of Dsg1 and 
Dsg3 but low levels of Dsg2 are grown in 12 well plates to form a confluent 
monolayer. After incubation with total serum or isolated PV-IgG, the 
staphylococcus aureus enzyme exfoliative toxin A (ETA) which specifically 
cleaves Dsg1 is added so that the remaining binding forces are mostly related 
to Dsg3. Cell sheets are then subjected to mechanical stress and cell 
dissociation is achieved. The number of keratinocyte particles correlates well 
with the pathogenic strength of added PV-IgG since sera from patients with 
active disease yield much higher fragmentation as sera from patients in 
remission or normal human sera. To exclude interassay variability Ishii et al. 
also established a dissociation score based on the positive control AK23 using 
the following formula: dissociation score = ((number of particles with serum – 
number of particles without serum) / (number of particles with serum – number 
of particles with AK23 or U114)) x 100 (Ishii et al. 2005).  
Primary human epidermal keratinocytes were seeded in 12-well plates and 
grown to confluence in CnT-57 medium (CELLnTEC Advanced Cell Systems). 
The day before the assay, cells were cultured in CnT-02 medium (CELLnTEC 
Advanced Cell Systems) containing 1.2 mM CaCl2 and incubated with purified 
antibodies (at 20 µg/mL), pooled control IgG (20 µg/mL), anti-Dsg3 monoclonal 
ab (AK23, 1µg/ml, Dr. Amagai, Keio University Tokyo, Japan) or anti-Dsc3 
monoclonal ab (U114, 1 µg/mL; Progen), overnight at 37°C. Recombinant 
exfoliative toxin A (Toxin Technology) was added at 0.5 µg/mL to cleave Dsg1 
for the last two hours of the assay. After 2 washes with PBS, the adherent 
keratinocyte monolayer was incubated at 37°C for 20 minutes with dispase I 
(Roche Applied Sciences) resulting in a non-adherent monolayer. The 
monolayers were carefully washed twice with PBS and subjected to mechanical 
stress by pipetting ten times with a 1 mL pipet. Fragments were fixed in 1 mL of 
a 10% formalin solution and stained with crystal violet. Images were captured 
using a digital camera and fragments were counted by five different blinded 
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observers. Relative dissociation scores were calculated using the number of 
keratinocyte fragments in relation to the maximal number of cell fragments 
obtained by the positive control (anti-Dsg3 monoclonal ab (AK23) or anti-Dsc3 
monoclonal ab (clone U114) respectively). 
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3 Results 
3.1 Purification and characterisation of desmoglein 3 extracellular 
subdomain-specific auto-antibodies from pemphigus vulgaris 
patients’ sera 
First we sought to establish a setting of experiments to investigate the 
pathogenicity of Dsg3-specific auto-Abs, in vitro. To achieve this aim we 
isolated epitope-specific Abs from PV patients who exhibited auto-Ab reactivity 
against certain subdomains of the extracellular portion of Dsg3. Eight PV 
patients were screened for their IgG reactivity against COOH-terminal epitopes 
of the Dsg3 extracellular domain. Four of these sera underwent affinity 
purification assays to isolate and to further characterise their antigen specific 
IgG in vitro. Affinity purification was performed using recombinant Dsg3 proteins 
produced in a baculovirus expression system (Muller et al. 2006). Figure 3.1 
shows a scheme of the recombinant Dsg and DsgEC proteins used in this 
study. 
 
 
Figure 3.1: Recombinant desmoglein 3 and desmoglein 3 extracellular subdomain 
proteins used in this study. (A) Scheme of the recombinant Dsg3 and Dsg3EC proteins 
applied in this study, i.e. the entire ectodomains of Dsg3EC1-5 and the 5 different extracellular 
domains of Dsg3, linked to E- and 6xHis-Tag. (B) Detection of the recombinant proteins by 
immunoblot analysis using an anti-E-tag monoclonal antibody (Muller R. et al. 2008). Molecular 
weight (MW) shown in kilo Dalton (kDa). 
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3.1.1 Clinical and serological characteristics of pemphigus vulgaris 
patients 
For this study we investigated the sera of eight PV patients who demonstrated 
high IgG titers against Dsg3. All PV patients presented with a clinical phenotype 
characteristic for pemphigus vulgaris, i.e. flaccid blisters and erosions on 
erythematous ground on the trunk and/or the mucous membranes as shown in 
figure 3.2. Histopathology of affected skin revealed suprabasal blister formation 
and intercellular IgG deposition by IF. Patients presented with active or chronic 
active stages of PV. 
 
 
Figure 3.2: Clinical features, immunoflurescence and histopathology of selected 
pemphigus patients. Shown are representative clinical pictures of patient 1 with erosions on 
mucous membranes and the skin (A and B). Direct immunofluorescence shows IgG deposition 
and an intercellular staining pattern of the epidermis (C). Histology of affected skin revealed 
suprabasal split formation (D). Pictures are courtesy of the Department of Dermatology and 
Allergy, Philipps Universität Marburg, and adapted from  (Kneisel et al. 2011a). 
 
The sera were screened for the presence of auto-Ab reactiv against the Dsg3 
extracellular subdomains by ELISA. As shown in figure 3.3 all patients reacted 
with recombinant Dsg3 whereas no unspecific protein reactivity, as shown by a 
negative reactivity against type 7 collagen, could be detected. Furthermore in 
the sera of patients 1, 2, 4 and 8 IgG reactivity against the NH2-terminal 
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subdomain, Dsg3EC1, was detected. A positive reaction against the carboxy-
terminal Dsg3 subdomain EC4 was seen in patient 1, 6 and 8. The optical 
density-(OD)-values of patient 7 were not sufficient to determine a clearly 
positive reactivity against any of the EC-constructs. Patients 2 and 3 showed 
additional IgG reactivity against Dsg1. These results lead to the selection of 
patients 1, 2, 6 and 8 for the following experiments since all but one (patient 2) 
expressed IgG-auto-Abs against the carboxy-terminal Dsg3-epitope EC4. 
Patient 2 was used later on as a reference for patients with exclusive reaction 
against NH2-terminal epitopes of Dsg3.  
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Figure 3.3: PV sera reactivity to recombinant desmoglein 3 and desmoglein 3 
extracellular subdomain proteins. ELISA showing serum reactivity of screened pemphigus 
patients against Dsg3 and Dsg3EC-proteins. A monoclonal anti-E-Tag-ab serves as loading 
control. All patients show positive reactivity against recombinant Dsg3EC1-5 as expected. 
Patient 1, 6 and 8 show additional reactivity against the EC4 domain of Dsg3. Positive EC1 
reactivity can be detected in the sera of patients 1, 2, 4 and 8. Normal human serum (nhs) 
serves as negative control. No unspecific protein reactivity against type 7 collagen (unspecific) 
could be detected. Cut off value is determined at an optical densitiy of 0.376 (405nm 
wavelength). 
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To reconfirm serum reactivity against the recombinant EC-proteins of Dsg3 in a 
different system we performed immunoblotting analysis for the selected PV-
patients’ sera. Recombinant proteins were separated by SDS-page and blotted 
onto nitrocellulose membranes. Pemphigus sera were incubated on the 
membranes overnight and IgG-reactivity was detected using a 
chemiluminescence system. As shown in figure 3.4 A, all patients’ sera 
contained auto-Abs against the whole Dsg3- extracellular domain. Furthermore 
patient 1 and 8 exhibited reactivity against the EC1 and EC4 subdomains of 
Dsg3, whereas patient 2 and 6 had additional auto-Abs directed against 
Dsg3EC1 or Dsg3EC4, respectively. A monoclonal mouse anti-E-tag antibody 
indicated the molecular size of the Dsg3-constructs and served as a positive 
control. Normal human serum of healthy individuals showed no reactivity to any 
of the recombinant Dsg3-proteins. Indirect immunofluorescence studies on 
cultured primary human keratinocytes were performed with the patient’s sera to 
confirm a positive reactivity with native Dsg3 as well. As seen in figure 3.4 B, all 
patients’ sera revealed a clear intercellular staining pattern as compared to the 
positive control, a mAb against Dsg3 (AK23), indicating the recognition of native 
human Dsg3 by IgG auto-Abs. Table 3.1 shows the definitive serological profile 
of the PV-patients’ sera. 
 
Figure 3.4: PV sera react with recombinant and native desmoglein 3. (A) Immunoblot 
confirming the antigen reactivity of the selected PV sera, i.e. patients 1, 2, 6 and 8 recognize the 
whole ectodomain of Dsg3, patients 1, 2 and 8 additionally recognize the Dsg3EC1 subdomain 
and finally Dsg3EC4 reactivity is detected for patients 1, 6 and 8. (B). All serum samples show a 
positive intercellular staining pattern using immunofluorescence studies on human primary 
keratinocytes indicating recognition of native Dsg3. Molecular weight (MW) in kilo Dalton (kDa). 
Recombinant proteins running at their expected size (arrows). 
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Table 3.1: Serological characteristics of selected pemphigus patients. 
Patient 
Dsg3-IgG 
ELISA/WB 
Dsg3EC1-IgG 
ELISA/WB 
Dsg3EC4-IgG 
ELISA/WB 
Dsg3EC5-IgG 
ELISA/WB 
IF 
1 +/+ +/+ +/+ - + 
2 +/+ +/+ -/- - + 
6 +/+ -/- +/+ - + 
8 +/+ +/+ +/+ - + 
 
Summary of the auto-antibody-profile of the selected patients showing enzyme-linked 
immunosorbent assay (ELISA), immunofluorescence (IF) and western blot (WB) analysis of the 
patients’ sera. 
 
Given these findings the four PV patients suited well to isolate and compare 
their domain-specific Abs since the NH2-terminal epitope Dsg3EC1 and the 
COOH-terminal epitope Dsg3EC4 were targeted by the selected patients’ auto-
Abs. 
 
3.1.2 Purification of antigen-specific auto-antibodies via affinity 
chromatography  
According to the serum reactivity of the patients’ sera three different antigen-
coupled-CNBr sepharose columns were established, namely a Dsg3-, an EC1- 
and an EC4-column, in order to isolate the corresponding auto-Abs. As 
schematically shown in figure 3.5 A, patients’ sera were subjected to antibody 
purification according to their previously defined autoantibody profile. Dsg3-
affinity purified antibodies were isolated from all the sera, whereas EC1- and 
EC4 affinity-purified antibodies were obtained from patients 1, 2 and 8 and 1, 6 
and 8, respectively. The amount of the purified antibodies was determined using 
a modified Lowry protein assay and the final concentration ranged between 100 
and 200 µg/mL. In addition whole IgG fractions from four healthy donors were 
purified using a protein A affinity chromatography column. This normal human 
IgG (nh-IgG) served as a negative control in the following analysis. Finally all 
Abs were subjected to western blot and ELISA as previuously done for the 
patients’ sera. This step was necessary to proof the successful antigen-specific 
isolation of the auto-Abs and to exclude a possible unspecific reactivity against 
other antigens.  
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Figure 3.5: Affinity chromatography of pemphigus IgG. (A) Scheme of Dsg3-specific affinity 
chromatography using antigen coupled sepharose B columns. (B) Western blot reactivity of two 
representative pemphigus sera (patient 2 + 8) against recombinant Dsg3 proteins prior and after 
antigen specific purification. Purified IgG shows specific reactivity against the recombinant 
proteins that were used to purify them, i.e. IgG from patient 2 affinity-purified by an EC1-column 
shows positive reaction with EC1, Dsg3 but not EC4. Furthermore IgG from patient 8 affinity-
purified by an EC4-column is specific for EC4, Dsg3 but not EC1. Molecular weight (MW) in kilo 
Dalton (kDa). Recombinant proteins running at their expected size (arrows). 
 
3.1.3 Purified pemphigus vulgaris immunoglobulin G is antigen-specific 
for recombinant extracellular subdomains of desmoglein 3 
Since all of the EC-constructs represent subdomains of the extracellular part of 
human Dsg3, the affinity purified Abs should always recognize the whole 
recombinant protein Dsg3 as well as the EC-construct which has been used for 
purification. Whereas Abs purified via the whole ectodomain should react with 
recombinant Dsg3 and one or more of the subdomains. Conformational epitope 
reactivity cannot be represented by this kind of western blot since the single 
proteins are blotted onto the membrane under denaturing conditions. Figure 3.5 
B shows representative western blots of patients 2 and 8 before and after 
affinity purification. Serum blots on the left side demonstrate that both patients’ 
sera have a positive IgG reactivity for the entire ectodomain of Dsg3. Patient 8 
shows additional reactivity with the EC1 and EC4 subdomains whereas the 
serum of patient 2 contains EC1-specific IgG. As expected after purification all 
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isolated auto-Abs showed a strong reaction with the whole Dsg3 ectodomain. 
However Abs of patient 2 affinity-purified via the EC1 domain expressed 
additional reactivity only against EC1. The same could be demonstrated for 
EC4-affinity-purified Abs of patient 8. None of these subdomain-specific auto-
Abs reacted with any other Dsg3 subdomain (data not shown). Successful 
antigen-specific purification was further reconfirmed by ELISA. All IgG eluates 
were tested for reactivity with Dsg3, Dsg3EC1, Dsg3EC4 and Dsg3EC5 
respectively as shown in figure 3.6. It can be clearly seen that EC1- and EC4-
affinity purified Abs express a strong IgG reactivity against their corresponding 
subdomain and the whole Dsg3 ectodomain while lacking reactivity for other 
subdomains, like EC5 (fig. 3.6). On the other side nh-IgG fractions did not show 
any positive reaction with the constructs used in this assay. Taken together 
these data confirmed the antigen specificity of our affinity purified Abs making it 
possible to subsequently investigate the pathogenic role of this highly specific 
IgG. 
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Figure 3.6: Antigen specificity of purified IgG shown by ELISA. Patients’ sera and affinity 
purified IgG reactivity against recombinant Dsg3 proteins. Antibodies purified via EC1 (EC1-
IgG) show exclusive binding to desmoglein 3 and the EC1 subdomain. Similarly, EC4 affinity 
purified IgG (EC4-IgG) shows positive reactivity with desmoglein 3 and EC4, respectively. 
Normal human IgG (nh-IgG) served as negative control and does not show any Dsg3 reactivity. 
Cut off value is determined at an optical densitiy of 0.376 (405nm wavelength). Optical density 
(OD) values are shown as mean values of the three or four affinity puried patients’ IgG fractions, 
respectively. 
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3.1.4 Extracellular subdomain 4-specific auto-antibodies belong to the 
immunoglobulin G1 and immunoglobulin G4 isotype classes 
Having proven the antigen specificity of the affinity purified antibodies, we now 
were interested in the IgG isotype profile present in the eluates. Therefore the 
purified antibodies of patient 1 were investigated on ELISA plates coated with 
the whole recombinant ectodomain of human Dsg3 (figure 3.7). Monoclonal 
mouse anti-human IgG Abs served to target the different human IgG isotypes, 
i.e. IgG1, IgG2, IgG3 and IgG4, as well as IgE and IgA. Total patients’ serum 
contained Abs of the IgG1, IgG2 and IgG4 isotypes. These isotypes were 
distributed within the purified Ab fractions as following: Purified Abs specific for 
the whole ectodomain of Dsg3 showed IgG1 and IgG4 reactivity. The same 
distribution could be obtained from Abs affinity purified via the EC4-subdomain. 
In contrast EC1-specific Abs belonged to the isotypes IgG1, IgG2 and IgG4. IgE 
or IgA Abs were not present at all. The presence of IgG1 and IgG4 isotypes goes 
in line with the clinical phenotype of (chronic) active PV (Bhol et al. 1995). 
However the presence of EC1-specific IgG2 Abs was surprising. Unfortunately 
this assay could not be performed for the purified Abs of the remaining patients 
due to shortage of eluted Ab material.   
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Figure 3.7: IgG isotype distribution of affinity purified pemphigus IgG. ELISA showing 
reactivity of affinity purified, antigen specific (Dsg3-, EC1- and EC4-IgG), total IgG and IgG 
isotypes from patient 1 against recombinant Dsg3. EC1-IgG contains IgG1, IgG2 and IgG4 
isotypes respectively whereas EC4-IgG only harbors IgG1 and IgG4 subclasses. IgA or IgE 
reactivity could not be detected. Optical densitiy measured at 405nm wavelength. 
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3.1.5 Recognition of desmoglein 3 extracellular subdomain 4 is calcium 
independent, whereas desmoglein 3 extracellular subdomain 1-
reactive immunoglobulin G binds to conformational epitopes 
It has been previously shown that in a cohort of 25 PV patients the pre-
treatment of the whole ectodomain of Dsg3 and the Dsg3 subdomain EC3 with 
denaturing agents (Urea, EDTA) leads to a significantly decreased IgG-
reactivity when tested by ELISA  (Muller R. et al. 2008). These results 
demonstrated clearly the presence of Abs recognizing conformational epitopes. 
However the IgG-reactivity in the sera did not differ when denaturing the 
extracellular Dsg3 subdomains EC1, EC2, EC4 and EC5 indicating IgG auto-
antibodies which recognize non-conformational epitopes. These findings 
prompted us to investigate the existence of conformation dependent recognition 
of Dsg3 in our purified Ab fractions. Therefore we coated the whole ectodomain 
of Dsg3 onto an ELISA plate under normal and denaturing conditions and 
incubated it with antigen specific Abs of patient 1 and 8 over night (figure 3.8). 
As suspected the serum IgG reactivity of the two patients against the whole 
ectodomain decreased dramatically but nevertheless did not fall under the cut of 
value of 0,376. A similar result could be obtained with the Dsg3-specific purified 
Abs indicating conformation dependent and independent epitope recognition 
within the Dsg3-specific Ab fraction. The most profound change in the IgG-
reactivity however could be observed in the EC1-specific Ab eluate. Denaturing 
of Dsg3 led to almost a complete loss of epitope recognition by EC1-specific 
IgG which goes in line with conformation dependent epitope reactivity. 
Interestingly antibodies affinity purified via the EC4 subdomain did not differ in 
their IgG-reactivity against Dsg3 highlighting the presence of non-
conformational epitope recognition within this auto-Ab subset.  
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Figure 3.8: Recognition of conformational desmoglein 3 epitopes. Reactivity of sera and 
purified antigen specific IgG from patients 1 and 8 against Dsg3 under normal (Dsg3+Ca), Ca
2+
-
depleted (Dsg3+EDTA) and denaturing conditions (Dsg3+Urea). PV sera and Dsg3-reactive 
IgG show a decreased but not negative reactivity under denaturing conditions indicating the 
presence of conformation dependent and independent epitope recognition. Recognition of the 
EC1 epitope of Dsg3 seems to be conformation dependent as seen by the reduced reactivity 
under denaturizing and Ca
2+
-depleted conditions. In contrast, EC4 specific IgG reactivity is not 
being altered by Dsg3 denaturation indicating conformation independent epitope recognition. 
Cut off value is determined at an optical densitiy of 0.376 (405nm wavelength). Optical density 
(OD) values are shown as mean values of the two affinity puried patients’ IgG fractions. 
 
3.1.6 Desmoglein 3 subdomain-specific imunoglobulin G recognizes 
native desmoglein 3 
Since the specificity of the isolated auto-Abs for their corresponding 
recombinant protein has been shown in previous experiments, we now sought 
to find out if these Abs exhibit the ability to recognize native Dsg3 as well. For 
this purpose indirect immunofluorescence studies were performed on cultured 
human primary epidermal keratinocytes (HPEK). To proof the expression of 
Dsg3 and the expected staining pattern on these cells we used the mAb AK23 
which is directed against the NH2-terminal region of Dsg3. As shown in figure 
3.9 AK23 stained the cell surfaces in a clear intercellular pattern, which is 
absolutely missing when looking at the negative control (nh-IgG). Affinity 
purified auto-Abs of PV patients expressed a similar staining pattern on human 
keratinocytes when compared with the positive control (figure 3.9). Taken 
together these data clearly demonstrate that Abs purified by recombinant Dsg3-
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constructs are able to recognize the native Dsg3 protein suggestive of a 
possible effect on desmoglein mediated keratinocyte adhesion. 
 
 
Figure 3.9: Affinity purified IgG recognizes native desmoglein 3. Immunofluorescence of 
human primary keratinocytes. The Dsg3-reactive monoclonal antibody AK23 serves as positive 
control and shows a clear intercellular staining pattern (left). Similarly antigen specific purified 
IgG of patients 1 and 8 shows an intercellular staining comparable with the positive control 
indicating recognition of native Dsg3 (right). Normal human IgG (nh-IgG) does not show any 
specific staining (left). 
 
3.1.7 Desmoglein 3 extracellular subdomain 4-specific immunoglobulin G 
induces loss of keratinocyte adhesion in vitro  
The positive Dsg3-staining pattern of the AK23 on HPEK made these cells 
suitable for an assay which can be used to demonstrate the pathogenic 
capacity of Dsg3-reactive IgG independent of Dsg1-driven adhesion. Ishii et al 
established the dispased based keratinocyte dissociation assay to investigate 
the pathogenic effect of patients’ sera or total IgG on keratinocyte adhesion in 
vitro (Ishii et al. 2005). We therefore used this functional assay to investigate a 
possible acantholytic effect of our Dsg3-purified Ab fractions. Patients’ sera and 
purified IgG were incubated with keratinocyte monolayers over night and the 
number of cell sheet fragments was measured on the next day after application 
of mechanical stress on the monolayer offering a semi-quantitive value for the in 
vitro pathogenic strength of the added Abs. Shown in figure 3.10 are the 
dissociation scores which reduce interassay variability and stand for a 
representative value. We performed the assay with the purified Abs in order to 
compare the pathogenic ability of EC1- and EC4-specific Abs in PV patients 
(figure 3.10). The mAb AK23 served as a positive control, since its acantholytic 
patient
1
8
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_______________________________________________________________Results 
 
66 
 
effect has been proven to be exclusively mediated by Dsg3-driven intercellular 
cohesion (Tsunoda et al. 2003). As expected the AK23 showed a profound 
dissociation of the keratinocyte monolayer at a concentration of 1µg/ml whereas 
neither normal human sera nor normal human IgG lead to a significant 
fragmentation (figure 3.10). In contrast all patients’ sera as well as all of the 
Dsg3- and Dsg3-subdomain specific IgG fractions induced strong keratinocyte 
dissociation comparable with the positive control antibody (AK23). These in vitro 
findings demonstrate that PV auto-Abs directed against the COOH-terminal 
subdomains of Dsg3, especially EC4, clearly impair keratinocyte adhesion to a 
similar extend like EC1-specific IgG.  
 
 
 
Figure 3.10: Affinity purified IgG induces loss of keratinocyte adhesion in vitro. PV-
patients’ sera as well as all affinity-purified antigen specific IgG, i.e. Dsg3-IgG, EC1-IgG and 
EC4-IgG, respectively, induce fragmentation of keratinocyte monolayers as illustrated by 
representative photographs of dissociation assays (lower panel). Pathogenicity of antigen 
specific IgG is quantified using the well established dissociation score (Ishii et al. 2005) which 
reduces interassay variability (upper panel). Results are shown as mean values of scores of 
three or four PV patients’ sera/IgG, normal human serum (nhs) or normal human IgG (nh-IgG), 
respectively. EC1 and EC4 specific IgG reach similar dissociation scores indicating strong 
pathogenic capacity for both auto-Abs in vitro. The Dsg3 specific monoclonal antibody AK23 
served as positive control. Neither normal human serum nor normal human IgG induce relevant 
acantholysis in this assay. Dissociation score = ((number of particles with serum – number of 
particles without serum) / (number of particles with serum – number of particles with AK23)) x 
100 (Ishii et al. 2005). 
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3.2 Purification and characterisation of desmocollin 3-specific 
auto-antibodies in atypical pemphigus patients 
Patients suffering from atypical pemphigus show IgG reactivity against a variety 
of auto-antigens including the second main group of desmosomal cadherins, 
the desmocollins (Dscs). Thus we were interested in characterising the 
pathogenic capacity of affinity purified Dsc-specific IgG using our previously 
established assays. When the methods to successfully affinity purify antigen 
specific auto-Abs from patients’ sera and subsequent in vitro pathogenicity 
testing were established, we applied this set of experiments on the sera of four 
atypical pemphigus patients, which were a kindly provided by Dr. Takeishi 
Hashimoto, Departement of Dermatology, Kurume University, Japan. To identify 
the desmosomal target proteins recognized by the IgG auto-Abs of these 
patients, the sera were incubated with defined baculovirus-derived proteins 
including Dsg1, Dsg3, and Dsc1, Dsc2, Dsc3, respectively. Figure 3.11 shows a 
schematic illustration and western blot-detection of these proteins by anti-E-Tag 
mAb and serum of a PNP patient.  
 
 
Figure 3.11: Recombinant desmoglein and desmocollin proteins used in this study. (A) 
Scheme of the recombinant proteins applied in this study, i.e. the entire ectodomains of Dsc1, 
Dsc2, Dsc3, Dsg1 and Dsg3, linked to E- and 6xHis-Tag (Muller et al. 2006; Muller et al. 2009). 
(B) Detection of the recombinant proteins by immunoblot analysis using an anti-E-tag 
monoclonal antibody (upper panel) or serum of a patient with paraneoplastic pemphigus (PNP) 
(lower panel) (Rafei et al. 2011). Molecular weight (MW) shown in kilo Dalton (kDa). 
Recombinant proteins running at their expected size at 72 kDa. 
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3.2.1 Clinical and serological characteristics of atypical pemphigus 
patients 
Sera of two patients with pemphigus herpetiformis and two patients with 
pemphigus vegetans were included in this study (table 3.2 and figure 3.12). 
Patients presented with multiple erythematous herpetiform erosions and with 
hypertrophic verrucous plaques with pustules and erosions, respectively, as 
illustrated in Figure 3.12. Histopathology analysis of lesional skin showed 
intraepidermal loss of keratinocyte adhesion at the suprabasilar layer. 
Furthermore, direct immunofluorescence revealed an intercellular staining 
pattern, i.e. positive IgG deposits on the surface of epidermal keratinocytes 
(data from Dr. Takeishi Hashimoto, Departement of Dermatology, Kurume 
University, Japan). 
 
Figure 3.12:  
Clinical phenotype of 
representative patients 
with atypical pemphigus. 
Clinical pictures of two 
representative patients with 
atypical pemphigus 
(pemphigus vegetans and 
pemphigus herpetiformis) 
showing hypertrophic 
verrucous plaques with 
pustules and erosions of the 
foot (A) and multiple 
erythematous herpetiform 
erosions of the trunk and 
extremities (B, C). Insets of A and B show IgG reactivity of the patients’ sera with human 
desmocollin 3-transfected COS-7 cells. Histopathology of lesional skin reveals intra-epidermal 
loss of keratinocyte adhesion at the suprabasilar level (D). Direct immunofluorescence shows 
IgG deposits on the surface of epidermal keratinocytes (E) (Rafei et al. 2011).  
 
 
 
 
 
D
B
C
E
A
_______________________________________________________________Results 
 
69 
 
Table 3.2: Synopsis of clinical and serological characteristics of atypical 
pemphigus patients.  
 
(Rafei et al. 2011) 
 
3.2.2 Desmocollin 3-reactive auto-antibodies in the sera of four patients 
with atypical pemphigus 
To evaluate the desmosomal target proteins recognized by the IgG auto-Abs of 
these patients, the sera were incubated with defined baculovirus-derived 
proteins including Dsg1, Dsg3, Dsc1, Dsc2 and Dsc3. Immunoblot analysis 
revealed the presence of IgG against Dsc3 in all the studied patients (figure 
3.13 upper pannel). In addition, the serum of patient 2 showed IgG reactivity 
against Dsg1. However no IgG-reactivity against Dsg3 could be detected at all 
(figure 3.13 upper pannel). As already mentioned the pathogenic role of Dsc3-
specific IgG is not fully understood. Whether they represent an epiphenomenon 
or have capacities to induce mucocutaneous lesions remains unclear at the 
moment. Therefore it seemed suitable to isolate the Dsc3-specific auto-Abs 
from these sera and to investigate their pathogenic effect in the keratinocyte 
dissociation assay. Unfortunately due to the small amounts of patients’ serum, 
specificity experiments were limited to western blot analysis and no ELISA was 
performed. 
 
Desmosomal target antigens
Patient Autoab 
isotype
Diagnosis Clinical characteristics Dsc1 Dsc2 Dsc3 Dsg1 Dsg3
#1 IgG Pemphigus vegetans Exophytic skin erosions and oral erosions - - + - -
#2 IgG Pemphigus vegetans Hypertrophic verrucous plaques with 
pustules and erosions on the foot, groin 
and scalp
- - + + -
#3 IgG Pemphigus herpetiformis Multiple pustules, erythematous 
herpetiform erosions, oral erosions
- - + - -
#4 IgG Pemphigus herpetiformis Erythematous cutaneous erosions - - + - -
_______________________________________________________________Results 
 
70 
 
 
 
Figure 3.13: Affinity purification of desmocollin 3-reactive IgG auto-antibodies from four 
patients with atypical pemphigus. Immunoblot analysis showing IgG reactivity of the four 
atypical pemphigus sera against the recombinant proteins before and after affinity purification 
using Dsc3 columns (upper panel). Serum of patient 2 shows additional IgG-reactivity with Dsg1 
prior to Dsc3-column-purification. Affinity purification technique using Dsc3-coupled CNBr 
columns is schematically shown in the lower panel (Rafei et al. 2011). 
 
3.2.3 Desmocollin 3-specific immunoglobulin G recognizes both 
recombinant and native desmocollin 3  
Serum samples of 4 atypical pemphigus patients were affinity purified using a 
Dsc3-coupled-CNBr sepharose column in order to obtain and further analyze 
the Dsc3-reactive IgG-fraction (figure 3.13 lower pannel). After purification, the 
IgG fractions of the four studied patients reacted exclusively with recombinant 
Dsc3 as shown by immunoblot analysis and were therefore thought to be highly 
Dsc3-specific (figure 3.13 upper pannel). To determine the reactivity of the 
Dsc3-purified IgG also with native Dsc3, immunofluorescence studies of 
cultured human keratinocytes (HaCat) and human skin samples was performed 
as well (figure 3.14). The anti-Dsc3 monoclonal ab U114 was used as a positive 
control and showed intercellular staining of both cultured keratinocytes and 
human skin, whereas pooled IgG from healthy control sera did not show any 
specific staining. The Dsc3-purified IgG fractions of patients 1-4 demonstrated 
intercellular reactivity with cultured human keratinocytes and human epidermis 
in a similar intensity as the positive control. In addition, indirect 
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immunofluorescence was performed on monkey esophagus to confirm the 
previous results. The anti-Dsc3 monoclonal ab, U114, elicited an intercellular 
staining pattern predominantly at the expected basal and suprabasal levels of 
the mucosal epithelium. Very similar results were obtained subjecting the Dsc3-
purified IgG fractions of patients 1-4 to immunofluorescent staining on monkey 
esophagus, demonstrating the binding of these Dsc3-purified auto-Abs to native 
Dsc3. Taken together the purified IgG-fraction of the four atypical PV patients 
were highly specific for recombinant Dsc3 and were able to stain native Dsc3 on 
three different substrates as well. 
 
 
 
Figure 3.14: Reactivity of the purified desmocollin 3-reactive IgG auto-antibodies with 
cultured human keratinocytes, human epidermis and monkey esophagus. Dsc3 affinity-
purified IgG from four patients with atypical pemphigus shows intercellular reactivity with 
cultured human keratinocytes (HaCaT cells) (patients 1-4 shown as C-F), human epidermis (I-L) 
and monkey esophagus (O-R). Monoclonal anti-Dsc3 antibody (clone U114) (A, G and M) and 
pooled IgG of healthy control sera (B, H and N) served as positive and negative controls, 
respectively (Rafei et al. 2011).  
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3.2.4 Desmocollin 3-specific immunoglobulin G induces loss of 
keratinocyte adhesion in vitro  
After confirming the reactivity of Dsc3-purified IgG auto-Abs with recombinant 
and native Dsc3, their pathogenic capacity was investigated in vitro. 
Interference with keratinocyte adhesion is considered the pathogenic hallmark 
of auto-Abs in pemphigus. Thus, we applied a well established in vitro system 
for evaluating the capability of Dsc3-purified IgG auto-Abs to induce loss of 
keratinocyte adhesion. Dsc3-purified IgG of pemphigus patients 1-4 was applied 
to a dispase-based keratinocyte dissociation assay using primary human 
keratinocytes. Confluently grown primary keratinocytes were incubated with 
Dsc3-purified IgG fractions of patients 1-4, and afterwards Dsg1 was degraded 
by incubation with exfoliatoxin A (ETA). Next, mechanical stress was applied to 
the keratinocyte monolayer in order to obtain cellular fragments illustrating the 
loss of keratinocyte adhesion in these keratinocyte cultures and thus, the 
pathogenicity of the Dsc3 auto-Abs studied. Figure 3.15 A shows that the anti-
Dsc3 monoclonal ab, U114, induces a dramatic weakening of keratinocyte 
adhesion, leading to a high number of keratinocyte fragments, while control IgG 
from pooled healthy individuals does not affect keratinocyte adhesion. 
Keratinocyte cell sheets incubated with Dsc3-purified IgG were dissociated into 
numerous smaller fragments, indicating that Dsc3-reactive IgG of patients’ sera 
is capable of inducing loss of keratinocyte adhesion (figure 3.15 A). In 
comparison Dsg3-specific purified IgG from a patient with classical pemphigus 
vulgaris induced cell dissociation to a very similar extend indicating comparable 
pathogenic capacities of Dsg3- and Dsc3-specific Abs. Furthermore, it was 
crucial to investigate whether this effect on keratinocyte adhesion was specific 
for the Dsc3-reactive auto-Abs and related to the presence of Dsc3 in 
desmosomes. Preadsorption of the Dsc3-purified IgG fractions with 
recombinant Dsc3 almost completely blocked the loss of keratinocyte adhesion 
in the dissociation assay. In contrast preadsorption with recombinant Dsg3 did 
not alter the pathogenic effect of the Dsc3-purified IgG fractions in this assay 
(figure 3.15 B). To exclude non-specific binding of IgG auto-Abs to recombinant 
Dsc3, we also applied Dsg3-purified IgG from PV patients to the keratinocyte 
dissociation assay. As previously described, Dsg3-reactive auto-Abs of a 
pemphigus vulgaris patient induces loss of keratinocyte adhesion in this assay. 
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However, preincubation of anti-Dsg3 IgG with recombinant Dsc3 protein did not 
abrogate this effect (figure 3.15 C). Thus, these results strongly suggest that the 
Dsc3-purified IgG fraction in the atypical pemphigus patients studied here is 
pathogenic and induces loss of keratinocyte adhesion by specifically binding 
and/or blocking Dsc3 and such effect can be blocked by preincubation with the 
recombinant Dsc3-protein but not with Dsg3.  
 
Figure 3.15: Desmocollin 3-affinity purified IgG from 
four patients with atypical pemphigus induces loss 
of keratinocyte adhesion. Shown are results of the 
dispase-based keratinocyte dissociation assay using 
primary human epidermal keratinocytes. Keratinocyte 
monolayers were incubated either with the monoclonal 
anti-Dsc3 IgG antibody (clone U114), Dsc3-affinity 
purified IgG from the four atypical pemphigus patients, 
pooled IgG from healthy donors or desmoglein 3 
(Dsg3)-affinity purified IgG from a pemphigus vulgaris patient. (A) Quantification of the 
keratinocyte fragments shown as dissociation scores. Representative images out of three 
independent experiments are shown below the diagram. (B) Number of keratinocyte fragments 
after incubation with Dsc3-affinity purified IgG from four atypical pemphigus patients (B, left 
column). The induction of keratinocyte dissociation is Dsc3-specific, since preadsorption of the 
Dsc3-affinity purified IgG fraction with recombinant Dsc3 (B, middle column and C, left panel) 
but not with human Dsg3 (B, right column) blocks keratinocyte dissociation. To exclude non-
specific binding of IgG to recombinant Dsc3 protein, Dsg3-purified IgG from a pemphigus 
vulgaris patient was pre-adsorbed with Dsc3 protein (C, right panel). Dsg3 affinity purified IgG 
induces loss of keratinocyte adhesion (A and C) which is not inhibited by preadsorption with 
human Dsc3 protein (C, right panel) (Rafei et al. 2011). Dissociation score = ((number of 
particles with serum – number of particles without serum) / (number of particles with serum – 
number of particles with U114)) x 100 (Ishii et al. 2005). 
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4 Discussion 
4.1 Role of anti-desmoglein 3 auto-antibodies recognizing carboxy-
terminal epitopes in the pathogenesis of pemphigus 
The results from the first part of this study clearly demonstrate that auto-Abs 
directed against non-amino-terminal epitopes of Dsg3, like the Dsg3EC4-
subdomain, react with native Dsg3 and are pathogenic in vitro. These findings 
challenge the dogma of Dsg3EC1-reactive IgG antibodies as the major 
pathogenic Abs to some extent, since auto-Abs directed against carboxy-
terminal epitopes may at least contribute to the induction of acantholysis in 
patients suffering from pemphigus (Amagai et al. 1992; Futei et al. 2000; 
Tsunoda et al. 2003; Muller R. et al. 2008). Shortly after identification of Dsg3 
as the major pathogenic antigen in PV, Amagai et al. using β-galactosidase 
fusion proteins (FP) produced by E.coli showed that in a cohort of 23 PV 
patients most were able to react with the EC1, EC2 and EC4 domains of human 
Dsg3 (Amagai et al. 1992). Antigen specific immunoadsorption of IgG out of 
these sera using Dsg3EC1-2 and Dsg3EC3-5 FPs and subsequent 
intraperitoneal injection into neonatal mice resulted in suprabasal split formation 
accounting only for the Dsg3EC1-2-affinity purified fraction. However, the pass 
through IgG of the Dsg3EC1-2 FP column still exhibited acantholitic capacity 
when injected intraperitoneally indicating the presence of pathogenic Dsg3-
epitopes other than EC1 and EC2 (Amagai et al. 1992). Data from Bhol et al. in 
1995 already suggested that EC2-specific IgG4 is probably the main 
acantholytic autoantibody, while EC1- specific IgG4 may act as a facilitator or 
enhancer of the pathogenic process (Bhol et al. 1995). Furthermore our group 
has previously shown that active stages of PV were associated with the 
presence of IgG directed against the NH2-terminus and Dsg3 subdomains EC2-
4 (Muller R. et al. 2008). Even more convincing, the same PV patients did not 
exhibit auto-Abs against these epitopes anymore while in remission. Finally 
Dsg3EC1-4 specific auto-Abs seemed to predominantly occur in patients with a 
mucosal dominant phenotype and in one case titers decreased, together with 
clinical improvement, upon treatment (Muller R. et al. 2008).  
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4.1.1 Epitope spreading and synergistic effects of “non-pathogenic” 
pemphigus vulgaris auto-antibodies 
A possible explanation for the above mentioned observations provides a study 
by Salato et al. using baculovirus-produced domain-swapped Dsg1 and Dsg3 
molecules, respectively (Salato et al. 2005). This study could show that in 
patients with mucosal dominant PV an intramolecular epitope spreading from 
carboxy- to NH2-terminal epitopes of Dsg3 preceded an intermolecular epitope 
spreading from Dsg3 to Dsg1 and the transition to a mucocutaneous 
phenotype. Patients with mucosal lesion had antibodies only reactive with 
COOH-terminal epitopes (Salato et al. 2005). However, our lab previously 
detected auto-Abs directed against the COOH-terminal epitope Dsg3EC5 in 
patients with mucocutaneous PV as well (Muller R. et al. 2008). Furthermore PV 
patients in remission still presented with high titers against the whole Dsg3-
ectodomain indicating the presence of pathogenic and non-pathogenic auto-Abs 
(Muller R. et al. 2008). This goes in line with findings from Payne et al. using 
phage display techniques to isolate a repertoire of monoclonal Dsg3-reactive 
antibodies as single-chain variable-region fragments (scFvs) from PV sera 
(Payne et al. 2005). Only two among several isolated scFvs showed pathogenic 
effects when injected in neonatal mice or tested in the keratinocyte dissociation 
assay (Payne et al. 2005). However, several of the “non-pathogenic” scFvs 
were not injected together to investigate a possible synergistic effect. But 
exactly this synergistic effect may provide an explanation of how primarily non-
pathogenic Dsg3 auto-Abs may contribute to the pathogenesis of PV. Kawasaki 
et al. demonstrated an additive pathogenic effect of monoclonal mouse Abs 
directed against middle- or carboxy-terminal extracellular regions of the Dsg3-
ectodomain when pooled in certain combinations. These pools were able to 
induce a PV like phenotype when injected into neonatal mice (Kawasaki et al. 
2006). Further evidence that intramolecular epitope spreading may modulate 
clinical activity in pemphigus comes from the endemic PF variant Fogo 
Selvagem (FS). Patients in preclinical stages presented with Abs against the 
EC5 subdomain of Dsg1 and with the onset of disease developed anti-
Dsg1EC1 and/or anti-Dsg1EC2 auto-Abs (Li et al. 2003). Finally sera from FS 
patients in remission showed reactivity restricted to Dsg3EC5 (Li et al. 2003). 
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The study presented here shows for the first time that specifically isolated 
antibodies directed against a COOH-terminal extracellular subdomain of Dsg3, 
i.e. Dsg3EC4, are able to induce keratinocyte dissociation in vitro and therefore 
may contribute to acantholysis in pemphigus. Three out of four patients in this 
study presented with EC1-specifc IgG and two of these had additional EC4-
reactive antibodies. Since pathogenicity in vitro could be demonstrated for both 
Dsg3EC1- and Dsg3EC4-affinity purified IgG respectively, it is not possible to 
determine the major pathogenic auto-Ab entity leading to the blistering 
phenotype. Interestingly patient 6 exhibited only Dsg3EC4-specific IgG but 
lacked auto-Abs directed against other Dsg3 subdomains and any other 
desmoglein or desmocollin, respectively. Thus it is very likely that EC4-specific 
IgG may induce acantholysis in this patient. Unfortunately it wasn’t possible to 
follow up serological changes in patient 6 which may have shown the 
appearance of auto-Abs reactive with NH2-terminal epitopes supporting the role 
of intramolecular epitope spreading in disease modulation. Therefore future 
studies should address the phenomenon of Dsg3-epitope spreading during the 
course of PV to further elucidate its relevance for disease progression. Ohyama 
et al. recently addressed this question in a large-scale longitudinal study using 
Dsg2-based domain-swapped molecules (Ohyama et al. 2012). Dsg1 and 
Dsg3EC-domain reactivity of 212 sera collected from 53 PV patients at multiple 
time points during the course of the disease was detected by 
immunoprecipitation-immunoblotting (Ohyama et al. 2012). Sera were 
incubated with Dsg2 molecules, previously swapped with one of the 
extracellular domains EC1-5 of Dsg1 and Dsg3, respectively, to determine 
epitope specific reactivity of the Dsg1-/Dsg3-reactive IgG. Since PV sera do not 
react with any Dsg2EC domain, positive reactivity in this assay can be directly 
related to the swapped Dsg1EC/Dsg3EC domains (Ohyama et al. 2012). 
Ohyama could show that epitope spreading occurred only in very few PV cases 
during the disease course and that most patients harboured a constantly high 
IgG reactivity against the NH2-terminal region of Dsg1 and Dsg3 going in line 
with several previous studies (Amagai et al. 1992; Futei et al. 2000; Payne et al. 
2005; Ohyama et al. 2012). Interesting, however 18.9% of all sera contained 
Abs against the Dsg3EC4 domain and around 17% of those antibodies were 
found during active and moderate disease (Ohyama et al. 2012). Even more 
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astonishing 12 out of 14 patients suffering from praneoplastic pemphigus which 
were also included into this study revealed a positive IgG reactivity against the 
Dsg3EC4 epitope indicating a high abundance of these auto-Abs among PNP 
patients (Ohyama et al. 2012). Furthermore, this study revealed high 
prevalence for other COOH-terminal epitope specific auto-Abs like Dsg3EC3-
IgG (50.5%) and Dsg3EC5-IgG (12.3%), respectively, in PV sera, similar to 
previous findings by our group (Muller R. et al. 2008; Ohyama et al. 2012). 
Taken together with the fact that around 61% of all sera showed a positive IgG 
reactivity against at least 3 or more Dsg3EC domains, a possible synergistic 
effect of these auto-Abs even if they recognize non-NH2-terminal epitopes can 
not be excluded. As already mentioned above, Kawasaki et al. were able to 
show that in mice primarily non pathogenic Dsg3-reactive auto-Abs can exert a 
pathogenic effect when pooled together (Kawasaki et al. 2006). Interestingly 
non-pathogenic mAbs directed against middle or COOH-terminal epitopes 
induced blister formation when injected into neonatal mice together with other 
non-pathogenic mAbs reactive with NH2-terminal epitopes indicating that IgG 
recognizing the middle to COOH-terminal extracellular domains of Dsg3 can 
also take part in the pathogenic process of blister formation (Kawasaki et al. 
2006). Finally, although epitope spreading in the auto-Ab profile of PV patients 
seems to be a rare event the presence of serum IgG reactive with several 
different Dsg3 epitopes including primarily non-pathogenic ones (specific for 
middle or COOH-terminal epitopes) together with our findings of pathogenic 
EC4-specific IgG in vitro clearly emphasize a possible synergistic effect of these 
auto-Abs in PV pathogenesis.   
 
4.1.2 Possible pathogenic molecular mechanisms of desmoglein 3 
extracellular subdomain 4-specific immunoglobulin G  
The molecular pathology of PV IgG reactive with middle or carboxy-terminal 
epitopes of Dsg3 is not known so far. Steric hindrance by direct inhibition of the 
adhesion interface seems unlikely since these Abs do not react with the NH2-
terminal part of the Dsg3-ectodomain (Heupel et al. 2008). However Dsg3EC4-
reactive Abs may induce allosteric hindrance through a conformational change 
of the extracellular portion of Dsg3 leading to impaired desmosomal adhesion, a 
mechanism that may act synergistically with direct inhibition at the adhesive 
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interface by EC1-specific IgG (Waschke 2008). Heupel et al. nicely 
demonstrated that Dsg1-reactive IgG from PF patients which was not able to 
block Dsg1 homophilic interactions under cell free conditions, induced 
dissociation of keratinocyte cell sheets and reduced binding of Dsg1 coated 
beads to the surface of cultured keratinocytes (Heupel et al. 2008). These 
findings indicate that PF IgG presumably excerts its pathologic effects rather via 
intracellular changes in the signalling cascades of the keratinocyte (Heupel et 
al. 2008). The authors also suggest that Dsg3-reactive PV IgG may harbour 
similar capacities to induce keratinocyte dissociation by activation of 
intracellular signalling in addition to direct inhibition (Heupel et al. 2008). Finally 
they mention the pathogenic effect of a mAb directed against the EC2 domain 
of Dsg1, suggesting allosteric conformational changes of Dsg1 (Heupel et al. 
2008). Although this effect could not be reproduced using mAbs specific for 
non-NH2-terminal epitopes of Dsg3, Heupel et al. did not examine a possible 
synergistic effect of these Abs when pooled together. Therefore the further 
investigation of our isolated Dsg3EC4-specific IgG in cell-dependent and 
independent pathogenicity assays are necessary to elucidate the molecular 
mechanisms underlying their pathogenic capacity in inducing acantholysis. 
Another hypothesis for the pathogenic effect emerging from PV-IgG binding to 
the keratinocyte surface is the induction of intracellular signalling pathways 
which may result in the depletion of membrane bound Dsg3 finally leading to 
impaired cell adhesion (Muller E.J. et al. 2008; Thomason et al. 2010). As 
already mentioned earlier several studies have investigated the effect of IgG 
binding to junctional/desmosomal and transadhering non-junctional/non-
desmosomal Dsg3 (Sato et al. 2000; Oktarina et al. 2011; Tsang et al. 2012). 
Targeting of this non-junctional, non-keratin-anchored Dsg3 by PV-IgG seems 
to induce two major mechanisms. On the one hand it leads to Dsg3 
internalisation and lysosomal degradation within 30-60 min after PV-IgG 
treatment thereby preventing its’ attachment to keratin filaments and its’ 
integration into mature desmosomes as demonstrated by time-lapsed labeling 
of cultured keratinocytes incubated with PV IgG (Sato et al. 2000). This goes in 
line with the finding that split formation between keratinocytes starts in the 
interdesmosomal areas since intraperitoneal PV-IgG injection into BALB/c mice 
resulted in early epidermal cell detachment after 1 h visible as widening of the 
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epidermal intercellular spaces (Takahashi et al. 1985). Six hours after PV IgG 
injection interdesmosomal areas of the cell membrane had detached 
completely. Desmosomal junctions separated at last, occurring at 12-18 hours 
upon injection (Takahashi et al. 1985). On the other hand binding of Dsg3-
specific IgG may induce an “outside-in” signal that alters protein 
phosphorylation and transcription finally leading to acantholysis promoting 
events (Muller E.J. et al. 2008). One of those signals may be the degradation of 
desmosomal Dsg3 but since changes in the desmosomal pool of Dsg3 do not 
seem to occur before 18-24 hours after PV-IgG treatment other intracellular 
mechanisms are speculated to be involved (Aoyama et al. 1999a; Aoyama et al. 
1999b; Yamamoto et al. 2007). 
Most of the observations on keratinocyte cell signalling have been performed in 
vitro using cultured keratinocytes mimicking the transitional phase, which is 
classified as the time point where the epidermal keratinocyte exits the stem cell 
compartment and becomes a transit amplifying cell until it is growth arrested 
and has committed to terminal differentiation (Muller E.J. et al. 2008). This 
applies for keratinocytes residing in the suprabasal layers of the epidermis, the 
site where blister formation occurs in PV (Amagai et al. 1996; Mahoney et al. 
1999a). The fact that at the beginning of the transitional phase Dsg3 and Dsc3 
are the main demsosomal cadherins displayed at the cell surface of 
keratinocytes renders these types of experiments a suitable setting to study the 
effects of PV-IgG and for example Dsc3- or Dsg3EC- affinity purified IgG 
binding (Green et al. 2000; Dusek et al. 2007).  
A sound explanation of how anti-Dsg3-IgG is involved in inducing acantholysis 
derives from the finding that disturbed cadherin transinteraction between 
opposing cells results in a hyperproliferative signal in correlation with an 
upregulation of c-Myc and disrupted desmosomal organization (Williamson et 
al. 2006; de Bruin et al. 2007). Under physiological conditions Dsg3 homophilic 
interaction leads to the Src-family-kinase dependent phosphorylation of Dsg3-
associated plakoglobin (PG) which then associates with phosphatidylinositol 
triphosphate kinase (PI3K) (Calautti et al. 1998). This complex induces 
increased activity of the serine-threonine protein kinase AKT finally resulting in 
the reduced expression of the proto-oncogene c-myc which renders the cell into 
cell cycle arrest (Muller E.J. et al. 2008). There is emerging evidence that anti-
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Dsg3 Abs oppose Dsg3-mediated signalling by disrupting transadhesion 
between non-junctional Dsg3 for example by steric and/or allosteric hindrance 
(Oktarina et al. 2011; Schulze et al. 2012; Tsang et al. 2012). This binding may 
provide a signal of “no cell contact”, epidermal growth factor receptor- (EGFR-
)signalling fails to be inhibited, keratinocytes in the basal layer of the epidermis 
continue to proliferate due to disinhibited c-myc expression, Dsg3 is being 
depleted from desmosomes leading to weekened adhesiveness and finally 
suprabasal blisters occur (Schulze et al. 2012). Further evidence derives from 
findings that PV-IgG treatment of cultured keratinocytes leads to increased 
EGFR activity (Chernyavsky et al. 2007) and c-myc overexpression is found in 
the epidermis of PV-patients (Williamson et al. 2007). Taken together Dsg3 
mediated antiproliferative events seem to physiologically act as a counterpart of 
EGFR-mediated proliferative signalling and thus PV-IgG binding may interfere 
with Dsg3 signalling leading to disinhibited EGFR activation and cell 
proliferation (Muller E.J. et al. 2008). 
Another proposed role for non-junctional “Dsg3-signalling” is its’ influence on 
the assembly and disassembly of adherens junctions. In this context the 
tyrosine kinase Src seems to play an essential role. Very recently is has been 
shown that non junctional human desmoglein 3 acts as an upstream regulator 
of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis 
of pemphigus vulgaris (Tsang et al. 2012). Src phosphorylation in response to 
PV-IgG binding preceeds EGFR- and P38MAPK activation in keratinocytes 
(Chernyavsky et al. 2007) and therefore may act as an early intracellular branch 
point that triggers further downstream pathways (Chernyavsky et al. 2007). The 
importance of P38MAPK in the pathogenesis of pemphigus has been weakened 
to some extend at least in early blister formation since in vitro studies have 
shown that p38 MAPK phosphorylation occurred after initial Dsg3 endocytosis 
(Mao et al. 2011). Nevertheless p38 MAPK seems to augment late Dsg3/Dsc3 
endocytosis and blister formation (Mao et al. 2011). In summary, activation of 
intracellular signalling pathways in response to PV-IgG binding to non-junctional 
cadherins provides a possible explanation of how initial blister formation is 
triggered in pemphigus.   
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4.1.3 Immunoglobulin G isotype distribution patterns of auto-antibodies 
ractive with amino- and carboxy-terminal epitopes of desmoglein 3 
In this study we showed that auto-Abs of a PV patient directed against the 
whole ectodomain of Dsg3 and its subdomains EC1 and EC4 mainly belonged 
to the IgG1 and IgG4 isotypes matching to a patient in a chronic active stage of 
the disease (Hertl et al. 2010). While EC4-specific IgG exclusively belonged to 
the IgG1 and IgG4 subclass the EC1-specific antibody pool further contained 
IgG2 auto-Abs which similar to IgG4 do not or only to a limited extend activate 
the classical complement pathway (Murphy et al. 2008). Furthermore IgG2 can 
not bind to Fc receptors on phagocytes highlighting a possible directly 
pathogenic role of this subtype. Interesting information about the distribution of 
Dsg3 specific IgG2 comes from a large study on Dsg3 reactivity in PV patients 
and healthy relatives using immunoblotting analysis (Torzecka et al. 2007). In 
this study circulating Dsg3 specific IgG2 isotype was observed in 60% of a 
cohort of relatives of PV patients and IgG4 was detected in 23.3% of them. On 
the other side in active PV patients IgG4 and IgG1 were the dominant isotypes 
(96 and 76% relatively) while in clinical remission Abs predominantly belonged 
to the IgG2 (75%) and IgG4 (37.5%) isotype (Torzecka et al. 2007). The 
frequency of IgG1 and IgG4 isotypes was significantly higher in acute disease 
compared to patients in clinical remission or seropositive healthy relatives 
(Torzecka et al. 2007). These results confirmed the dependence of the different 
IgG isotypes in pemphigus on certain stages of the disease (Bhol et al. 1995; 
Torzecka et al. 2007). Together with our findings these data indicate that EC4 
specific IgG1 and IgG4 belong to the major pathogenic IgG isotypes which are 
present in active PV. On the other hand, EC1 specific IgG2 may play a minor 
role in pemphigus pathogenesis since IgG2 reactive with Dsg3 is frequently 
found in healthy relatives of PV patients or patients in remission.  
 
4.1.4 Conformation dependence of amino- and carboxy-terminal epitopes 
of desmoglein 3 
Denaturing of the whole extracellular domain of Dsg3 by calcium depletion 
using EDTA or treatment upon urea lead to a reduced binding of Dsg3- and 
Dsg3EC1-affinity purified Abs indicating the recognition of conformational 
epitopes by these auto-Abs. These data perfectly match with the findings of 
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Tsunoda et al. who identified the pathogenic monoclonal antibody AK23 
recognizing a calcium-dependent conformational epitope within the EC1 
subdomain of Dsg3 (Tsunoda et al. 2003). However our study shows that Dsg3 
epitope recognition by EC4-affinity purified IgG does not differ among 
denaturation or calcium depletion indicating the presence of non-conformational 
epitopes within the EC4 subdomain of Dsg3. These findings were recently 
confirmed by Ohyama et al. using domain swapped Dsg2/Dsg3 and Dsg2/Dsg1 
molecules (Ohyama et al. 2012). According to their findings anti-Dsg1 and anti-
Dsg3 IgG Abs recognize calcium-dependent epitopes of the EC1-3 domains of 
Dsg1 and Dsg3, respectively, whereas recognition of epitopes on the EC4-5 
domains is calcium independent (Ohyama et al. 2012). Furthermore in a large 
cohort of pemphigus patients our group has previously shown by ELISA 
analysis that IgG-reactivity to the recombinant extracellular domain EC4 was 
not being diminished by denaturising the protein or by reducing the Ca2+-level 
(Muller R. et al. 2008). Taken together these data indicate that EC4-recognition 
is conformation independent and thus EC4-affinity purification using 
recombinant proteins seems to be a suitable tool to isolate and investigate EC4-
specific IgG in PV patients’ sera. 
 
4.1.5 Role of carboxy-terminal subdomains of desmoglein 3 in 
maintaining keratinocyte adhesion 
Most knowledge about how desmosomal cadherins interact on the molecular 
level derives from studies on classical cadherins, like E- or C-Cadherin. 
Nevertheless these findings are thought to be widely applicable on desmosomal 
cadherins as well since they share approximately 30% amino acid identity with 
classical cadherins and harbour the same basic structure in their extracelllular 
domains (Garrod et al. 2002). There are two different hypotheses how 
cadherins first interact when arriving on the cell surface before assembling into 
mature desmosomes. One is the formation of cis dimers between two 
neighbouring cadherins on the same cell which then come together on adjacent 
cells to interact in trans, followed by a zippering of the adhesive interface 
(Green et al. 2010). A possible site for a cis interaction represent the EC1 
domain and interestingly a region close to the interdomain EC4-EC5 as shown 
by cryo-electron tomography of vitreous sections of human epidermis (Al-
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Amoudi et al. 2007). The second hypothesis favours the initial formation of 
weakly bound trans dimers between two molecules protruding from opposing 
cells which is subsequently strengthened by lateral cadherin clustering and 
cytoskeleton attachment (Green et al. 2010). Although the above mentioned 
trans interaction seems to be largely dependent on two EC1 domains forming 
adhesive complexes between adjacent cells, the strength of this interaction is 
rather low (Green et al. 2010). To enlarge trans binding forces another 
possibility is the involvement of other EC domains into this kind of interaction. 
The importance of the involvement of more than only one Dsg-EC-domain into 
trans interaction has been elucidated by Chappuis-Flament et al. using bead 
aggregation and cell attachment-based adhesion assays (Chappuis-Flament et 
al. 2001). Sivasankar et al. proposed that rather than binding in a single unique 
orientation, cadherins adhere in three distinct alignments. The strongest 
adhesion was observed when opposing extracellular fragments were completely 
interdigitated including the involvement of the carboxy-terminal regions EC4 
and/or EC5 (Sivasankar et al. 2001). Taken together both initial cis or trans 
interactions between adjacent or opposing cadherins seem to include middle or 
COOH-terminal EC domains as well highlighting those regions as important 
players in maintaining cellular adhesion and giving rise to the possibility that 
auto-Abs in pemphigus sera directed against the EC4 or EC5 domain of Dsg3 
may interfere with desmosomal adhesion as well.  
 
4.2 Role of desmocollin 3-specific auto-antibodies in the 
pathogenesis of pemphigus 
4.2.1 Evidence for pathogenic desmocollin 3-specific auto-antibodies 
This study shows for the first time that affinity-purified Dsc3-reactive auto-Abs 
from patients with atypical pemphigus induce loss of epidermal keratinocyte 
adhesion in vitro. These results extend recent findings of Spindler et al who 
identified Dsc3 as a crucial component of desmosomal adhesion especially in 
the suprabasal layers of the epidermis (Spindler et al. 2009). First, incubation of 
human skin biopsies with a mAb against Dsc3 (U114) induced suprabasal split 
formation, the site where acantholysis usually starts in PV patients (Spindler et 
al. 2009). Using adhesion force measurement experiments Spindler et al. 
investigated single molecule homophilic and heterophilic interactions between 
____________________________________________________________Discussion 
 
84 
 
different desmosomal cadherins (Spindler et al. 2009). They were able to show 
that Dsc3 does not only interact homophilically but also heteophilically with 
Dsg1. Heterophililic interaction was based on an additional hydrogen bond and 
hydrophobic interactions and seemed to be even slightly stronger (Spindler et 
al. 2009). Although hetreophilic Dsc3/Dsg1 interaction could be blocked by 
incubation with mAbs against Dsc3 and Dsg1, respectively, the addition of PF-
IgG exclusively reactive with Dsg1 did not reduce the heterophililic binding 
activity in this cell free system. Interestingly heterophilic binding of Dsc3 to Dsg3 
could not be detected indicating that heterophilic cadherin interaction does not 
seem to be a general rule (Spindler et al. 2009). Furthermore Spindler et al. 
tested the influence of impaired Dsc3 function in the keratinocyte dissociation 
assay, which has been used in our work as well. Dsc3 gene silencing using 
small hairpin RNA (shRNA) and incubation with a mAb against human Dsc3 
(U114) increased fragmentation of the cell monolayer significantly (Spindler et 
al. 2009). Finally, Dsc3-coated bead binding to keratinocyte monolayers was 
impaired by mAbs against Dsc3 and Dsg1 as well as Dsg1 reactive human IgG 
(Spindler et al. 2009). Strikingly preincubation of keratinocyte monolayers with 
the P38 MAPK inhibitor SB202190 abolished the effect of Dsg1-reactive IgG 
indicating the involvement of cellular signalling mechanisms subsequently to Ab 
binding leading to impaired Dsc3 bead binding (Spindler et al. 2009). 
Nevertheless, the PV and PF sera used in this study were not tested for their 
reaction against non-desmosomal antigens like cholinergic receptors. Thus the 
acantholytic effects seen here may not be exclusively related to Dsg1- and/or 
Dsg3- reactive IgG (Grando 2012).  
The best evidence that Dsc3 is critically involved in desmosomal adhesion of 
epidermal keratinocytes comes from a recently established conditional Dsc3-
knock out mouse model (Chen et al. 2008). Mice with a targeted Dsc3 
deficiency in the skin and hair follicles show an impressive phenotype with 
extensive intra-epidermal blistering and telogen hair loss. This phenotype was 
even more profound than the one found in mice deficient of Dsg3, the auto-
antigen of PV, where mostly mucosal lesions evolved (Koch et al. 1997; Chen 
et al. 2008). In addition, cultured keratinocytes from the Dsc3 conditional knock 
out mice showed impaired cellular adhesion when tested in the keratinocyte 
dissociation assay similar to the findings of Spindler et al. as mentioned above 
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(Chen et al. 2008; Spindler et al. 2009). Knowledge about impaired Dsc3 
function in humans is rarely found in the literature. Since total knock out of Dsc3 
in mice resulted in a pre-implantation lethal phenotype suggesting an essential 
role of this cadherin in early embryonic development (Den et al. 2006), 
hereditary defects of Dsc3 in humans may also result in prenatal abortion. 
However, Ayub et al. were able to identify a homozygous nonsense mutation in 
the human Dsc3 gene that affected four members of a large afghan family. All 
individuals were affected with hereditary hypotrichosis and the appearance of 
recurrent skin vesicle formation (Ayub et al. 2009). Thus, in addition to Dsg3 
and Dsg1, Dsc3 must be considered as a relevant component for desmosomal 
adhesion of epidermal keratinocytes.  
Very recently Mao et al. identified 6 out of 38 PV sera that were able to 
immunoprecipitate recombinant human Dsc3-protein (Mao et al. 2010). One of 
these sera belonged to a patient with mucosal dominant PV and exclusively 
reacted with Dsc3. Isolated IgG of this patient was able to induce acantholysis 
in the keratinocyte dissociation assay and preincubation of anti-Dsc3-IgG with 
recombinant Dsc3 abolished this effect indicating a specific disruption of Dsc3-
mediated adhesion (Mao et al. 2010). But again, the PV sera used in this study 
were not investigated for additional reactivity against non-desmosomal 
antigens. Therfore isolated IgG fractions from these patients may still harbour 
pathogenic Abs against non-desmosomal pathogenic antigens. In our approach 
we specifically isolated PV IgG using recombinant human Dsc3. Isolated IgG 
fractions showed no cross-reactivity with other desmosomal cadherins and were 
able to induce acantholysis in vitro. Since acantholysis could only be blocked by 
preincubation with recombinant Dsc3, these effects can be directly referred to 
the action of Dsc3 reactive IgG. Finally these findings provide the first evidence 
that specific targeting of Dsc3 by auto-Abs in pemphigus patients induces loss 
of keratinocyte adhesion in vitro and may contribute to the blistering phenotype.   
 
4.2.2 Presence of desmocollin-reactive immunoglobulin G in clinical 
pemphigus variants 
IgG auto-Abs against Dsc3 are not the only auto-Ab-specificity detected in 
atypical pemphigus since our group and others have also identified IgG 
reactivity against Dsg1 and Dsg3 in single cases of pemphigus herpetiformis 
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(Kozlowska et al. 2003; Lebeau et al. 2010). Furthermore, Mao et al. identified 6 
patients suffering from classical pemphigus demonstrating Dsc3-reactive auto-
Abs (Mao et al. 2010). Until now, there was only circumstantial evidence for a 
pathogenic role of IgG auto-Abs against distinct Dsc isoforms. Dsc1 has been 
previously identified as a target antigen of IgA auto-Abs in the subcorneal 
pustular dermatosis type of IgA pemphigus (Hashimoto et al. 1997; Heng et al. 
2006). Except for the findings of a single in vitro study, there is currently no 
clear evidence for the pathogenicity of IgA auto-Abs on desmosomal cell-cell 
adhesion (Supapannachart et al. 1993). IgG- and IgA-auto-Abs against Dsc 
have been occasionally identified in patients with atypical pemphigus 
(Dmochowski et al. 1995; Hashimoto et al. 1995; Kozlowska et al. 2003; 
Hisamatsu et al. 2004; Muller et al. 2009) and paraneoplastic pemphigus 
(Chorzelski et al. 1994; Hashimoto 2001; Muller et al. 2009). It is currently a 
matter of debate whether IgG or IgA auto-Abs against Dsc are a rare 
epiphenomen in pemphigus or whether their detection is limited by the currently 
available diagnostic tools. Hisamatsu et al. did not detect IgG or IgA auto-Abs 
against Dsc1-3 in 45 sera from classical pemphigus patients by ELISA with 
recombinant proteins (Hisamatsu et al. 2004). The sensitivity of the Dsc-ELISA 
was limited since all the sera from eight patients with IgA pemphigus showed 
IgA reactivity with Dsc1 expressed on COS cells but only one serum was IgA 
positive by ELISA (Hisamatsu et al. 2004). Utilizing baculovirus-derived, 
eukaryotic recombinants of Dsc1, Dsc2, and Dsc3, Müller et al. were not able to 
detect Dsc-specific IgG in the sera of a cohort of 74 European patients with PV 
by ELISA and immunoblot, respectively (Muller et al. 2009). However, a 
considerable number of sera from patients with atypical forms of pemphigus, 
paraneoplastic pemphigus and IgA pemphigus showed either IgG or IgA 
reactivity with Dsc1, Dsc2, or Dsc3 (Muller et al. 2009). This observation is also 
reflected by the findings of the present study that four Dsc3-reactive sera were 
collected from patients with atypical pemphigus (pemphigus vegetans and 
pemphigus herpetiformis) and only one patient demonstrated IgG-reactivity 
against Dsg1 (Rafei et al. 2011). Thus, the low detection rate of Dsc-reactive 
IgG auto-Abs in PV and PF is presumably not due to technical limitations of the 
respective assays but rather due to the low prevalence of Dsc-reactive auto-Abs 
in classical PV or PF (Rafei et al. 2011). In summary, the present findings 
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demonstrate that IgG auto-Abs against Dsc3 induce loss of keratinocyte 
adhesion in vitro strongly suggesting their pathogenic relevance in pemphigus. 
Since Dsc3-reactive IgG is rarely found in patients with classical PV or PF, the 
observed in vitro pathogenicity of anti-Dsc3 IgG auto-Abs provides a sound 
explanation why Dsc3-reactive patients with atypical pemphigus lacking IgG 
against Dsg3 or Dsg1 develop skin blistering (Rafei et al. 2011). 
 
4.3 Potential role of antigen-specific immunoadsorption in the 
therapy of pemphigus 
As mentioned before one additional second line treatment strategy in 
pemphigus is to remove large amounts of circulating IgG from the patients’ 
serum by immunoadsorption including the pathogenic auto-Abs (Eming et al. 
2006a). More precisely blood is withdrawn from the patient using peripheral or 
central venous catheters and cellular components are seperated from plasma 
by centrifugation or filtration. The plasma is passed through an adsorber with 
high affinity to human immunoglobulin, such as protein A, a major cell wall 
component of staphylococcus aureus. Protein A harbours high affinity to human 
IgG, especially IgG1, IgG2 and IgG4 and to a lesser extend IgG3 (Eming et al. 
2006a). 
This immunoadsorption technique eliminates Abs via their Fc-portion including  
IgG specific for auto-antigens like Dsg3 as well as protective pathogen-specific 
Abs such as measles- or CMV/EBV-reactive IgG. Nevertheless, 
immunoadsorption has already been successfully applied and well tolerated in 
the treatment of difficult to treat pemphigus patients (Luftl et al. 2003; Schmidt 
et al. 2003; Eming et al. 2006b). Furthermore, immunoadsorption in 
combination with the B-cell depleting mAb rituximab induced fast and prolonged 
remissions in difficult to treat pemphigus (Behzad et al. 2011). The first antigen 
specific approach is the “Coraffin adsorber” which has been developed based 
on peptide epitopes recognized by anti-β1 adrenergic receptor antibodies in 
patients suffering from idiopathic dilatative cardiomyopathy, thus removing 
predominantly antigen specific auto-Abs from patients’ plasma (Eming et al. 
2006a). There have been many pieces of evidence that antigen-specific 
immunoadsorption of IgG from pemphigus sera can successfully ameliorate 
their pathogenicity. Amagai and collegues nicely showed that recombinant 
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proteins produced in a baculovirus expression system can be used to remove 
Dsg1- and/or Dsg3-specific IgG from PV sera. Those preadsorbed sera were 
not able to induce blister formation upon injection into neonatal mice anymore 
(Amagai et al. 1994a; Amagai et al. 1995a). These studies already suggested 
antigen-specific immunoadsorption as a possible therapeutic strategy in the 
treatment of patients suffering from pemphigus. Since subsequent studies using 
a phage display technique have demonstrated that Dsg3 harbours pathogenic 
and non-pathogenic epitopes (Payne et al. 2005) it is obvious to think about a 
more epitope specific elimination of circulating pathogenic auto-Abs in PV 
patients. This work for the first time identifies EC4 as a potential additional 
pathogenic epitope of Dsg3 since EC4-specific isolated IgG showed an 
ancantholytic effect in vitro. Thus epitope-based plasmapheresis may represent 
a more targeted therapy in pemphigus treatment in the future. On the other 
hand desmocollins, and in particular Dsc3, have emerged as relevant non-
desmoglein auto-antigens in the pathogenesis of pemphigus (Muller et al. 2009; 
Spindler et al. 2009). This study has shown that purified Dsc3-reactive IgG is 
pathogenic in vitro and that preadsorption of Dsc3-IgG using recombinant 
proteins can significantly reduce their pathogenicity (Rafei et al. 2011). Taken 
together antigen-specific immunoadsorption represents a promising method to 
reduce circulating pathogenic antibodies from the blood of pemphigus patients 
which might lead to a far more specific treatment option with less side effects. 
However, since additive pathogenic functions of auto-Abs directed against 
primarily non-pathogenic desmosomal and/or non-desmosomal epitopes can’t 
be ruled out, it may be still necessary to eliminate all epitope-specific IgG from 
the blood to avoid these additive effects (Grando 2012). Figure 4.1 gives a 
summarised picture of the potential pathogenic mechanisms in pemphigus.  
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Figure 4.1: Synopsis of potential pathogenic mechanisms in pemphigus. The initial trigger 
for the loss of tolerance in pemphigus pathogenesis might be the liberation of antigen, i.e. 
desmoglein 3 or desmocollin 3, through keratinocyte lysis and subsequent protein uptake by B-
cells and antigen presentation to auto-reactive CD4+T-cells. Intra- and/or inter-molecular 
epitope spreading may take place at this point of B- and T-cell cross-talk. Reduced control of 
these T-cells by impaired functioning of regulatory T-cells (Treg) may facilitate this process. B-
cells then transform into plasma-cells producing auto-Abs directed against different epitopes of 
desmogleins and/or desmocollins. Auto-Abs may excert their pathogenic capacity by direct 
inhibition of desmosomal adhesion through binding at NH2-terminal and/or COOH-terminal 
epitopes or induction of intracellular signalling cascades finally leading to loss of keratinocyte 
adhesion and blister formation. In addition, auto-antibodies directed against different epitopes of 
desmoglein 3 may act synergistically to induce acantholysis probably by mechanisms of 
allosteric hindrance. Presence of desmocollin 3-reactive IgG may contribute to the pathogenesis 
in pemphigus as well. Finally desmoglein 3- as well as desmocollin 3-specific IgG may not only 
reduce homophilic desmoglein 3- and desmocollin 3-binding, respectively, but may also 
interfere with heterophilic binding between desmoglein 1 and desmocollin 3. Clinical pictures 
are courtesy of the Department of Dermatology and Allergy at the Philipps-Universität Marburg. 
P38 MAPK = P38 mitogen-activated protein kinase, SRC = sarcoma oncogene tyrosine kinase, 
PKC = protein kinas C, Treg = regulatory T cell, KC = keratinocyte.  
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5 Conclusions 
 
 There is compelling evidence that cis interactions between neighbouring 
Dsg3 molecules at COOH-terminal regions play an important role in 
maintaining cellular adhesion of epidermal keratinocytes.  
 IgG against COOH-terminal epitopes of Dsg3 are found in a great number of 
pemphigus patients including atypical variants, such as pemphigus 
herpetiformis and pemphigus vegetans. 
 Although single monoclonal-Abs against COOH-terminal epitopes were not 
found to be pathogenic in vivo, they may act synergistically to facilitate 
blister formation in pemphigus. 
 Dsg3EC4-specific IgG causes acantholysis in vitro and is likely to contribute 
to the blistering phenotype in pemphigus. 
 Dsg3EC4-specific IgG recognizes conformation independent epitopes and 
belongs to the IgG1 and IgG4 isotypes.  
 The exact mechanism how Dsg3EC4-specific IgG disrupts desmosomal 
adhesion remains unknown. Allosteric hindrance and the induction of 
intracellular signalling pathways are very promising hypotheses and need to 
be further investigated. 
 IgG auto-Abs against Dscs are found in classical as well as in atypical 
pemphigus variants some of them exclusively react to Dsc3. 
 Dsc3-specific IgG causes keratinocyte dissociation in vitro and may 
therefore provide an explanation why Dsg-negative pemphigus patients 
develop blisters. 
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6 Outlook  
 
 Further in vitro and in vivo studies are needed to investigate the importance 
and the mode of action of auto-Abs directed against COOH-terminal 
epitopes of Dsg3 and against Dsc3, respectively. 
 The pathogenic relevance of other epitopes of Dsg3, especially Dsg3EC5, 
needs to be addressed and if these pathogenic effects are exerted 
separately or in an additive manner. 
 Screening of the presence of Dsc3-reactive IgG in the sera of pemphigus 
patients should provide further knowledge about the pathogenic role of these 
auto-Abs in pemphigus pathogenesis and their possible correlation with 
atypical pemphigus variants. 
 Antigen-specific immunoadsorption is a promising targeted therapy option in 
auto-immune diseases. Therefore the investigation of the relevant repertoire 
of pathogenic epitopes in pemhigus should help to develop ways to 
specifically eliminate acantholytic auto-Abs. 
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8 ELISA-Messdaten und dissociation scores 
PV sera reactivity to recombinant Dsg3 and Dsg3EC-constructs (figure 3.3).  
Values = optical density at 405nm wavelength. Unspecific = type 7 collagen. 
 
 
 
 
 
 
 
 
Confirmation of antigen specificity of purified IgG to recombinant Dsg3 and Dsg3EC-constructs (figure 3.6).                                     
Values = optical density at 405nm wavelength. 
 
Dsg3 Dsg3EC1 Dsg3EC4 Dsg3EC5 
Antibodies/Sera Pat. 1 Pat. 2 Pat. 6 Pat. 8 Pat. 1 Pat. 2 Pat. 6 Pat. 8 Pat. 1 Pat. 2 Pat. 6 Pat. 8 Pat. 1 Pat. 2 Pat. 6 Pat. 8 
PV-Serum 1,412 2,0465 0,9675 1,1205 0,6375 0,921 0,199 0,3385 0,5115 0,4515 1,203 1,373 0,3785 0,1915 0,182 0,2915 
Dsg3-IgG 0,9665 1,6945 0,7835 1,0635 0,1690 1,0300 0,4220 0,3240 0,2965 0,6020 0,5850 1,3280 0,1700 0,2845 0,2625 0,2230 
Dsg3EC1-IgG 1,1260 1,9680 n/a 1,0845 0,8578 1,0125 n/a 0,6020 0,1860 0,3700 n/a 0,1380 0,1400 0,1715 n/a 0,1425 
Dsg3EC4-IgG 1,1650 n/a 0,9465 0,8515 0,2385 n/a 0,2435 0,2845 0,7290 n/a 1,5470 1,7825 0,1705 n/a 0,1830 0,3370 
PV-patient 
Serum Dsg3 Dsg3EC1 Dsg3EC2 Dsg3EC3 Dsg3EC4 Dsg3EC5 Dsg1 unspecific 
1 0,6465 0,6265 0,2575 0,2750 0,7115 0,3010 0,3600 0,2245 
2 1,1045 0,5665 0,2900 0,2380 0,2570 0,2295 0,7080 0,2575 
3 0,9440 0,3880 0,3875 0,3850 0,3625 0,2390 0,7635 0,2180 
4 0,6065 0,5895 0,2010 0,2225 0,1900 0,1830 0,2270 0,2420 
5 1,1830 0,3755 0,4060 0,3710 0,3855 0,1730 0,3195 0,2320 
6 0,6810 0,2635 0,2735 0,3485 1,2140 0,1765 0,3540 0,2300 
7 1,3575 0,4725 0,5350 0,3905 0,4515 0,2795 0,3660 0,1980 
8 0,8570 0,6720 0,2470 0,2270 0,8545 0,2510 0,2555 0,2445 
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IgG subclass distribution of affinity purified pemphigus IgG of patient 1 (fig. 3.7). 
Values = optical density at 405nm wavelength. 
Antibodies/serum 
of patient 1 IgG IgG1 IgG2 IgG3 IgG4 IgA IgE 
PV-Serum 2,8135 1,4025 0,7730 0,1325 2,0715 0,4130 0,1275 
Dsg3-IgG 1,6690 0,7165 0,2645 0,1250 0,9595 0,2075 0,1275 
Dsg3EC1-IgG 2,6145 1,1875 0,6875 0,1545 1,9020 0,3010 0,1465 
Dsg3EC4-IgG 1,8060 0,7100 0,2270 0,1465 0,7080 0,2110 0,1525 
  
Conformation dependent recognition of Dsg3 epitopes by affinity purified IgG of 
patient 1 and 8 (figure 3.8). Values = optical density at 405nm wavelength. 
 
Dsg3 + Ca2+ Dsg3 + EDTA Dsg3 + Urea 
Antibodies/Sera patient 1 patient 8 patient 1 patient 8 patient 1 patient 8 
PV-Serum 1,1730 1,5045 0,4915 0,9445 0,4420 0,8900 
Dsg3-IgG 1,0045 0,8195 0,7190 0,5965 0,6250 0,5440 
Dsg3EC1-IgG 1,4665 1,3850 0,5735 0,5615 0,4360 0,4940 
Dsg3EC4-IgG 0,8215 0,7995 0,8015 0,7860 0,7170 0,6960 
  
Dissociation-Scores of Dsg3 and Dsg3-subdomain-specific IgG (figure 3.10). 
Dissociation score = ((number of particles with serum – number of particles without serum) / 
(number of particles with serum – number of particles with AK23)) x 100. 
patient Serum Dsg3-IgG Dsg3EC1-IgG Dsg3EC4-IgG 
1 49,13044 33,47826 93,47826 82,17391 
2 85,66038 112,8302 146,0377 n/a 
6 143,0303 87,27273 n/a 34,54546 
8 83,39484 59,4096 76,75277 178,9668 
 
Dissociation-Scores of Dsc3-specific IgG (figure 3.15).                           
Dissociation score = ((number of particles with serum – number of particles without serum) / 
(number of particles with serum – number of particles with U114)) x 100. 
patient Dsc3-IgG Dsc3-preadsorbed patients' IgG Dsg3-preadsorbed patients' IgG 
1 41,95 1,46 28,38 
2 32,17 5,53 39,31 
3 43,59 2,07 32,15 
4 26,24 4,18 40,36 
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